<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000022.pub3" GROUP_ID="ARI" ID="064799081614131976" MERGED_FROM="" MODIFIED="2013-01-28 07:35:36 +0000" MODIFIED_BY="Liz Dooley" REVIEW_NO="A016" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2013-01-28 07:35:36 +0000" MODIFIED_BY="Liz Dooley">
<TITLE>Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care</TITLE>
<CONTACT MODIFIED="2013-01-28 07:35:36 +0000" MODIFIED_BY="Liz Dooley"><PERSON ID="11485" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Roberto</FIRST_NAME><LAST_NAME>D'Amico</LAST_NAME><POSITION>Assistant professor</POSITION><EMAIL_1>roberto.damico@unimore.it</EMAIL_1><MOBILE_PHONE>+39 3316213042</MOBILE_PHONE><ADDRESS><DEPARTMENT>Statistics Unit, Department of clinical and diagnostic medicine and public health, University of Modena and Reggio Emilia, Modena, Italy</DEPARTMENT><ORGANISATION>University of Modena and Reggio Emilia</ORGANISATION><ADDRESS_1>Via del Pozzo 71</ADDRESS_1><CITY>Modena</CITY><ZIP>41121</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 059 4223865</PHONE_1><FAX_1>+39 059 4223235</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-01-28 07:35:36 +0000" MODIFIED_BY="Liz Dooley"><PERSON ID="11485" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Roberto</FIRST_NAME><LAST_NAME>D'Amico</LAST_NAME><POSITION>Assistant professor</POSITION><EMAIL_1>roberto.damico@unimore.it</EMAIL_1><MOBILE_PHONE>+39 3316213042</MOBILE_PHONE><ADDRESS><DEPARTMENT>Statistics Unit, Department of clinical and diagnostic medicine and public health, University of Modena and Reggio Emilia, Modena, Italy</DEPARTMENT><ORGANISATION>University of Modena and Reggio Emilia</ORGANISATION><ADDRESS_1>Via del Pozzo 71</ADDRESS_1><CITY>Modena</CITY><ZIP>41121</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 059 4223865</PHONE_1><FAX_1>+39 059 4223235</FAX_1></ADDRESS></PERSON><PERSON ID="11527" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Silvia</FIRST_NAME><LAST_NAME>Pifferi</LAST_NAME><EMAIL_1>silviapifferi@libero.it</EMAIL_1><ADDRESS><ORGANISATION>Policlinico San Matteo, Pavia</ORGANISATION><ADDRESS_1>Via F. Sporza 35</ADDRESS_1><CITY>Milano</CITY><ZIP>20122</ZIP><COUNTRY CODE="IT">Italy</COUNTRY></ADDRESS></PERSON><PERSON ID="19385" ROLE="AUTHOR"><FIRST_NAME>Valter</FIRST_NAME><LAST_NAME>Torri</LAST_NAME><SUFFIX>MD</SUFFIX><EMAIL_1>torri@marionegri.it</EMAIL_1><ADDRESS><DEPARTMENT>Laboratorio di Epidemiologia Clinica</DEPARTMENT><ORGANISATION>Mario Negri Institute</ORGANISATION><ADDRESS_1>Via Eritrea 62</ADDRESS_1><CITY>Milano</CITY><ZIP>20157</ZIP><REGION>Milano</REGION><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 2 3901 4528</PHONE_1><FAX_1>+39 2 3320 0231</FAX_1></ADDRESS></PERSON><PERSON ID="11468" ROLE="AUTHOR"><FIRST_NAME>Luca</FIRST_NAME><LAST_NAME>Brazzi</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>UO di Anestesia e Rianimazione - AOU di Sassari</POSITION><EMAIL_1>lbrazzi@uniss.it</EMAIL_1><EMAIL_2>brazzi@policlinico.mi.it</EMAIL_2><ADDRESS><DEPARTMENT>Dipartimento di Scienze Chirurgiche, Microchirurgiche e Mediche</DEPARTMENT><ORGANISATION>Università degli Studi di Sassari</ORGANISATION><ADDRESS_1>Via le San Peitro, 43 - Palazzo Clemente</ADDRESS_1><CITY>Sassari</CITY><ZIP>07100</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 079 228270</PHONE_1><FAX_1>+39 079 210585</FAX_1></ADDRESS></PERSON><PERSON ID="0F5A963682E26AA2010AB3F2C88DAF73" ROLE="AUTHOR"><FIRST_NAME>Elena</FIRST_NAME><LAST_NAME>Parmelli</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>elena.parmelli@unimore.it</EMAIL_1><ADDRESS><DEPARTMENT>Department of Oncology, Hematology and Respiratory Diseases</DEPARTMENT><ORGANISATION>University of Modena and Reggio Emilia</ORGANISATION><ADDRESS_1>Via del Pozzo 71</ADDRESS_1><CITY>Modena</CITY><ZIP>41100</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 059 4223032</PHONE_1><FAX_1>+39 059 4223073</FAX_1></ADDRESS></PERSON><PERSON ID="6387" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Alessandro</FIRST_NAME><LAST_NAME>Liberati</LAST_NAME><POSITION>Director</POSITION><URL>www.cochrane.it</URL><ADDRESS><DEPARTMENT>Italian Cochrane Centre</DEPARTMENT><ORGANISATION>Mario Negri Institute for Pharmacological Research</ORGANISATION><ADDRESS_1>Via La Masa, 19</ADDRESS_1><CITY>Milan</CITY><ZIP>20156</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 02 39014 327</PHONE_1><PHONE_2>+39 02 39014 517</PHONE_2><FAX_1>+39 02 3559048</FAX_1></ADDRESS><FOOTNOTE>Deceased</FOOTNOTE></PERSON></CREATORS>
<DATES MODIFIED="2012-03-20 07:36:14 +1000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="13" MONTH="3" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="13" MONTH="3" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="13" MONTH="3" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="1997"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2012-03-20 07:36:43 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-03-20 07:36:43 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="20" MONTH="3" YEAR="2012"/>
<DESCRIPTION>
<P>Byline citation updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-03-20 07:35:31 +1000" MODIFIED_BY="Liz Dooley">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-03-20 07:35:31 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="19" MONTH="5" YEAR="2011"/>
<DESCRIPTION>
<P>Searches conducted</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-08-05 11:58:08 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="13" MONTH="3" YEAR="2009"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2010-08-05 11:58:08 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="13" MONTH="3" YEAR="2009"/>
<DESCRIPTION>
<P>One study has been included in this update (<LINK REF="STD-Camus-2005" TYPE="STUDY">Camus 2005</LINK>). Two studies, whose data were reported in congress proceedings (<LINK REF="STD-Lenhart-1994" TYPE="STUDY">Lenhart 1994</LINK>) and were unpublished (<LINK REF="STD-Stoutenbeek-2" TYPE="STUDY">Stoutenbeek 2</LINK>), have been replaced by <LINK REF="STD-Krueger-2002" TYPE="STUDY">Krueger 2002</LINK> and <LINK REF="STD-Stoutenbeek-2007" TYPE="STUDY">Stoutenbeek 2007</LINK> which are their published versions in peer-reviewed journals.</P>
<P>One study (<LINK REF="STD-Jacobs-1995" TYPE="STUDY">Jacobs 1995</LINK>) included in the previous version of this review as a personal contact with the principal investigator, has been excluded due to lack of feedback from the trial author. To date, this study has not been published.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-01-06 08:25:07 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="30" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-01-06 08:26:45 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="5" MONTH="9" YEAR="2003"/>
<DESCRIPTION>
<P>Searches conducted. Updated review published Issue 4, 2002</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-01-06 08:26:42 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="5" MONTH="12" YEAR="1999"/>
<DESCRIPTION>
<P>Searches conducted. Review published Issue 3, 1997</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-01-06 08:27:07 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="5" MONTH="12" YEAR="1995"/>
<DESCRIPTION>
<P>Searches conducted. Updated review published Issue 1, 2004</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Italian Cochrane Centre</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-01-28 17:34:53 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-07-29 10:37:24 +1000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-01-06 08:28:11 +1000" MODIFIED_BY="Liz Dooley">Antibiotics to help reduce mortality and respiratory infections in people receiving intensive care in hospital</TITLE>
<SUMMARY_BODY MODIFIED="2009-07-29 10:37:24 +1000" MODIFIED_BY="[Empty name]">
<P>Infections acquired in intensive care units (ICUs) are important complications of the treatment of patients with very severe diseases who need ventilation (mechanical breathing support). Some people will die because of these infections. Considerable efforts have been made to evaluate methods for reducing this problem; one of these involves the use of antibiotics administered as preventative intervention, usually referred to as selective decontamination of the digestive tract (SDD). This review includes 36 studies involving 6914 patients treated in ICUs to investigate whether the administration of antibiotics prevents the development of infections. Antibiotics were administered in two different ways. In some studies antibiotics were applied both directly to the oropharynx via a nasogastric tube (topical) and intravenously (systemic). In other studies they were applied only topically. Our results show that when patients received the combination of topical plus systemic antibiotics there were less infections and deaths. When patients received only topical treatment there were less infections but the number of deaths was not changed. Although this treatment seems to work it is not widely used in clinical practice because there is concern about the possible development of antibiotic resistance (that is, bacteria become unresponsive to drugs).</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-01-28 17:26:18 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-07-28 16:22:29 +1000" MODIFIED_BY="Clare Dooley">
<P>Pneumonia is an important cause of mortality in intensive care units (ICUs). The incidence of pneumonia in ICU patients ranges between 7% and 40%, and the crude mortality from ventilator-associated pneumonia may exceed 50%. Although not all deaths in patients with this form of pneumonia are directly attributable to pneumonia, it has been shown to contribute to mortality in ICUs independently of other factors that are also strongly associated with such deaths.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-07-28 16:23:39 +1000" MODIFIED_BY="Clare Dooley">
<P>To assess the effects of prophylactic antibiotic regimens, such as selective decontamination of the digestive tract (SDD) for the prevention of respiratory tract infections (RTIs) and overall mortality in adults receiving intensive care.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-01-28 17:26:18 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2009, issue 1), which contains the Cochrane Acute Respiratory Infections (ARI) Group's Specialised Register; MEDLINE (January 1966 to March 2009); and EMBASE (January 1990 to March 2009).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-07-28 16:25:02 +1000" MODIFIED_BY="Clare Dooley">
<P>Randomised controlled trials (RCTs) of antibiotic prophylaxis for RTIs and deaths among adult ICU patients.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-02-11 15:42:15 +1000" MODIFIED_BY="[Empty name]">
<P>At least two review authors independently extracted data and assessed trial quality.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-07-29 10:28:05 +1000" MODIFIED_BY="[Empty name]">
<P>We included 36 trials involving 6914 people. There was variation in the antibiotics used, patient characteristics and risk of RTIs and mortality in the control groups. In trials comparing a combination of topical and systemic antibiotics, there was a significant reduction in both RTIs (number of studies = 16, odds ratio (OR) 0.28, 95% confidence interval (CI) 0.20 to 0.38) and total mortality (number of studies = 17, OR 0.75, 95% CI 0.65 to 0.87) in the treated group. In trials comparing topical antimicrobials alone (or comparing topical plus systemic versus systemic alone) there was a significant reduction in RTIs (number of studies = 17, OR 0.44, 95% CI 0.31 to 0.63) but not in total mortality (number of studies = 19, OR 0.97, 95% CI 0.82 to 1.16) in the treated group.<BR/>
</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-07-31 23:07:30 +1000" MODIFIED_BY="[Empty name]">
<P>A combination of topical and systemic prophylactic antibiotics reduces RTIs and overall mortality in adult patients receiving intensive care. Treatment based on the use of topical prophylaxis alone reduces respiratory infections but not mortality. The risk of resistance occurring as a negative consequence of antibiotic use was appropriately explored only in one trial which did not show any such effect.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-01-28 17:34:53 +1000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-01-28 17:27:41 +1000" MODIFIED_BY="Liz Dooley">
<CONDITION MODIFIED="2009-08-03 08:32:27 +1000" MODIFIED_BY="[Empty name]">
<P>Infections acquired in the intensive care unit (ICU), especially pneumonia, are important complications of the treatment of critically ill patients, increasing morbidity and mortality. The incidence of pneumonia has been reported to vary from 7% to more than 40% in ICU patients (<LINK REF="REF-Chevret-1996" TYPE="REFERENCE">Chevret 1996</LINK>; <LINK REF="REF-Fagon-1996" TYPE="REFERENCE">Fagon 1996</LINK>). The mortality rate for patients with ventilator-associated pneumonia (VAP) may exceed 50%. Although not all deaths in patients with pneumonia are directly attributable to pneumonia, it has been shown to contribute to ICU mortality, independently of other factors that are also strongly associated with deaths in these patients (<A HREF="http://archie.cochrane.org/sections/documents/view?version=455EA7E882E26AA2004DD5A137699C0E&amp;format=REVMAN_GRAPHS#REF-Fagon-1996#REF-Fagon-1996">Fagon 1996</A>). In a case-controlled study an increase in mortality of 27% attributable to pneumonia was evidenced in ventilated patients (<A HREF="http://archie.cochrane.org/sections/documents/view?version=455EA7E882E26AA2004DD5A137699C0E&amp;format=REVMAN_GRAPHS#REF-Fagon-1996#REF-Fagon-1996">Fagon 1996</A>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-07-28 15:35:48 +1000" MODIFIED_BY="Clare Dooley">
<P>Considerable efforts have been made to evaluate methods for reducing respiratory tract infections (RTIs). One strategy involves the use of selective decontamination of the digestive tract (SDD). Different SDD protocols have been used in different trials and investigators often disagree on which is the most appropriate definition of SDD. Traditionally, SDD indicates a method designed to prevent infection by eradicating and preventing carriage of aerobic, potentially pathogenic micro-organisms from the oropharynx, stomach and gut. It consists of antimicrobials applied topically to the oropharynx through a nasogastric tube. In some trials systemic antibiotic therapy has been added in the first days after the patients' admission to prevent 'early' infections.</P>
</INTERVENTION>
<THEORY MODIFIED="2013-01-28 17:27:41 +1000" MODIFIED_BY="[Empty name]">
<P>The use of oral non-absorbable antibiotics was first reported by Stoutenbeek (<LINK REF="REF-Stoutenbeek-1994" TYPE="REFERENCE">Stoutenbeek 1994</LINK>) in an SDD protocol based upon a group of multiple trauma patients. The incidence of nosocomial (hospital-acquired) infection was reduced from 81% to 16% in a non-randomised comparison with an historical control group. Further studies tested the efficacy of SDD in ICU patients, with infection-related morbidity as the main endpoint. The results showed that SDD reduced infection but it was not clear whether there was a reduction in mortality.</P>
<P>Between 1991 and 2008 nine different systematic review and meta-analyses (<LINK REF="REF-D_x0027_Amico-1998" TYPE="REFERENCE">D'Amico 1998</LINK>; <LINK REF="REF-Heyland-1994" TYPE="REFERENCE">Heyland 1994</LINK>; <LINK REF="REF-Hurley-1995" TYPE="REFERENCE">Hurley 1995;</LINK> <LINK REF="REF-Kollef-1994" TYPE="REFERENCE">Kollef 1994</LINK>; <LINK REF="REF-Nathens-1999" TYPE="REFERENCE">Nathens 1999</LINK>; <LINK REF="REF-Redman-2001" TYPE="REFERENCE">Redman 2001</LINK>; <LINK REF="REF-Silvestri-2007" TYPE="REFERENCE">Silvestri 2007</LINK>; <LINK REF="REF-SDD-Group-1993" TYPE="REFERENCE">SDD Group 1993</LINK>; <LINK REF="REF-Vanderbrouk_x002d_Gra-1991" TYPE="REFERENCE">Vanderbrouk-Gra 1991</LINK>) on the effect of SDD on RTIs and mortality were published. Their results are summarised in the table below.</P>
<TABLE COLS="5" ROWS="10">
<TR>
<TD VALIGN="TOP">
<P>
<B>SR</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>N° of studies</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>N° of patients</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Mortality</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RTIs</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Vanderbrouk-Gra 1991 </B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>491</P>
</TD>
<TD VALIGN="TOP">
<P>Odds ratio (OR) 0.70<BR/>95% confidence intervals (CI) 0.45 to 1.09</P>
</TD>
<TD VALIGN="TOP">
<P>OR 0.12<BR/>95% CI 0.08 to 0.19</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>SDD Group 1993</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>4142</P>
</TD>
<TD VALIGN="TOP">
<P>OR 0.90<BR/>95% CI 0.79 to 1.04</P>
</TD>
<TD VALIGN="TOP">
<P>OR 0.37<BR/>95% CI 0.31 to 0.43</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Heyland 1994</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>3312</P>
</TD>
<TD VALIGN="TOP">
<P>Risk ratio (RR) 0.87<BR/>95% CI 0.79 to 0.97</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.46<BR/>95% CI 0.39 to 0.56</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Kollef 1994</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>2270</P>
</TD>
<TD VALIGN="TOP">
<P>Risk difference (RD) 0.019<BR/>95% CI - 0.016 to 0.054<BR/>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Pneumonia</B>
<BR/>RD 0.145<BR/>95% CI 0.116 to 0.174</P>
<P>
<B>Tracheobronchitis</B>
<BR/>RD 0.052<BR/>95% CI 0.017 to 0.087</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Hurley 1995 </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>26</P>
</TD>
<TD VALIGN="TOP">
<P>3768</P>
</TD>
<TD VALIGN="TOP">
<P>OR 0.86<BR/>95% CI 0.74 to 0.99</P>
</TD>
<TD VALIGN="TOP">
<P>OR 0.35<BR/>95% CI 0.30 to 0.42</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>D'Amico 1998</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>5727</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Topical plus systemic</B> (16 trials; 3361 pts)<BR/>OR 0.80<BR/>95% CI 0.69 to 0.93</P>
<P>
<B>Topical alone</B> (17 trials; 2366 pts)<BR/>OR 1.01<BR/>95% CI 0.84 to 1.22</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Topical plus systemic</B> (16 trials; 3361 pts)<BR/>OR 0.35<BR/>95% CI 0.29 to 0.41</P>
<P>
<B>Topical alone</B> (17 trials; 2366 pts)<BR/>OR 0.56<BR/>95% CI 0.46 to 0.68</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Nathens 1999 </B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>21</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Surgical patients</B>
<BR/>OR 0.7<BR/>95% CI 0.52 to 0.93</P>
<P>
<B>Medical patients</B>
<BR/>OR 0.91<BR/>95% CI 0.71 to 1.18</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Redman 2001 </B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Ventilator-associated pneumonia (VAP)</B>
<BR/>OR 0.36<BR/>95% CI 0.28 to 0.46</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Silvestri 2007 </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>51</P>
</TD>
<TD VALIGN="TOP">
<P>8065</P>
</TD>
<TD VALIGN="TOP">
<P>OR 0.8<BR/>95% CI 0.69 to 0.94</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
</TR>
</TABLE>
<P>All studies assessing RTIs confirmed their statistically significant reduction, though the magnitude of the treatment effect varied from one review to another probably due to different numbers of studies and inclusion criteria among them. The estimated impact on overall mortality was less evident.</P>
<P>This is an update to the previous version published in <I>The Cochrane Library</I> which included trials published up to 2003.</P>
</THEORY>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-07-28 16:00:26 +1000" MODIFIED_BY="Clare Dooley">
<P>To determine whether antibiotic prophylaxis reduces RTIs and overall mortality in adult patients treated in ICUs.<BR/>
</P>
<P>Specifically, the main question left unanswered by existing randomised controlled trials (RCTs) and previous meta-analyses was whether different forms of antibiotic prophylaxis (that is, topical antimicrobials or a combination of topical and systemic drugs) are effective in reducing overall mortality.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-01-28 17:34:53 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-01-28 17:28:21 +1000" MODIFIED_BY="Liz Dooley">
<CRIT_STUDIES MODIFIED="2009-01-14 22:17:53 +1000" MODIFIED_BY="[Empty name]">
<P>RCTs on antibiotic prophylaxis for preventing RTIs and deaths in adult ICU patients. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-07-28 17:26:02 +1000" MODIFIED_BY="Clare Dooley">
<P>Adult patients admitted to an ICU. Studies based on specific pre-selected types of patients (that is, patients undergoing elective oesophageal resection, cardiac or gastric surgery, liver transplant or suffering from acute liver failure) were excluded because these patients need co-interventions that may interact with the main treatment. Studies where the majority of patients (&gt; 50%) did not undergo mechanical ventilation for more than 48 hours were also excluded. The characteristics of excluded studies are reported in the 'Characteristics of excluded studies' table.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-07-29 10:50:44 +1000" MODIFIED_BY="[Empty name]">
<P>Available RCTs have been grouped into two categories, defined according to the type of antibiotic prophylaxis:</P>
<OL>
<LI>studies where a combination of systemic and topical antibiotics was tested against no prophylactic treatment (thereafter referred to as 'topical plus systemic versus no prophylaxis'); and</LI>
<LI>studies where the experimental treatment tested was a topical preparation applied in the oropharynx (thereafter referred to as 'topical versus control').</LI>
</OL>
<P>For further details about preparation and administration of antibiotic prophylaxis see the 'Characteristics of included studies' table.</P>
<P>In this latter category two RCT subgroups have been lumped together, that is, those where topical antibiotics were tested against an untreated control group and those where the combination of topical plus systemic drugs was compared with a protocol based on a systemic antimicrobial only.</P>
<P>Any topical or systemic antimicrobial combination (that is: type of drugs) was accepted, because there was no data to assume a difference in effect among the considered prophylactic treatments. This obviously does not mean that all topical and systemic regimens are truly equivalent, but simply reflects our pragmatic working assumption.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-01-28 17:28:21 +1000" MODIFIED_BY="Liz Dooley">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-01-28 17:28:21 +1000" MODIFIED_BY="Clare Dooley">
<P>Primary outcome measures considered for this review were RTIs and overall mortality.<BR/>
<BR/>No restriction was made on the type of RTIs considered, or on the RTIs diagnostic criteria chosen by the trialists. Both tracheobronchitis and pneumonia were acceptable. Pragmatically, both primary (diagnosed within 48 hours from admission) and acquired (diagnosed after 48 hours from admission) infections were considered, even though we used data on acquired infections (the most appropriate outcome to assess treatment effect) when both pieces of information were available. Mortality was evaluated at hospital discharge if this information was provided; otherwise mortality in ICU was used.</P>
</CRIT_OUTCOMES_PRIMARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-01-28 17:34:53 +1000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-01-28 17:34:53 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2009, issue 1); MEDLINE (January 1966 to March 2009); and EMBASE (January 1990 to March 2009).</P>
<P>MEDLINE was searched using the following search strategy in conjunction with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximising version (2008 revision); Ovid format (<LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>). The same strategy was used to search CENTRAL and adapted to search EMBASE.com (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</P>
<P>
<B>MEDLINE (Ovid)</B>
<BR/>1 exp Respiratory Tract Infections/<BR/>2 respiratory tract infection*.tw.<BR/>3 exp Pneumonia/<BR/>4 pneumon*.tw.<BR/>5 (HAP or VAP).tw.<BR/>6 bronchopneumonia*.tw.<BR/>7 pleuropneumonia*.tw.<BR/>8 exp Bronchitis/<BR/>9 bronchit*.tw.<BR/>10 bronchiolit*.tw.<BR/>11 exp Pharyngitis/<BR/>12 pharyngit*.tw.<BR/>13 Tracheitis/<BR/>14 tracheit*.tw.<BR/>15 or/1-14<BR/>16 exp Intensive Care Units/<BR/>17 icu.tw.<BR/>18 exp Critical Care/<BR/>19 critical care.tw.<BR/>20 intensive care.tw.<BR/>21 burn unit*.tw.<BR/>22 care unit*.tw.<BR/>23 recovery room*.tw.<BR/>24 Critical Illness/<BR/>25 (critic* adj ill*).tw.<BR/>26 exp Ventilators, Mechanical/<BR/>27 mechanical ventilat*.tw.<BR/>28 ventilator*.tw.<BR/>29 Respiration, Artificial/<BR/>30 artificial respiration*.tw.<BR/>31 respirator*.tw.<BR/>32 or/16-31<BR/>33 15 and 32<BR/>34 Pneumonia, Ventilator-Associated/<BR/>35 33 or 34<BR/>36 Antibiotic Prophylaxis/<BR/>37 exp Anti-Bacterial Agents/<BR/>38 antibiotic*.tw.<BR/>39 or/36-38<BR/>40 35 and 39</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-07-29 10:51:53 +1000" MODIFIED_BY="[Empty name]">
<P>There were no language or publication restrictions. We searched reference lists of articles from January 1984 to March week 1 2009 and proceedings of scientific meetings from January 1984 to April 2002. We also contacted investigators in the field. We evaluated other studies listed in previous meta-analyses. We did not make any formal enquiries through pharmaceutical companies. We stopped the search for conference proceedings after the early phase of this review in 2002 when we decided that in subsequent updates we will include new data only if reported in fully published papers.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-01-28 17:30:25 +1000" MODIFIED_BY="Liz Dooley">
<STUDY_SELECTION MODIFIED="2009-03-26 14:58:05 +1000" MODIFIED_BY="Liz Dooley">
<P>Three review authors (LB, EP, SP) independently screened the titles and abstracts of all the references retrieved by the search strategy. The full text of relevant studies were assessed independently to determine whether they met the inclusion criteria. Disagreements were resolved by discussion with the two review authors (AL, RD).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-03-26 14:58:33 +1000" MODIFIED_BY="Liz Dooley">
<P>Three review authors (LB, EP, SP) independently extracted data from all the included studies using an ad hoc extraction form. Disagreements were solved by discussion with two review authors (AL, RD).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-01-28 17:29:24 +1000" MODIFIED_BY="Liz Dooley">
<P>At least two review authors (LB, EP, SP) independently assessed the methodological validity of selected trials according to two quality criteria:</P>
<UL>
<LI>quality of randomisation procedures ('adequate' versus 'unclear, inadequate or not done' which will be referred hereafter as 'not adequate'); and</LI>
<LI>blinding of patients and doctors to allocated treatment ('double-blind' versus 'open').</LI>
</UL>
<P>We resolved outstanding issues by consensus.</P>
<P>Only RCTs were accepted in order to prevent possible selection bias. Studies including adult patients admitted to an ICU were included. Studies based on specific pre-selected types of patients (that is, patients undergoing elective oesophageal resection, cardiac or gastric surgery, liver transplant or suffering from acute liver failure) were excluded.<BR/>
</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-07-29 10:53:29 +1000" MODIFIED_BY="[Empty name]">
<P>Crude proportions of RTIs and mortality were our main treatment end-points. Odds ratios (OR) for each trial and for each outcome were calculated and they were summarised by using the fixed-effect model, whereas the random-effects model was used in cases of statistically significant heterogeneity (P = 0.1). We also computed the number of ICU patients who need to be treated in order to prevent one infection and one death. The calculation was based on the median rates of RTIs and deaths in untreated controls and the common OR for all trials.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2009-02-23 08:08:27 +1000" MODIFIED_BY="Liz Dooley">
<P>We contacted study investigators in order to obtain data for intention-to-treat analysis. In 25 out of 36 studies we obtained data on patients lost to follow-up while for the remaining 11 studies we relied on published information only. </P>
</MISSING_DATA>
<DATA_SYNTHESIS MODIFIED="2009-07-28 17:39:01 +1000" MODIFIED_BY="Clare Dooley">
<P>Results from the trials were combined using a fixed-effect model to calculate odds ratio (OR) with 95% confidence intervals (CI) for dichotomous data. In case of statistically significant heterogeneity a random-effects model was used.<BR/>
<BR/>The number needed to treat to benefit (NNTB) was calculated.<BR/>
</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2009-02-23 08:09:09 +1000" MODIFIED_BY="Liz Dooley">
<P>Two pre-specified subgroup analyses based on quality criteria were carried out within the two main groups of RCTs specified above:</P>
<UL>
<LI>quality of randomisation procedures; and</LI>
<LI>blinding of patients and doctors to allocated treatment.</LI>
</UL>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-01-28 17:32:40 +1000" MODIFIED_BY="Liz Dooley">
<STUDY_DESCRIPTION MODIFIED="2009-07-29 10:54:23 +1000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2009-03-26 14:59:51 +1000" MODIFIED_BY="Liz Dooley">
<P>Sixty potentially eligible RCTs were identified from the electronic searches.<BR/>
</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-07-29 10:54:23 +1000" MODIFIED_BY="[Empty name]">
<P>Thirty-six RCTs were finally included, all of them were published (34 as full reports and two in abstract form). Seventeen RCTs compared topical and systemic antibiotic treatment versus no treatment or placebo; 14 RCTs compared topical treatment to no treatment or placebo; and five trials compared topical and systemic antibiotic treatment versus systemic antibiotic only.</P>
<P>We included two studies (<LINK REF="STD-Gaussorgues-1991" TYPE="STUDY">Gaussorgues 1991</LINK>; <LINK REF="STD-Laggner-1994" TYPE="STUDY">Laggner 1994</LINK>) among the 'topical SDD plus systemic antibiotic versus systemic antibiotic only' group even if their design did not explicitly foresee the use of systemic antibiotics because all patients in both arms were treated with systemic antibiotics on admission. Similarly, we included the Jacobs (<LINK REF="STD-Jacobs-1992" TYPE="STUDY">Jacobs 1992</LINK>) study among the 'topical SDD plus systemic antibiotics versus control' group because more than 90% of patients received a systemic antibiotic on admission.</P>
<P>The four studies with a three-arm comparison were analysed as follows. In two studies (<LINK REF="STD-Aerdts-1991" TYPE="STUDY">Aerdts 1991</LINK>; <LINK REF="STD-Verwaest-1997" TYPE="STUDY">Verwaest 1997</LINK>) the two control groups were pooled together and compared to the treatment group. In another study (<LINK REF="STD-Lingnau-1997" TYPE="STUDY">Lingnau 1997</LINK>) we split the study into two comparisons in which two different treatment arms were compared to the same control arm. In one study (<LINK REF="STD-Palomar-1997" TYPE="STUDY">Palomar 1997</LINK>) one of the two control arms was excluded because patients received only sucralfate. Another study (<LINK REF="STD-Camus-2005" TYPE="STUDY">Camus 2005</LINK>) was a four-arm factorial design in which we considered only two arms comparing antibiotic prophylaxis versus placebo.</P>
<P>Overall, the total number of patients randomised to either antibiotic prophylaxis versus placebo or no treatment was 6914. The final meta-analysis was based upon 36 trials with 37 comparisons.</P>
<P>Two studies (<LINK REF="STD-Cerra-1992" TYPE="STUDY">Cerra 1992</LINK>; <LINK REF="STD-Gaussorgues-1991" TYPE="STUDY">Gaussorgues 1991</LINK>) could not contribute to the RTIs analysis as they reported the number of episodes of RTIs and not the number of infected patients. Moreover, one trial (<LINK REF="STD-de-Jonge-2003" TYPE="STUDY">de Jonge 2003</LINK>) did not assess RTIs as an endpoint.</P>
<P>Mortality was evaluated in ICU in 24 trials; hospital mortality was available only for six RCTs; two trials reported mortality in both ICU and hospital (<LINK REF="STD-de-Jonge-2003" TYPE="STUDY">de Jonge 2003</LINK>; <LINK REF="STD-Georges-1994" TYPE="STUDY">Georges 1994</LINK>) and the exact time of assessment of mortality was not determined in four trials (<LINK REF="STD-Cerra-1992" TYPE="STUDY">Cerra 1992</LINK>; <LINK REF="STD-Jacobs-1992" TYPE="STUDY">Jacobs 1992</LINK>; <LINK REF="STD-Kerver-1988" TYPE="STUDY">Kerver 1988</LINK>; <LINK REF="STD-Pneumatikos-2002" TYPE="STUDY">Pneumatikos 2002</LINK>).</P>
<P>Most RCTs included general ICU patients. A few trials included mostly trauma (<LINK REF="STD-Boland-1991" TYPE="STUDY">Boland 1991</LINK>; <LINK REF="STD-Georges-1994" TYPE="STUDY">Georges 1994</LINK>; <LINK REF="STD-Lingnau-1997" TYPE="STUDY">Lingnau 1997</LINK>; <LINK REF="STD-Pneumatikos-2002" TYPE="STUDY">Pneumatikos 2002</LINK>; <LINK REF="STD-Quinio-1995" TYPE="STUDY">Quinio 1995</LINK>; <LINK REF="STD-Stoutenbeek-1996" TYPE="STUDY">Stoutenbeek 1996</LINK>; <LINK REF="STD-Stoutenbeek-2007" TYPE="STUDY">Stoutenbeek 2007</LINK>) or surgical patients (<LINK REF="STD-Cerra-1992" TYPE="STUDY">Cerra 1992</LINK>; <LINK REF="STD-Krueger-2002" TYPE="STUDY">Krueger 2002</LINK>).</P>
<P>One-hundred percent of patients were mechanically ventilated in 26 studies; this percentage was lower in six trials (<LINK REF="STD-Brun_x002d_Buisson-1989" TYPE="STUDY">Brun-Buisson 1989</LINK>; <LINK REF="STD-Blair-1991" TYPE="STUDY">Blair 1991</LINK>; <LINK REF="STD-Cockerill-1992" TYPE="STUDY">Cockerill 1992</LINK>; <LINK REF="STD-de-Jonge-2003" TYPE="STUDY">de Jonge 2003</LINK>; <LINK REF="STD-Ulrich-1989" TYPE="STUDY">Ulrich 1989</LINK>; <LINK REF="STD-Winter-1992" TYPE="STUDY">Winter 1992</LINK>) and unknown in four (<LINK REF="STD-Camus-2005" TYPE="STUDY">Camus 2005</LINK>; <LINK REF="STD-Cerra-1992" TYPE="STUDY">Cerra 1992</LINK>; <LINK REF="STD-Finch-1991" TYPE="STUDY">Finch 1991</LINK>; <LINK REF="STD-Krueger-2002" TYPE="STUDY">Krueger 2002</LINK>). In Brun-Buisson's study (<LINK REF="STD-Brun_x002d_Buisson-1989" TYPE="STUDY">Brun-Buisson 1989</LINK>) the percentage of ventilated patients was very low (59%) probably because the setting of the study included both 'acute' and 'intermediate' areas of a medical ICU.</P>
<P>The percentage of immunocompromised patients was usually lower than 10%; it was higher only in four trials (<LINK REF="STD-Brun_x002d_Buisson-1989" TYPE="STUDY">Brun-Buisson 1989</LINK>; <LINK REF="STD-Finch-1991" TYPE="STUDY">Finch 1991</LINK>; <LINK REF="STD-Gastinne-1992" TYPE="STUDY">Gastinne 1992</LINK>; <LINK REF="STD-Laggner-1994" TYPE="STUDY">Laggner 1994</LINK>). Sucralfate was routinely used in all patients for stress ulcer prophylaxis in nine trials (<LINK REF="STD-Abele_x002d_Horn-1997" TYPE="STUDY">Abele-Horn 1997</LINK>; <LINK REF="STD-Bergmans-2001" TYPE="STUDY">Bergmans 2001</LINK>; <LINK REF="STD-Ferrer-1994" TYPE="STUDY">Ferrer 1994</LINK>; <LINK REF="STD-Gaussorgues-1991" TYPE="STUDY">Gaussorgues 1991</LINK>; <LINK REF="STD-Jacobs-1992" TYPE="STUDY">Jacobs 1992</LINK>; <LINK REF="STD-Krueger-2002" TYPE="STUDY">Krueger 2002</LINK>; <LINK REF="STD-Laggner-1994" TYPE="STUDY">Laggner 1994</LINK>; <LINK REF="STD-Quinio-1995" TYPE="STUDY">Quinio 1995</LINK>; <LINK REF="STD-Verwaest-1997" TYPE="STUDY">Verwaest 1997</LINK>). In many RCTs only RTIs acquired in ICU (that is, diagnosed after 48 hours from admission) were considered. Data on primary and acquired infections were considered together only in three trials (<LINK REF="STD-Boland-1991" TYPE="STUDY">Boland 1991</LINK>; <LINK REF="STD-Stoutenbeek-1996" TYPE="STUDY">Stoutenbeek 1996</LINK>; <LINK REF="STD-Stoutenbeek-2007" TYPE="STUDY">Stoutenbeek 2007</LINK>). Most studies (26 RCTs) evaluated only the occurrence of pneumonia, while seven RCTs also evaluated tracheobronchitis; information was lacking in three RCTs. Diagnostic criteria differed across trials. Few trial authors provided quantitative details on the cut-off point used as positive bacteriological confirmation.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2009-03-26 17:26:17 +1000" MODIFIED_BY="[Empty name]">
<P>Twenty-six trials were excluded (see 'Charateristics of excluded studies' table) (<LINK REF="STD-Arnow-1996" TYPE="STUDY">Arnow 1996</LINK>; <LINK REF="STD-Barret-2001" TYPE="STUDY">Barret 2001</LINK>; <LINK REF="STD-Bion-1994" TYPE="STUDY">Bion 1994</LINK>; <LINK REF="STD-Bouter-2002" TYPE="STUDY">Bouter 2002</LINK>; <LINK REF="STD-de-la-Cal-2005" TYPE="STUDY">de la Cal 2005</LINK>; <LINK REF="STD-de-Smet-2009" TYPE="STUDY">de Smet 2009</LINK>; <LINK REF="STD-Flaherty-1990" TYPE="STUDY">Flaherty 1990</LINK>; <LINK REF="STD-Garbino-2002" TYPE="STUDY">Garbino 2002</LINK>; <LINK REF="STD-Hellinger-2002" TYPE="STUDY">Hellinger 2002</LINK>; <LINK REF="STD-Hunefeld-1989" TYPE="STUDY">Hunefeld 1989</LINK>; <LINK REF="STD-Jacobs-1995" TYPE="STUDY">Jacobs 1995</LINK>; <LINK REF="STD-Lipman-1994" TYPE="STUDY">Lipman 1994</LINK>; <LINK REF="STD-Luiten-1995" TYPE="STUDY">Luiten 1995</LINK>; <LINK REF="STD-Martinez-1994" TYPE="STUDY">Martinez 1994</LINK>; <LINK REF="STD-Martinez_x002d_Pellus-1993" TYPE="STUDY">Martinez-Pellus 1993</LINK>; <LINK REF="STD-Nardi-2001" TYPE="STUDY">Nardi 2001</LINK>; <LINK REF="STD-Rayes-2002" TYPE="STUDY">Rayes 2002</LINK>; <LINK REF="STD-Rolando-1996" TYPE="STUDY">Rolando 1996</LINK>; <LINK REF="STD-Ruza-1998" TYPE="STUDY">Ruza 1998</LINK>; <LINK REF="STD-Lenhart-1994" TYPE="STUDY">Lenhart 1994</LINK>; <LINK REF="STD-Stoutenbeek-2" TYPE="STUDY">Stoutenbeek 2</LINK>; <LINK REF="STD-Schardey-1997" TYPE="STUDY">Schardey 1997</LINK>; <LINK REF="STD-Smith-1993" TYPE="STUDY">Smith 1993</LINK>; <LINK REF="STD-Tetteroo-1990" TYPE="STUDY">Tetteroo 1990</LINK>; <LINK REF="STD-Zobel-1991" TYPE="STUDY">Zobel 1991</LINK>; <LINK REF="STD-Zwaveling-2002" TYPE="STUDY">Zwaveling 2002</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-01-28 17:32:40 +1000" MODIFIED_BY="Liz Dooley">
<P>Study quality was assessed looking at two criteria. These two quality criteria were used to perform one-way subgroup analyses for two treatment comparisons (topical plus systemic versus no treatment and topical alone versus no treatment) on the two main outcomes (RTIs and overall mortality).</P>
<ALLOCATION MODIFIED="2013-01-28 17:32:00 +1000" MODIFIED_BY="Liz Dooley">
<P>A = adequate; B = unclear; C = inadequate; D = not used. Allocation concealment was evaluated according to the criteria in the <I>Cochrane Handbook for Systematic Reviews of Interventions (</I>
<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>
<I>)</I>.<BR/>
</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-01-28 17:32:04 +1000" MODIFIED_BY="Liz Dooley">
<P>Double-blind, open.</P>
</BLINDING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-07-29 10:54:43 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">RTIs</HEADING>
<P>Results from 33 RCTs including 5697 patients were available for the analysis on the effects of different types of antibiotic prophylaxis on RTIs. The frequency of RTIs was 19% among treated patients and 40% among controls in RCTs using a combination of topical plus systemic antibiotic and 20% and 31%, respectively, in RCTs testing the effectiveness of topical prophylaxis. Overall, the ORs were less than 1 in all but two trials (<LINK REF="STD-Lingnau-1997" TYPE="STUDY">Lingnau 1997</LINK>; <LINK REF="STD-Wiener-1995" TYPE="STUDY">Wiener 1995</LINK>) and reached conventional statistical significance (P &lt; 0.05) in 22/34 comparisons.</P>
<P>Since statistically significant heterogeneity was observed, a random-effects model was used to summarise study results. Results indicate a strong protective effect in RCTs where the combination of topical and systemic treatment (OR 0.28, 95% CI 0.20 to 0.38) was tested. A significant protection emerged when topical prophylaxis was considered (OR 0.44, 95% CI 0.31 to 0.63). The effect was stronger in RCTs where topical antimicrobials were tested against no prophylaxis (OR 0.34, 95% CI 0.21 to 0.55). Less extreme results were observed in trials testing the combination of topical and systemic antibiotic against systemic prophylaxis (OR 0.79, 95% CI 0.56 to 1.13). </P>
<P>These results indicate that four (95% CI 3 to 5) or seven (95% CI 6 to 12) patients need to be treated to prevent at least one infection, depending on whether a combination of topical and systemic treatment or topical antimicrobials alone were tested (assuming, as baseline risk, the median values of 46% and 27%, respectively, among control patients).</P>
<P>Regarding the pre-defined subgroup analyses, a statistically significant difference in the estimates of treatment effect was only found for quality of allocation concealment in the topical versus control comparison.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mortality</HEADING>
<P>Overall, 36 RCTs including 6,914 patients were available for the mortality analysis. The mortality was 24% among treated patients and 30% among controls on RCTs using a combination of topical plus systemic antibiotic; while it was 26% and 25% respectively in RCTs testing the effectiveness of topical SDD. The ORs were less than 1 in 26/38 comparisons but reached conventional statistical significance in three RCTs (<LINK REF="STD-de-Jonge-2003" TYPE="STUDY">de Jonge 2003</LINK>; <LINK REF="STD-Krueger-2002" TYPE="STUDY">Krueger 2002</LINK>; <LINK REF="STD-Stoutenbeek-1996" TYPE="STUDY">Stoutenbeek 1996</LINK>); no trial showed a significant harmful effect of antibiotic prophylaxis.</P>
<P>Regarding mortality no statistically significant heterogeneity was observed among study results.</P>
<P>Results indicated a statistically significant reduction in mortality attributable to the use of a combination of topical and systemic treatment (OR 0.75, 95% CI 0.65 to 0.87). This suggests that 18 patients (95% CI 12 to 36) (assuming a baseline risk of 29%, median among control patients) need to be treated to prevent one death. On the other hand, no treatment effect emerged when RCTs testing topical antimicrobials were analysed (OR 0.97; 95% CI 0.82 to 1.16).</P>
<P>The subgroup analyses produced the following results:</P>
<SUBSECTION>
<HEADING LEVEL="5">Topical versus control</HEADING>
<P>Allocation concealment: adequate (OR 0.64, 95% CI 0.27 to 1.52), not adequate (OR 0.99, 95% CI 0.83 to 1.18).<BR/>Blind design: double blind (OR 0.99, 95% CI 0.83 to 1.20), open (OR 0.88, 95% CI 0.56 to 1.37).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Topical plus systemic versus no prophylaxis</HEADING>
<P>Allocation concealment: adequate (OR 0.77, 95% CI 0.66 to 0.90), not adequate (OR 0.67, 95% CI 0.48 to 0.93).<BR/>Blind design: double blind (OR 0.63, 95% CI 0.48 to 0.83), open (OR 0.80, 95% CI 0.68 to 0.95).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-01-28 17:33:35 +1000" MODIFIED_BY="Liz Dooley">
<P>Since antibiotic prophylaxis based on SDD was introduced as a preventative measure against infection in critically ill patients, it has remained a controversial intervention (<A HREF="stoutenbeek%201994">Stoutenbeek 1994</A>). Due to the lack of a standard protocol and insufficient patient numbers, it has proved difficult to derive meaningful conclusions from individual clinical trials. Following initial enthusiasm from results of early uncontrolled studies and RCTs, antibiotic prophylaxis is not widely used as a routine treatment in ICUs. Concerns about the risk of antimicrobial resistance and increased costs are often quoted as important factors preventing its widespread adoption. A conservative attitude in introducing a new treatment into practice is understandable as long as doubts about its efficacy exist. Studies on prevention of VAP in ICU patients are complex, as patients are heterogeneous, diagnosis of pneumonia is controversial and outcomes depend upon a variety of factors. Despite the fact that antibiotic prophylaxis reduces the emergence of RTIs with remarkable consistency across individual trials, the effect on mortality was individually statistically significant in only three trials. An historical examination of review articles and editorials in this area indicates that for many years it was not fully realised that this could have been due to the small sample sizes of individual studies.</P>
<P>The meta-analysis reported here combines data across several studies in order to estimate treatment effects with more precision than is possible in a single study. The main limitation of this type of pooled analysis is that the patient population, the antibiotic regimen and the outcome definitions are not the same across studies. Nonetheless, we believe that it provides the best global picture of the effectiveness of the intervention despite some recent criticisms on the quality of primary studies and their combination (<LINK REF="REF-van-Nieuwenhove-2001" TYPE="REFERENCE">van Nieuwenhove 2001</LINK>) which we feel we have convincingly addressed (<LINK REF="REF-Liberati-2001" TYPE="REFERENCE">Liberati 2001</LINK>). Compared to the other six published meta-analyses (<LINK REF="REF-Heyland-1994" TYPE="REFERENCE">Heyland 1994</LINK>; <LINK REF="REF-Hurley-1995" TYPE="REFERENCE">Hurley 1995</LINK>; <LINK REF="REF-Kollef-1994" TYPE="REFERENCE">Kollef 1994</LINK>; <LINK REF="REF-Nathens-1999" TYPE="REFERENCE">Nathens 1999</LINK>; <LINK REF="REF-SDD-Group-1993" TYPE="REFERENCE">SDD Group 1993</LINK>; <LINK REF="REF-Vanderbrouk_x002d_Gra-1991" TYPE="REFERENCE">Vanderbrouk-Gra 1991</LINK>) we decided in our previously published review (<LINK REF="REF-D_x0027_Amico-1998" TYPE="REFERENCE">D'Amico 1998</LINK>) to analyse separately trials testing a combination of systemic and topical antibiotics and those testing topical antimicrobials. Though there is no consensus on the best way to classify antibiotic prophylaxis regimens, eventually it seemed more appropriate to consider the two groups of trials as two distinct approaches to antibiotic prophylaxis. This decision was made a priori, independently of knowing their results.</P>
<P>As already shown in our previous review (<LINK REF="REF-D_x0027_Amico-1998" TYPE="REFERENCE">D'Amico 1998</LINK>) and confirmed in this update, both types of prophylaxis have a strong protective effect on RTIs - with the effect being more marked when patients are treated with a protocol using topical plus systemic antibiotics. This effect looks consistent in all subgroup analyses, regardless of study design (adequate / not adequate allocation concealment, double-blind / open design). Overall, these results appear convincing even though it is acknowledged that no diagnostic test or procedure is ideal to diagnose RTIs in ICU patients.</P>
<P>More importantly, this updated review confirms that the use of a combination of topical and systemic antibiotics reduces overall mortality significantly. This treatment effect looks important from a clinical and public health point of view (in terms of the therapeutic implications for the care of ventilated patients in ICUs) and is also relevant from the scientific standpoint, as it suggests the future directions that research in this field should take.</P>
<P>Publication bias is unlikely to have influenced our results because we made a thorough effort to trace unpublished studies and because the vast majority of trials did not show statistically significant reduction in mortality on their own. Moreover, inspection of the relevant funnel plot for overall mortality reduction in patients receiving the combined treatment (see additional analysis, <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) does not provide evidence of publication bias. Finally, if one ranks studies by their size, larger ones are those showing a statistically significant treatment effect on their own.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-07-28 18:50:34 +1000" MODIFIED_BY="Clare Dooley">
<IMPLICATIONS_PRACTICE MODIFIED="2009-07-28 18:44:59 +1000" MODIFIED_BY="Clare Dooley">
<P>This systematic review indicates that a protocol testing a combination of topical and systemic antibiotics reduces the occurrence of RTIs and overall mortality. These results were initially obtained in an individual patient meta-analysis reported elsewhere (<LINK REF="REF-D_x0027_Amico-1998" TYPE="REFERENCE">D'Amico 1998</LINK>), which we have now updated using data reported in trials published between 1999 and 2007. The yield of the treatment expressed in terms of patients needed to be treated to prevent one infection and one death is substantial - 4 and 18 respectively - and compares very favourably with several interventions largely used in clinical practice. Though 11/17 trials used an identical regimen, including polymyxin, tobramycin and amphotericin as the topical combination and cefotaxime as the systemic component (<LINK REF="STD-Abele_x002d_Horn-1997" TYPE="STUDY">Abele-Horn 1997</LINK>; <LINK REF="STD-Blair-1991" TYPE="STUDY">Blair 1991</LINK>; <LINK REF="STD-de-Jonge-2003" TYPE="STUDY">de Jonge 2003</LINK>; <LINK REF="STD-Ferrer-1994" TYPE="STUDY">Ferrer 1994</LINK>; <LINK REF="STD-Hammond-1992" TYPE="STUDY">Hammond 1992</LINK>; <LINK REF="STD-Jacobs-1992" TYPE="STUDY">Jacobs 1992</LINK>; <LINK REF="STD-Kerver-1988" TYPE="STUDY">Kerver 1988</LINK>; <LINK REF="STD-Palomar-1997" TYPE="STUDY">Palomar 1997</LINK>; <LINK REF="STD-Rocha-1992" TYPE="STUDY">Rocha 1992</LINK>; <LINK REF="STD-Stoutenbeek-1996" TYPE="STUDY">Stoutenbeek 1996</LINK>; <LINK REF="STD-Stoutenbeek-2007" TYPE="STUDY">Stoutenbeek 2007</LINK>), this review does not allow a unique regimen to be recommended. The use of a prophylaxis testing topical antimicrobials is, on the other hand, not warranted by available data.</P>
<P>Results of this review should be carefully considered by those who have been sceptical about the effectiveness of antibiotic prophylaxis, mostly on the grounds of a potentially harmful effect in terms of antibiotic resistance (<LINK REF="REF-Collard-2003" TYPE="REFERENCE">Collard 2003</LINK>). Moreover, important new information has become available in a large randomised trial (<LINK REF="STD-de-Jonge-2003" TYPE="STUDY">de Jonge 2003</LINK>) that was the first to be formally designed to reliably assess the occurrence of antibiotic resistance by randomising ICUs rather than patients and monitoring the units for more than two years after the inception of treatment use: de Jonge et al reported that no patients were colonised with meticillin-resistant staphylococcus aureus, only 1% was colonised with vancomicin-resistant enterococcus and in 16% and 26% (in SDD and control patients, respectively) colonisation with gram negative bacteria resistant to ceftazidime, ciprofloxacin, imipenem, polymyxin E and tobramycin occurred (<LINK REF="STD-de-Jonge-2003" TYPE="STUDY">de Jonge 2003</LINK>).</P>
<P>We believe that insufficient data on cost-effectiveness and antibiotic resistance should stimulate future research rather than preventing the adoption of a seemingly effective intervention. The impact of antibiotic prophylaxis on costs has so far been evaluated only rarely and, more importantly, in an improper way (the analysis being essentially based on comparisons of lengths of stay and computation of charges due to antibiotic use). A proper economic analysis is, on the other hand, likely to be difficult in a highly specialised setting such as an ICU, given that it is hard to quantify the relative contribution of single procedures.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-07-28 18:50:34 +1000" MODIFIED_BY="Clare Dooley">
<P>The number of RCTs so far conducted on antibiotic prophylaxis is substantial and provides sufficient statistical power to detect a moderate but humanly worthwhile effect of the treatment on mortality. According to this systematic review, the combination of topical and systemic antibiotics should be the standard against which new treatments should be tested. A logical next step for future trials would be the comparison of this protocol against a regimen based on a systemic antimicrobial only; only six trials included in this review chose this as their study design. However, it is unlikely that one or more even large conventional trial can satisfy the concerns of those who are afraid that antimicrobial resistance may occur as a consequence of widespread use of antibiotics. However, the trial by de Jonge (<LINK REF="STD-de-Jonge-2003" TYPE="STUDY">de Jonge 2003</LINK>) has shown that trials with innovative designs are possible and that they allow for a more reliable assessment of the occurrence of antibiotic resistance.</P>
<P>At the current stage of development of this intervention there does not seem to be a commercial interest by pharmaceutical companies to support further trials. Similarly, the intensivists' community seems rather sceptical about the merits of the intervention and it is not willing to embark on new, properly designed and conducted studies.<BR/>
<BR/>A systematic analysis of the quality and reliability of existing data on resistance might, in this sense, be important to get a more comprehensive view of the yield of the treatment. Such a review should be carried out even though it is highly likely that the necessary harms data are not available in published trials.<BR/>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-08-04 14:26:57 +1000" MODIFIED_BY="[Empty name]">
<P>This systematic review would have not been possible without the continuous and enthusiastic support of most of the trials investigators. They collaborated in the different phases of this review up to the publication of our earlier review (<LINK REF="REF-D_x0027_Amico-1998" TYPE="REFERENCE">D'Amico 1998</LINK>) by providing information on the design and conduct of their studies, checking the accuracy of the data before the final analysis, attending a meeting where preliminary results were presented and, finally, reviewing earlier drafts of the manuscript. They are listed below:<BR/>M Abele-Horn 1997 (Ludwig-Maximilians-Universitat, Munich, Germany); SJA Aerdts 1991 (Sophia Hospital, Zwolle, The Netherlands); P Blair 1991, B J Rowlands, H Webb and K Lowry (Royal Victoria Hospital, Belfast, Northern Ireland); JP Boland 1991, D Sadler, A Stewart and J Pollock (Health Science Center Charlestone, West Virginia University, West Virginia, USA); C Brun-Buisson 1989 (Hopital Henry Mondor, Creteil, France); FB Cerra 1992 (University of Minnesota Hospital and Clinic, Minneapolis, USA); FR Cockerill 1992 and RL Thompson (Mayo Clinic, Rochester, Minnesota, USA); M Ferrer 1992 and A Torres (Servei de Pneumologia, Hospital Clinic, Barcelona, Spain); RG Finch 1991, P Tomlinson and G Rocker (Nottingham City Hospital, Nottingham, United Kingdom); H Gastinne 1992 (on behalf of the French study group on Selective Decontamination of the Digestive Tract - France); P Gaussorgues 1991 (Hopital Eduoard Herriot, Lyon, France); B Georges 1994 (Hopital de Rangueil, Toulouse, France); JMJ Hammond 1992, PD Potgieter (Groote Schuur Hospital, Cape Town, South Africa); S Jacobs (University Hospital of Wales, Cardiff, United Kingdom); S Jacobs and M Zuleika (Riyadh Armed Forces Hospital, Riyadh, Saudi Arabia); AJH Kerver 1988 (Sint Franciskus Hospital, Rotterdam, Utrecht, The Netherlands); AM Korinek 1993 (Hopital Pitie-Salpetriere, Paris, France); AN Laggner 1994 (Vienna General Hospital, Vienna, Austria); FP Lenhart 1994 (University of Munich, Germany); W Lingnau (Leopold-Franzens-Universitat Innsbruck, Innsbruck, Austria); A Martinez-Pellus and J Rodriguez-Rolda 1990 (University Hospital Virgen de la Arrixaca, El Palmar, Murcia, Spain); M Palomar 1997 (Hospital Vall d'Hebron, Barcelona, Spain); J Pugin 1991 and P Suter (University Hospital, Geneva, Switzerland); C Martin, B Quinio 1995 and J Albanese (Hopital Nord, Marseilles, France); LA Rocha 1992 (Hospital Juan Canalejo, La Coruna, Spain); M Sanchez-Garcia 1992 (Hospital PPE Asturias, Alcala de Henares, Spain); CP Stoutenbeek 1994 (Academisch Ziekenhuis, Universiteit van Amsterdam, Amsterdam, The Netherlands); C Ulrich 1989 and J E Harinck-De Weerd (Westeinde Hospital, The Hague, The Netherlands); K Unertl 1987 (Klinikum Grosshadern, Munich, Germany); J Verhaegen and C Verwaest (University Hospital Gasthuisberg, Leuven, Belgium); J Wiener 1995 (Michael Reese Hospital, Chicago, USA); R Winter 1992 (Queens Medical Centre University Hospital, Nottingham, United Kingdom).</P>
<P>This review was originally initiated at the request of the French Society of Intensive Care in preparation for the consensus conference on Selective Decontamination of the Digestive Tract (Paris, December 1991) and led to the first publication in 1993 (<LINK REF="REF-SDD-Group-1993" TYPE="REFERENCE">SDD Group 1993</LINK>). It was then continued and updated between 1993 and 1998 through resources made available from the Mario Negri Institute, Milan, Italy and an unrestricted grant provided by Hoechst Marion Roussel Italy, the sponsors had no control on the protocol preparation, data analysis and manuscript review and their support was sought after the decision of undertaking the review by the review authors. Since 2004 the review has been updated without any specific research grant attached using institutional resources of the review authors.<BR/>
<BR/>Finally, the review authors wish to thank the following referees for commenting on the 2009 updated review: Janet Wale, Tim Kenealy,<B> </B>Max Bulsara, and Jenny Doust.<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-02-12 14:43:09 +1000" MODIFIED_BY="[Empty name]">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-08-04 14:19:42 +1000" MODIFIED_BY="[Empty name]">
<P>Alessandro Liberati prepared the protocol and review, oversaw the data collection and critical appraisal of studies, updated the review and prepared the final version of the manuscript.<BR/>Roberto D'Amico prepared the protocol and review, oversaw the data collection and critical appraisal of studies, carried out the statistical analysis, updated the review and prepared the final version of the manuscript.<BR/>Luca Brazzi collaborated in the preparation of the protocol, the identification of trials and their critical appraisal.<BR/>Valter Torri collaborated in the preparation of the protocol and the statistical analysis.<BR/>Silvia Pifferi collaborated in the identification and critical appraisal of trials.<BR/>Elena Parmelli collaborated in the update of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-01-28 17:36:01 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-07-28 19:21:19 +1000" MODIFIED_BY="Clare Dooley">
<INCLUDED_STUDIES MODIFIED="2009-07-28 19:21:19 +1000" MODIFIED_BY="Clare Dooley">
<STUDY DATA_SOURCE="PUB" ID="STD-Abele_x002d_Horn-1997" MODIFIED="2009-07-28 19:10:48 +1000" MODIFIED_BY="Clare Dooley" NAME="Abele-Horn 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-07-28 19:10:48 +1000" MODIFIED_BY="Clare Dooley" NOTES="&lt;p&gt;Abele-Horn M, Dauber A, Bauernfeind A, Russwurm W, Seyfarth-Metzger I, Gleich P and Ruckdeschel G. Decrease in nosocomial pneumonia in ventilated patients by selective oropharyngeal decontamination (SOD). Intensive Care Med 1997;23:187-195.&lt;/p&gt;" NOTES_MODIFIED="2009-07-28 19:10:48 +1000" NOTES_MODIFIED_BY="Clare Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abele-Horn M, Dauber A, Bauernfeind A, Russwurm W, Seyfarth-Metzger I, Gleich P, et al</AU>
<TI>Decrease in nosocomial pneumonia in ventilated patients by selective oropharyngeal decontamination (SOD)</TI>
<SO>Intensive Care Medicine</SO>
<YR>1997</YR>
<VL>23</VL>
<NO>2</NO>
<PG>187-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Aerdts-1991" MODIFIED="2009-07-28 19:12:10 +1000" MODIFIED_BY="Clare Dooley" NAME="Aerdts 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-07-28 19:12:10 +1000" MODIFIED_BY="Clare Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aerdts SJA, van Dalen R, Clasener HAL, Festen J, van Lier HJJ, Vollaard EJ</AU>
<TI>Antibiotic prophylaxis of respiratory tract infection in mechanically ventilated patients</TI>
<SO>Chest</SO>
<YR>1991</YR>
<VL>100</VL>
<NO>3</NO>
<PG>783-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergmans-2001" MODIFIED="2009-07-28 19:13:21 +1000" MODIFIED_BY="Clare Dooley" NAME="Bergmans 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-07-28 19:13:21 +1000" MODIFIED_BY="Clare Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergmans DCJJ, Bonten MJM, Gailard CA, Paling JC, van der Geest S, van Tiel FH, et al</AU>
<TI>Prevention of ventilator-associated pneumonia by oral decontamination: a prospective randomized, double blind, placebo controlled study</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2001</YR>
<VL>164</VL>
<NO>3</NO>
<PG>382-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Blair-1991" MODIFIED="2009-07-28 19:14:18 +1000" MODIFIED_BY="Clare Dooley" NAME="Blair 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-07-28 19:14:18 +1000" MODIFIED_BY="Clare Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blair P, Rowlands BJ, Lowry K, Webb H, Amstrong P, Smilie J</AU>
<TI>Selective decontamination of the digestive tract: a stratified, randomized, prospective study in a mixed intensive care unit</TI>
<SO>Surgery</SO>
<YR>1991</YR>
<VL>110</VL>
<NO>2</NO>
<PG>303-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Boland-1991" NAME="Boland 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Boland JP, Sadler DL, Stewart W, Wood DJ, Zerick W, Snodgrass KR. Reduction of nosocomial respiratory tract infections in the multiple trauma patients requiring mechanical ventilation by selective parenteral and enteral antisepsis regimen (SPEAR) in the intensive care. [Abstract] Berlin: XVII Congress of Chemotherapy,1991. [0465]&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Boland JP, Sadler DL, Stewart W, Wood DJ, Zerick W, Snodgrass KR</AU>
<TI>Reduction of nosocomial respiratory tract infections in the multiple trauma patients requiring mechanical ventilation by selective parenteral and enteral antisepsis regimen (SPEAR) in the intensive care</TI>
<SO>XVII Congress of Chemotherapy</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Brun_x002d_Buisson-1989" MODIFIED="2009-07-28 19:15:53 +1000" MODIFIED_BY="Clare Dooley" NAME="Brun-Buisson 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-07-28 19:15:53 +1000" MODIFIED_BY="Clare Dooley" NOTES="&lt;p&gt;Brun-Buisson C, Legrand P, Rauss A, Richard C, Montravers F, Besbes M, et al. Intestinal decontamination for control of nosocomial multiresistant Gram-negative bacilli. Ann Intern Med 1989;110:873-81.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-07-28 19:15:53 +1000" NOTES_MODIFIED_BY="Clare Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brun-Buisson C, Legrand P, Rauss A, Richard C, Montravers F, Besbes M, et al</AU>
<TI>Intestinal decontamination for control of nosocomial multiresistant Gram-negative bacilli</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1989</YR>
<VL>110</VL>
<NO>11</NO>
<PG>873-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Camus-2005" MODIFIED="2009-01-06 07:29:07 +1000" MODIFIED_BY="Liz Dooley" NAME="Camus 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-06 07:29:07 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Camus C, Bellissant E, Sebille W, Perrotin D, Garo B, Legras A, et al</AU>
<TI>Prevention of acquired infections in intubated patients with combination of two decontaminations regimens</TI>
<SO>Critical Care Medicine</SO>
<YR>2005</YR>
<VL>33</VL>
<NO>2</NO>
<PG>307-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Cerra-1992" MODIFIED="2009-07-28 19:17:42 +1000" MODIFIED_BY="Clare Dooley" NAME="Cerra 1992" YEAR="1992">
<REFERENCE MODIFIED="2009-07-28 19:17:42 +1000" MODIFIED_BY="Clare Dooley" NOTES="&lt;p&gt;Cerra FB, Maddaus MA, Dunn DL, Wells CL, Konstantinides NN, Lehmann SL, et al. Selective gut decontamination reduces nosocomial infections and length of stay but not mortality or organ failure in surgical intensive care unit patients. Arch Surg 1992;127:163-9.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-07-28 19:17:42 +1000" NOTES_MODIFIED_BY="Clare Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cerra FB, Maddaus MA, Dunn DL, Wells CL, Konstantinides NN, Lehmann SL, et al</AU>
<TI>Selective gut decontamination reduces nosocomial infections and length of stay but not mortality or organ failure in surgical intensive care unit patients</TI>
<SO>Archives of Surgery</SO>
<YR>1992</YR>
<VL>127</VL>
<NO>2</NO>
<PG>163-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Cockerill-1992" MODIFIED="2009-07-28 19:20:15 +1000" MODIFIED_BY="Clare Dooley" NAME="Cockerill 1992" YEAR="1992">
<REFERENCE MODIFIED="2009-07-28 19:20:15 +1000" MODIFIED_BY="Clare Dooley" NOTES="&lt;p&gt;Cockerill FR III, Muller SR, Anhalt JP, Marsh HM, Farnell MB, Mucha P, et al. Prevention of infection in critically ill patients by selective decontamination of the digestive tract. Ann Intern Med 1992;117:545-53.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-07-28 19:20:15 +1000" NOTES_MODIFIED_BY="Clare Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cockerill FR III, Muller SR, Anhalt JP, Marsh HM, Farnell MB, Mucha P, et al</AU>
<TI>Prevention of infection in critically ill patients by selective decontamination of the digestive tract</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1992</YR>
<VL>117</VL>
<NO>7</NO>
<PG>545-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Jonge-2003" MODIFIED="2009-07-28 19:21:19 +1000" MODIFIED_BY="Clare Dooley" NAME="de Jonge 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-28 19:21:19 +1000" MODIFIED_BY="Clare Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Jonge E, Schultz JM, Spanjaard L, Bossuyt PMM, Vroom MB, Dankert J, et al</AU>
<TI>Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>362</VL>
<NO>9389</NO>
<PG>1011-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Ferrer-1994" MODIFIED="2008-04-12 01:42:54 +1000" MODIFIED_BY="[Empty name]" NAME="Ferrer 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-02-07 14:33:35 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ferrer M, Torres A, Gonz&amp;#224;les J, de la Bellacasa JP, El-Ebiary M, Roca M, et al. Utility of selective digestive decontamination in mechanically ventilated patients. Ann Intern Med 1994;120:389-95.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-02-07 14:33:35 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferrer M, Torres A, Gonzàles J, de la Bellacasa JP, El-Ebiary M, Roca M, et al</AU>
<TI>Utility of selective digestive decontamination in mechanically ventilated patients</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1994</YR>
<VL>120</VL>
<PG>389-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Finch-1991" NAME="Finch 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Finch RG, Tomlinson P, Holliday M, Sole K, Stack C, Rocker G. Selective decontamination of the digestive tract (SDD) in the prevention of secondary sepsis in a medical/surgical intensive care unit. [Abstract] Berlin: XVII International Congress Chemotherapy,1991.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Finch RG, Tomlinson P, Holliday M, Sole K, Stack C, Rocker G</AU>
<TI>Selective decontamination of the digestive tract (SDD) in the prevention of secondary sepsis in a medical/surgical intensive care unit</TI>
<SO>XVII International Congress Chemotherapy</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Gastinne-1992" NAME="Gastinne 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Gastinne H, Wolff M, Delatour F, Faurisson F, Chevret S. A controlled trial in intensive care units of selective decontamination of the digestive tract with nonabsorbable antibiotics. N Engl J Med 1992;326:594-9.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gastinne H, Wolff M, Delatour F, Faurisson F, Chevret S</AU>
<TI>A controlled trial in intensive care units of selective decontamination of the digestive tract with nonabsorbable antibiotics</TI>
<SO>New England Journal of Medicine</SO>
<YR>1992</YR>
<VL>326</VL>
<PG>594-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Gaussorgues-1991" MODIFIED="2009-01-06 07:31:44 +1000" MODIFIED_BY="Liz Dooley" NAME="Gaussorgues 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-01-06 07:31:44 +1000" MODIFIED_BY="Liz Dooley" NOTES="&lt;p&gt;Gaussorgues P, Salord F, Sirodot M, Tigaud S, Cagnin S,&lt;br&gt;Gerard M, et al. Efficacit&amp;#233; de la d&amp;#233;contamination digestive sur la survenue des bact&amp;#233;ri&amp;#233;mies nosocomiales chez les patients sous ventilation m&amp;#233;canique et recevant des betamim&amp;#233;tiques. R&amp;#233;an Soins Intens M&amp;#233;d Urg 1991;7:169-74.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-01-06 07:31:44 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaussorgues P, Salord F, Sirodot M, Tigaud S, Cagnin S, Gerard M, et al</AU>
<TO>Efficacité de la décontamination digestive sur la survenue des bactériémies nosocomiales chez les patients sous ventilation mécanique et recevant des betamimétiques</TO>
<SO>Reanimation, Soins Intensifs, Medicine d'Urgence</SO>
<YR>1991</YR>
<VL>7</VL>
<PG>169-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Georges-1994" MODIFIED="2009-01-06 07:31:57 +1000" MODIFIED_BY="Liz Dooley" NAME="Georges 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-01-06 07:31:57 +1000" MODIFIED_BY="Liz Dooley" NOTES="&lt;p&gt;Georges B, Mazerolles M, Decun JF, Rouge P, Pomies S, Cougot P, et al. D&amp;#233;contamination digestive s&amp;#233;lective r&amp;#233;sultats d'une &amp;#232;tude chez le polytraumatis&amp;#233;. R&amp;#233;an Urg 1994;3:621-627.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-01-06 07:31:57 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Georges B, Mazerolles M, Decun JF, Rouge P, Pomies S, Cougot P, et al</AU>
<TO>Décontamination digestive sélective résultats d'une ètude chez le polytraumatisé</TO>
<SO>Reanimation d'Urgence</SO>
<YR>1994</YR>
<VL>3</VL>
<PG>621-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Hammond-1992" NAME="Hammond 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hammond JMJ, Potgieter PD, Saunders GL, Forder AA</AU>
<TI>Double blind study of selective decontamination of the digestive tract in intensive care</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>340</VL>
<PG>5-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Jacobs-1992" NAME="Jacobs 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Jacobs S, Foweraker JE, Roberts SE. Effectiveness of selective decontamination of the digestive tract (SDD) in an ICU with a policy encouraging a low gastric pH. Clin Intens Med 1992;3:52-8.&lt;br&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs S, Foweraker JE, Roberts SE</AU>
<TI>Effectiveness of selective decontamination of the digestive tract (SDD) in an ICU with a policy encouraging a low gastric pH</TI>
<SO>Clinical Intensive Care</SO>
<YR>1992</YR>
<VL>3</VL>
<PG>52-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kerver-1988" MODIFIED="2008-02-07 14:34:42 +1000" MODIFIED_BY="[Empty name]" NAME="Kerver 1988" YEAR="1988">
<REFERENCE MODIFIED="2008-02-07 14:34:42 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Kerver AJH, Rommes JH, Mevissen-Verhage EAE, Hulstaert PF, Vos A, Verhoef J, et al. Prevention of colonization and infection in critically ill patients: A prospective randomized study. Crit Care Med 1988;16:1087.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-02-07 14:34:42 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kerver AJH, Rommes JH, Mevissen-Verhage EAE, Hulstaert PF, Vos A, Verhoef J, et al</AU>
<TI>Prevention of colonization and infection in critically ill patients: A prospective randomized study</TI>
<SO>Critical Care Medicine</SO>
<YR>1988</YR>
<VL>16</VL>
<PG>1087</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Korinek-1993" NAME="Korinek 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Korinek AM, Laisne MJ, Raskine L, Deroin V, Sanson-Lepors MJ. Selective decontamination of the digestive tract in neurosurgical care units patients: a double blind, randomized, placebo-controlled study. Crit Care Med 1993;21:1466-73.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Korinek AM, Laisne MJ, Raskine L, Deroin V, Sanson-Lepors MJ</AU>
<TI>Selective decontamination of the digestive tract in neurosurgical care units patients: a double blind, randomized, placebo-controlled study</TI>
<SO>Critical Care Medicine</SO>
<YR>1993</YR>
<VL>21</VL>
<PG>1466-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krueger-2002" MODIFIED="2008-02-07 14:44:54 +1000" MODIFIED_BY="[Empty name]" NAME="Krueger 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-02-07 14:44:54 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krueger WA, Lenhart FP, Neeser G, Ruckdeschel G, Schreckhase H, Eissner HJ, et al</AU>
<TI>Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions and mortality in critically ill surgical patients</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>166</VL>
<PG>1029-37</PG>
<CY>Vienna</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Laggner-1994" MODIFIED="2008-02-07 14:45:14 +1000" MODIFIED_BY="[Empty name]" NAME="Laggner 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-02-07 14:45:14 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Laggner AN, Tryba M, Georgopoulos A, Lenz K, Grimm G, Graninger W, et al. Oropharyngeal decontamination with gentamicin for long-term ventilated patients on stress ulcer prophylaxis with sucralfate? Wien Klin Wochenschr 1994;106:15-19.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-02-07 14:45:14 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laggner AN, Tryba M, Georgopoulos A, Lenz K, Grimm G, Graninger W, et al</AU>
<TI>Oropharyngeal decontamination with gentamicin for long-term ventilated patients on stress ulcer prophylaxis with sucralfate?</TI>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>1994</YR>
<VL>106</VL>
<PG>15-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Lingnau-1997" NAME="Lingnau 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Lingnau W, Berger J, Javorsky F, Lejeune P, Mutz N, Benzer H. Selective intestinal decontamination in multiple trauma patients: prospective, controlled trials. J Trauma 1997;42:687-694.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lingnau W, Berger J, Javorsky F, Lejeune P, Mutz N, Benzer H</AU>
<TI>Selective intestinal decontamination in multiple trauma patients: prospective, controlled trials</TI>
<SO>Journal of Trauma</SO>
<YR>1997</YR>
<VL>42</VL>
<PG>687-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Lingnau-1997b" NAME="Lingnau 1997b" YEAR="1997b">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lingnau W, Berger J, Javorsky F, Lejeune P, Mutz N, Benzer H</AU>
<TI>Selective intestinal decontamination in multiple trauma patients: prospective, controlled trials</TI>
<SO>Journal of Trauma</SO>
<YR>1997</YR>
<VL>42</VL>
<PG>687-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Palomar-1997" NAME="Palomar 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Palomar M, Alvarez-Lerma F, Jorda R, Bermejo B</AU>
<TI>Prevention of nosocomial infection in mechanically ventilated patients: Selective digestive decontamination versus sucralfate</TI>
<SO>Clinical Intensive Care</SO>
<YR>1997</YR>
<VL>8</VL>
<PG>228-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pneumatikos-2002" NAME="Pneumatikos 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pneumatikos I, Koulouras V, Nathanail C, Goe D, Nakos G</AU>
<TI>Selective decontamination of subgloottic area in mechanically ventilated patients with multiple trauma</TI>
<SO>Intensive Care Medicine</SO>
<YR>2002</YR>
<VL>28</VL>
<PG>432-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Pugin-1991" NAME="Pugin 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pugin J, Auckenthaler R, Lew DP, Suter PM</AU>
<TI>Oropharyngeal decontamination decreases incidence of ventilator-associated pneumonia</TI>
<SO>JAMA</SO>
<YR>1991</YR>
<VL>265</VL>
<PG>2704-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Quinio-1995" NAME="Quinio 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quinio B, Albanèse J, Bues-Charbit M, Viviand X, Martin C</AU>
<TI>Selective Decontamination of the digestive tract in multiple trauma patients: prospective, double blind, randomised, placebo-controlled study</TI>
<SO>Chest</SO>
<YR>1996</YR>
<VL>109</VL>
<PG>765-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rocha-1992" MODIFIED="2008-02-07 14:46:44 +1000" MODIFIED_BY="[Empty name]" NAME="Rocha 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-02-07 14:46:44 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Rocha LA, Martin MJ, Pita S, Paz J, Seco C, Margusino L, et al. Prevention of nosocomial infection in critically ill patients by selective decontamination of digestive tract. Intensive Care Med 1992;18:398-404.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-02-07 14:46:44 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rocha LA, Martin MJ, Pita S, Paz J, Seco C, Margusino L, et al</AU>
<TI>Prevention of nosocomial infection in critically ill patients by selective decontamination of digestive tract</TI>
<SO>Intensive Care Medicine</SO>
<YR>1992</YR>
<VL>18</VL>
<PG>398-404</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rodriguez_x002d_Rolda-1990" MODIFIED="2008-02-07 14:46:50 +1000" MODIFIED_BY="[Empty name]" NAME="Rodriguez-Rolda 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-02-07 14:46:50 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Rodr&amp;#236;guez-Rold&amp;#224;n JM, Altuna-Cuesta A, L&amp;#242;pez A, Carrillo A, Garcia J, Le&amp;#242;n J, Mart&amp;#236;nez-Pell&amp;#249;s AJ. Prevention of nosocomial lung infection in ventilated patients:use of an antimicrobial pharyngeal nonabsorbable paste. Crit Care Med 1990;18:1239-42.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-02-07 14:46:50 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodrìguez-Roldàn JM, Altuna-Cuesta A, Lòpez A, Carrillo A, Garcia J, Leòn J, et al</AU>
<TI>Prevention of nosocomial lung infection in ventilated patients:use of an antimicrobial pharyngeal nonabsorbable paste</TI>
<SO>Critical Care Medicine</SO>
<YR>1990</YR>
<VL>18</VL>
<PG>1239-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sanchez_x002d_Garcia-1992" MODIFIED="2008-02-07 14:47:10 +1000" MODIFIED_BY="[Empty name]" NAME="Sanchez-Garcia 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-02-07 14:47:10 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez-Garcia M, Cambronero JA, Lopez J, Cerda E, Rubio J, et al</AU>
<TI>Effectiveness and cost of selective decontamination of the digestive tract (SDD) in critically ill intubated patients. A randomized, double blind, placebo-controlled, multicentric trial</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1998</YR>
<VL>158</VL>
<PG>908-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stoutenbeek-1996" MODIFIED="2008-02-07 14:47:35 +1000" MODIFIED_BY="[Empty name]" NAME="Stoutenbeek 1996" YEAR="1984">
<REFERENCE MODIFIED="2008-02-07 14:47:35 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Stoutenbeek CP, Van Saene HKF, Zandstra DF. Prevention of multiple organ failure by selective decontamination of the digestive tract in multiple trauma patients. In: Immune consequences of trauma, shock and sepsis. Mechanisms and therapeutic approaches eds; Faist E, Baue AE, Schildberg FW. Pabst Science Publishers, Berlin, 1996;2:1055-66.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-02-07 14:47:35 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stoutenbeek CP, Van Saene HKF, Miranda D R, Zandstra DF</AU>
<TI>The effect of selective decontamination of the digestive tract on colonization and infection rate in multiple trauma patients</TI>
<SO>Intensive Care Medicine</SO>
<YR>1984</YR>
<VL>10</VL>
<PG>185-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stoutenbeek-2007" MODIFIED="2009-01-06 07:55:29 +1000" MODIFIED_BY="Liz Dooley" NAME="Stoutenbeek 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-01-06 07:55:29 +1000" MODIFIED_BY="Liz Dooley" NOTES="&lt;p&gt;Stoutenbeek CP (unpublished)&lt;/p&gt;" NOTES_MODIFIED="2009-01-06 07:55:29 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stoutenbeek CP, Van Saene HKF, Little RA , Whitehead A</AU>
<TI>The effect of selective decontamination on the digestive tract on mortality in multiple trauma patients: a multicentre randomized controlled trial</TI>
<SO>Intensive Care Medicine</SO>
<YR>2007</YR>
<VL>33</VL>
<PG>261-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Ulrich-1989" MODIFIED="2008-02-07 14:49:41 +1000" MODIFIED_BY="[Empty name]" NAME="Ulrich 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-02-07 14:49:41 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ulrich C, Harinck-deWeerd JE, Bakker NC, Jacz K, Doornbos L,&lt;br&gt;de Ridder VA. Selective decontamination of the digestive tract with norfloxacin in the prevention of ICU-acquired infections: a prospective randomized study. Intensive Care Med 1989;15:424-31.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-02-07 14:49:41 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ulrich C, Harinck-deWeerd JE, Bakker NC, Jacz K, Doornbos L, de Ridder VA</AU>
<TI>Selective decontamination of the digestive tract with norfloxacin in the prevention of ICU-acquired infections: a prospective randomized study</TI>
<SO>Intensive Care Medicine</SO>
<YR>1989</YR>
<VL>15</VL>
<PG>424-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Unertl-1987" MODIFIED="2009-01-06 07:56:05 +1000" MODIFIED_BY="Liz Dooley" NAME="Unertl 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-01-06 07:56:05 +1000" MODIFIED_BY="Liz Dooley" NOTES="&lt;p&gt;Unertl K, Ruckdeschel G, Selbmann HK, Jensen U, Forst H, Lenhart FP, et al. Prevention of colonization and respiratory infections in long term ventilated patients by local antimicrobial prophylaxis. Intensive Care Med 1987;13:106-13.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-01-06 07:56:05 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Unertl K, Ruckdeschel G, Selbmann HK, Jensen U, Forst H, Lenhart FP, et al</AU>
<TI>Prevention of colonization and respiratory infections in long term ventilated patients by local antimicrobial prophylaxis</TI>
<SO>Intensive Care Medicine</SO>
<YR>1987</YR>
<VL>13</VL>
<PG>106-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Verwaest-1997" MODIFIED="2008-02-07 14:50:09 +1000" MODIFIED_BY="[Empty name]" NAME="Verwaest 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-02-07 14:50:09 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Verwaest C, Verhaegen J, Ferdinande P, Schets M, Van der Berghe G, Verbist L, et al. Randomized, controlled trial of selective digestive decontamination in 600 mechanically ventilated patients in a multidisciplinary intensive care unit. Crit Care Med 1997;25:63-71.&lt;/p&gt;" NOTES_MODIFIED="2008-02-07 14:50:09 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verwaest C, Verhaegen J, Ferdinande P, Schets M, Van der Berghe G, Verbist L, et al</AU>
<TI>Randomized, controlled trial of selective digestive decontamination in 600 mechanically ventilated patients in a multidisciplinary intensive care unit</TI>
<SO>Critical Care Medicine</SO>
<YR>1997</YR>
<VL>25</VL>
<PG>63-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiener-1995" NAME="Wiener 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Wiener J, Itokazu G, Nothan C, Kabins SA, Weinstein RA. A randomized, double-blind, placebo-controlled trial of selective digestive decontamination in a medical-surgical intensive care unit. Clin Infect Dis 1995;20:861-7.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiener J, Itokazu G, Nothan C, Kabins SA, Weinstein RA</AU>
<TI>A randomized, double-blind, placebo-controlled trial of selective digestive decontamination in a medical-surgical intensive care unit</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1995</YR>
<VL>20</VL>
<PG>861-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Winter-1992" NAME="Winter 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Winter R, Humphreys H, Pick A, MacGowan AP, Willatts SM, Speller DCE. A controlled trials of selective decontamination of the digestive tract in intensive care and its effect on nosocomial infection. J Antimicrob Chemother 1992;30:73-87.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winter R, Humphreys H, Pick A, MacGowan AP, Willatts SM, Speller DCE</AU>
<TI>A controlled trials of selective decontamination of the digestive tract in intensive care and its effect on nosocomial infection</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1992</YR>
<VL>30</VL>
<PG>73-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-03-26 17:19:30 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Arnow-1996" MODIFIED="2009-01-06 07:56:55 +1000" MODIFIED_BY="Liz Dooley" NAME="Arnow 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-01-06 07:56:55 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arnow PM, Carandanq GC, Irwin ME</AU>
<TI>Randomized controlled trial of selective bowel decontamination for prevention of infections following liver transplantation</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1996</YR>
<VL>22</VL>
<PG>997-1003</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barret-2001" MODIFIED="2009-03-26 17:19:30 +1000" MODIFIED_BY="[Empty name]" NAME="Barret 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barret JP, Jeschke MG, Herndon DN</AU>
<TI>Selective decontamination of the digestive tract in severely burned pediatric patients</TI>
<SO>Burns</SO>
<YR>2001</YR>
<VL>27</VL>
<PG>439-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bion-1994" MODIFIED="2008-02-07 14:52:11 +1000" MODIFIED_BY="[Empty name]" NAME="Bion 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-02-07 14:52:11 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Bion JF, Badger I, Crosby HA, Hutchings P, Kong KL, Baker J, et al. Selective decontamination of the digestive tract reduces Gram-negative pulmonary colonization but not systemic endotoxemia in patients undergoing elective liver transplantation. Crit Care Med 1994;22:40-9.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-02-07 14:52:11 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bion JF, Badger I, Crosby HA, Hutchings P, Kong KL, Baker J, et al</AU>
<TI>Selective decontamination of the digestive tract reduces Gram-negative pulmonary colonization but not systemic endotoxemia in patients undergoing elective liver transplantation</TI>
<SO>Critical Care Medicine</SO>
<YR>1994</YR>
<VL>22</VL>
<PG>40-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bouter-2002" MODIFIED="2008-02-07 14:53:09 +1000" MODIFIED_BY="[Empty name]" NAME="Bouter 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-02-07 14:53:09 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bouter H, Schippers EF, Luelmo SAC, Verteegh MIM, et al</AU>
<TI>No effect of preoperative selective gut decontamination on endotoxemia and cytokine activation during cardiopulmonary bypass: A randomized, placebo controlled study</TI>
<SO>Critical Care Medicine</SO>
<YR>2002</YR>
<VL>30</VL>
<PG>38-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-la-Cal-2005" MODIFIED="2009-01-06 07:57:46 +1000" MODIFIED_BY="Liz Dooley" NAME="de la Cal 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-06 07:57:46 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de la Cal MA, Cerdà E, Garcia-Hierro P, et al</AU>
<TI>Survival benefit in critically hill burned patients receiving selective decontamination of the digestive tract. A randomized, placebo-controlled, double-blind trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1992</YR>
<VL>117</VL>
<PG>545-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Smet-2009" MODIFIED="2009-03-26 15:06:08 +1000" MODIFIED_BY="Liz Dooley" NAME="de Smet 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-03-26 15:06:08 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Smet AMGA, Kluytmans JAJW, Cooper BS, Mascini EM, Benus RFJ, van der Werf TS, et al</AU>
<TI>Decontamination of the digestive tract and oropharynx in ICU patients</TI>
<SO>NEJM</SO>
<YR>2009</YR>
<VL>360</VL>
<PG>20-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flaherty-1990" NAME="Flaherty 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Flaherty J, Nathan C, Kabins SA, Weinstein RA. Pilot trial of selective decontamination for prevention of bacterial infection in an intensive care unit. J Infect Dis 1990;162:1393-7.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flaherty J, Nathan C, Kabins SA, Weinstein RA</AU>
<TI>Pilot trial of selective decontamination for prevention of bacterial infection in an intensive care unit</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1990</YR>
<VL>162</VL>
<PG>1393-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garbino-2002" NAME="Garbino 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garbino J, Lew DP, Romand JA, Hogonnet S, Auckenthaler R, Pittet D</AU>
<TI>Prevention of severe candida infections in nonneutropenic high risk, crically ill patients: a randomized, double blinded, placebo controlled trial in patients treated by severe digestive decontamination</TI>
<SO>Intensive Care Medicine</SO>
<YR>2002</YR>
<VL>28</VL>
<PG>1708-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hellinger-2002" MODIFIED="2008-02-07 14:53:59 +1000" MODIFIED_BY="[Empty name]" NAME="Hellinger 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-02-07 14:53:59 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hellinger WC, Yao JD, Alvarez S, Blair JE, et al</AU>
<TI>A randomized, prospective, double blinded evaluation of selective bowel decontamination in liver transplantation</TI>
<SO>Transplantation</SO>
<YR>2002</YR>
<VL>73</VL>
<PG>1904-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Hunefeld-1989" NAME="Hunefeld 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Hunefeldt G. Klinische Studie zur selectiven Darmdekolonisation bei 204 langzeitbeatmeten abdominal und unfallchirurgischen&lt;br&gt;Intensivpatienten. Anaesthesiol Reanim 1989;14:131-153.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hunefeldt G</AU>
<TO>Klinische Studie zur selectiven Darmdekolonisation bei 204 langzeitbeatmeten abdominal und unfallchirurgischen Intensivpatienten</TO>
<SO>Anaesthesiologie und Reanimation</SO>
<YR>1989</YR>
<VL>14</VL>
<PG>131-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Jacobs-1995" MODIFIED="2009-01-14 00:22:23 +1000" MODIFIED_BY="[Empty name]" NAME="Jacobs 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-01-14 00:22:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Jacobs S, Zuleika M</AU>
<TI>no title</TI>
<SO>provided by the authors</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lenhart-1994" MODIFIED="2009-01-06 07:59:12 +1000" MODIFIED_BY="Liz Dooley" NAME="Lenhart 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-01-06 07:59:12 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lenhart FP, Unertl K, Neeser G, Ruckdeschel G, Eckart J, Peter K</AU>
<TI>Selective decontamination and sucralfate for prevention of acquired infections in intensive care</TI>
<SO>17th International Congress Chemotherapy, Vienna 1994 (K101)</SO>
<YR>1994</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Lipman-1994" MODIFIED="2009-02-23 07:49:04 +1000" MODIFIED_BY="Liz Dooley" NAME="Lipman 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-02-23 07:49:04 +1000" MODIFIED_BY="Liz Dooley" NOTES="&lt;p&gt;Lipman J, Klugman K, Luyt D, Kraus P, Litmanovitch M, Johnson D, et al. Unique trial design shows SDD to decrease and alter colonization of upper respiractory tract in a multidisciplinary ICU. [Abstract] Crit Care Med .[141].&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-02-23 07:49:04 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lipman J, Klugman K, Luyt D, Kraus P, Litmanovitch M, Johnson D, et al</AU>
<TI>Unique trial design shows SDD to decrease and alter colonization of upper respiractory tract in a multidisciplinary ICU</TI>
<SO>Critical Care Medicine</SO>
<YR>1994</YR>
<VL>22</VL>
<PG>1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luiten-1995" NAME="Luiten 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Luiten EJ, Hop WC, Lange JF, Bruining HA. Controlled clinical trial of selective decontamination for the treatment of severe acute pancreatitis. Ann Surg 1995;222:57-65.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luiten EJ, Hop WC, Lange JF, Bruining HA</AU>
<TI>Controlled clinical trial of selective decontamination for the treatment of severe acute pancreatitis</TI>
<SO>Annals of Surgery</SO>
<YR>1995</YR>
<VL>222</VL>
<PG>57-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinez-1994" NAME="Martinez 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Martinez PAE, Bru M, Jara P, Ruiz J, Sanmiguel MT, Garcia PT</AU>
<TI>Does cefotaxime prevent early pneumonia in trauma patients receiving pharyngeal decontamination?</TI>
<SO>Medicina Intensiva</SO>
<YR>1994</YR>
<VL>18</VL>
<PG>245-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinez_x002d_Pellus-1993" MODIFIED="2008-02-07 14:56:19 +1000" MODIFIED_BY="[Empty name]" NAME="Martinez-Pellus 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-02-07 14:56:19 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Martinez-Pellus AE, Merino P, Bru M, Coneyero R, Seller G, Munoz C, et al. Can selective digestive decontamination avoid the endotoxemia and cytokine activation promoted by cardiopulmonary bypass? Crit Care Med 1993;2:1684-91.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-02-07 14:56:19 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinez-Pellus AE, Merino P, Bru M, Coneyero R, Seller G, Munoz C, et al</AU>
<TI>Can selective digestive decontamination avoid the endotoxemia and cytokine activation promoted by cardiopulmonary bypass?</TI>
<SO>Critical Care Medicine</SO>
<YR>1993</YR>
<VL>2</VL>
<PG>1684-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nardi-2001" MODIFIED="2008-02-07 14:58:43 +1000" MODIFIED_BY="[Empty name]" NAME="Nardi 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-02-07 14:58:43 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nardi G, Di Silvestre A, De Monte A, Massarutti D, Proietti A, Grazia Troncon M, et al</AU>
<TI>Reduction in gram positive pneumonia and antibiotic consumption following the use of a SDD protocol including nasal nad oral mupirocin</TI>
<SO>European Journal of Emergency Medicine</SO>
<YR>2001</YR>
<VL>8</VL>
<PG>203-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rayes-2002" MODIFIED="2008-02-07 14:59:05 +1000" MODIFIED_BY="[Empty name]" NAME="Rayes 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-02-07 14:59:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rayes N, Seehofer D, Hansen S, Boucsein K, et al</AU>
<TI>Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients</TI>
<SO>Transplatation</SO>
<YR>2002</YR>
<VL>74</VL>
<PG>123-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rolando-1996" MODIFIED="2008-02-07 14:59:12 +1000" MODIFIED_BY="[Empty name]" NAME="Rolando 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-02-07 14:59:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rolando N, Wade J, Stangou A, Gimson AE, Wendon J, Philpott-Howard J, et al</AU>
<TI>Prospective study comparing the efficacy of prophylactic parenteral antimicrobials, with or without enteral decontamination, in patients with acute liver failure</TI>
<SO>Liver Transplantation and Surgery</SO>
<YR>1996</YR>
<VL>2</VL>
<PG>8-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruza-1998" MODIFIED="2008-02-07 15:03:19 +1000" MODIFIED_BY="[Empty name]" NAME="Ruza 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-02-07 15:03:19 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruza F, Alvarado F, Herruzo R, Delgado MA, García S, Dorao P, et al</AU>
<TI>Prevention of nosocomial infection in a pediatric intensive care unit (PICU) through the use of selective digestive decontamination</TI>
<SO>European Journal of Epidemiology</SO>
<YR>1998</YR>
<VL>14</VL>
<PG>719-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Schardey-1997" MODIFIED="2009-01-06 08:00:50 +1000" MODIFIED_BY="Liz Dooley" NAME="Schardey 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-01-06 08:00:50 +1000" MODIFIED_BY="Liz Dooley" NOTES="&lt;p&gt;Schardey HM, Joosten U, Finke U, Stanbach KH, Schauer R, Heiss A, et al. Decontamination in the prevention of anastomotic insufficiency following gastrectomy: A prospective double-blind, randomized and placebo-controlled clinical multicenter trial. [Abstract] British J Surg. Berlin,1994 [81].&lt;/p&gt;" NOTES_MODIFIED="2009-01-06 08:00:50 +1000" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schardey HM, Joosten U, Finke U, Stanbach KH, Schauer R, Heiss A, et al</AU>
<TI>The prevention of anastomotic leakage after total gastrectomy with local decontamination. A prospective double-blind, randomized and placebo-controlled clinical multicenter trial</TI>
<SO>Annals of Surgery</SO>
<YR>1997</YR>
<VL>225</VL>
<PG>172-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1993" MODIFIED="2008-02-07 15:05:16 +1000" MODIFIED_BY="[Empty name]" NAME="Smith 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-02-07 15:05:16 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith SD, Jackson RJ, Hannakan CJ, Wadowsky RM, Tzakis AG, Rowe MI, et al</AU>
<TI>Selective decontamination in pediatric liver transplant. A randomized prospective study</TI>
<SO>Transplantation</SO>
<YR>1993</YR>
<VL>55</VL>
<PG>1306-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Stoutenbeek-2" MODIFIED="2008-03-29 02:12:39 +1000" MODIFIED_BY="[Empty name]" NAME="Stoutenbeek 2" YEAR="1994">
<REFERENCE MODIFIED="2008-03-29 02:12:34 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Stoutenbeek CP, Van Saene HKF, Little RA, Whitehead A</AU>
<TI>The effect of selective decontamination of the digestive tratct on mortality in multiple trauma patients.</TI>
<SO>Contact with authors</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Tetteroo-1990" NAME="Tetteroo 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Tetteroo GWM, Wagenvoort JHT, Castelei A, Tilanus HW, Ince&lt;br&gt;C, Bruining HA. Selective decontamination to reduce gram-negative colonisation and infections after oesophageal resection. Lancet 1990;335:704-7.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tetteroo GWM, Wagenvoort JHT, Castelei A, Tilanus HW, Ince C, Bruining HA</AU>
<TI>Selective decontamination to reduce gram-negative colonisation and infections after oesophageal resection</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>335</VL>
<PG>704-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zobel-1991" MODIFIED="2008-02-07 15:07:29 +1000" MODIFIED_BY="[Empty name]" NAME="Zobel 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-02-07 15:07:29 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zobel G, Kutting M, Grubbauer HM, Semmelrock HJ, Thiel W</AU>
<TI>Reduction of colonization and infection rate during pediatric intensive care by selective decontamination of digestive tract</TI>
<SO>CritIical Care Medicine</SO>
<YR>1991</YR>
<VL>19</VL>
<PG>1242-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zwaveling-2002" MODIFIED="2008-02-07 15:27:31 +1000" MODIFIED_BY="[Empty name]" NAME="Zwaveling 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-02-07 15:27:31 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zweveling JH, Maring JK, Klompmaker IJ, Haagsma EB Bottema JT, Laseur M, et al</AU>
<TI>Selective decontamination of the digestive tract to prevent postoperative infection: a randomized placebo-controlled trial in liver transplant patients</TI>
<SO>Critical Care Medicine</SO>
<YR>2002</YR>
<VL>30</VL>
<NO>6</NO>
<PG>1204-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-01-28 17:36:01 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-01-28 17:36:01 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Chevret-1996" MODIFIED="2009-08-03 08:36:28 +1000" MODIFIED_BY="[Empty name]" NAME="Chevret 1996" TYPE="JOURNAL_ARTICLE">
<AU>Chevret S, Hemmer M, Carlet J, Langer M</AU>
<TI>Incidence and risk factors of pneumonia acquired in intensive care units. Results from a multicenter prospective study on 996 patients. European Cooperative Group on Nosocomial Pneumonia</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>275</VL>
<NO>11</NO>
<PG>866-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collard-2003" MODIFIED="2008-02-07 15:33:07 +1000" MODIFIED_BY="[Empty name]" NAME="Collard 2003" TYPE="JOURNAL_ARTICLE">
<AU>Collard HR, Saint S, Matthay MA</AU>
<TI>Prevention of ventilator-associated pneumonia: an evidence-based systematic review</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2003</YR>
<VL>138</VL>
<NO>6</NO>
<PG>494-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fagon-1996" NAME="Fagon 1996" TYPE="JOURNAL_ARTICLE">
<AU>Fagon JY, Chastre J, Vuagnat A, Trouillet JL, Novara A, Gibert C</AU>
<TI>Nosocomial pneumonia and mortality among patients in Intensive care unit</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>275</VL>
<PG>866-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heyland-1994" NAME="Heyland 1994" TYPE="JOURNAL_ARTICLE">
<AU>Heyland DK, Cook DJ, Jaescher R, Griffith L, Lee HN, Guyatt GH</AU>
<TI>Selective decontamination of the digestive tract. An overview</TI>
<SO>Chest</SO>
<YR>1994</YR>
<VL>105</VL>
<PG>1221-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2008-03-28 21:10:00 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="BOOK">
<AU>Higgins JPT, Green S</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<EN>Version 5.0.0</EN>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hurley-1995" NAME="Hurley 1995" NOTES="&lt;p&gt;Hurley JC. Prophylaxis with enteral antibiotics in ventilated patients: selective decontamination or selective cross-infection? Antimicrob Agents Chemother 1995;39:941-7.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Hurley JC</AU>
<TI>Prophylaxis with enteral antibiotics in ventilated patients: selective decontamination or selective cross-infection?</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1995</YR>
<VL>39</VL>
<PG>941-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kollef-1994" NAME="Kollef 1994" NOTES="&lt;p&gt;Kollef MH. The role of selective digestive tract decontamination on mortality and respiratory tract infections. A meta-analysis. Chest 1994;105:1101-08.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kollef MH</AU>
<TI>The role of selective digestive tract decontamination on mortality and respiratory tract infections. A meta-analysis</TI>
<SO>Chest</SO>
<YR>1994</YR>
<VL>105</VL>
<PG>1101-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2008" MODIFIED="2013-01-28 17:36:01 +1000" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2008" TYPE="BOOK_SECTION">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<ED>Higgins JP, Green S</ED>
<PB>Wiley</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liberati-2001" NAME="Liberati 2001" TYPE="JOURNAL_ARTICLE">
<AU>Liberati A, D'Amico R, Brazzi L, Pifferi S</AU>
<TI>Influence of methodological quality on study conclusions</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>286</VL>
<PG>2544-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nathens-1999" NAME="Nathens 1999" TYPE="JOURNAL_ARTICLE">
<AU>Nathens AB</AU>
<TI>Selective decontamination of digestive tract in surgical patients: a systematic review of evidence</TI>
<SO>Archives of Surgery</SO>
<YR>1999</YR>
<VL>134</VL>
<PG>170-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Redman-2001" MODIFIED="2008-03-28 23:37:13 +1000" MODIFIED_BY="[Empty name]" NAME="Redman 2001" TYPE="CONFERENCE_PROC">
<AU>Redman R, Ludington E</AU>
<TI>Analysis of respiratory and non-respiratory infections in published trials of selective digestive decontamination</TI>
<SO>Intensive Care Medicine (14th Annual Congress of the European Society of Intensive Care Medicine 2001)</SO>
<YR>2001</YR>
<NO>Suppl 2</NO>
<PG>285</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silvestri-2007" MODIFIED="2008-03-28 23:46:02 +1000" MODIFIED_BY="[Empty name]" NAME="Silvestri 2007" TYPE="JOURNAL_ARTICLE">
<AU>Silvestri L, van Saene HKF et al</AU>
<TI>Selective decontamination of the digestive tract reduces bacterial bloodstreem infection and mortality in critically ill patients. Systematic review of randomized controlled trials</TI>
<SO>Journal of Hospital Infection</SO>
<YR>2007</YR>
<VL>65</VL>
<PG>187-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stoutenbeek-1994" NAME="Stoutenbeek 1994" NOTES="&lt;p&gt;Stoutenbeek CP, Van Saene HKF, Miranda DR, Zandstra DF. The effect of selective decontamination of the digestive tract on colonization and infection rate in multiple trauma patients. Intensive Care Med 1994;10:185-92.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Stoutenbeek CP, Van Saene HKF, Miranda DR, Zandstra DF</AU>
<TI>The effect of selective decontamination of the digestive tract on colonization and infection rate in multiple trauma patients</TI>
<SO>Intensive Care Medicine</SO>
<YR>1994</YR>
<VL>10</VL>
<PG>185-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Nieuwenhove-2001" NAME="van Nieuwenhove 2001" TYPE="JOURNAL_ARTICLE">
<AU>van Nieuwenhoven CA, Buskens E, van Tiel FH, Bonten MJ</AU>
<TI>Reletionship between methodological trial quality and the effects of selective digestive decontamination on pneumonia and mortality in critically ill patients</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>286</VL>
<PG>335-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vanderbrouk_x002d_Gra-1991" NAME="Vanderbrouk-Gra 1991" TYPE="JOURNAL_ARTICLE">
<AU>Vanderbrouk-Grauls CM, Vanderbrouke-Grauls JP</AU>
<TI>Effect of selective decontamination of the digestive tract on respiratory tract infections and mortality in intensive care unit</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>338</VL>
<PG>859-62</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-02-07 15:54:02 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-D_x0027_Amico-1998" MODIFIED="2008-02-07 15:53:41 +1000" MODIFIED_BY="[Empty name]" NAME="D'Amico 1998" TYPE="JOURNAL_ARTICLE">
<AU>D'Amico R, Pifferi S, Leonetti C, Torri V, Tinazzi A, Liberati A, et al</AU>
<TI>Effectiveness of antibiotic prophylaxis in critically ill adult patients: systematic review of randomised controlled trials</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>316</VL>
<PG>1275-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liberati-1997" MODIFIED="2008-02-07 15:53:55 +1000" MODIFIED_BY="[Empty name]" NAME="Liberati 1997" TYPE="COCHRANE_REVIEW">
<AU>Liberati A, D'Amico R, Pifferi S, Leonetti C, Torri V, Brazzi L, et al</AU>
<TI>Antibiotic prophylaxis in adult patients treated in Intensive Care Units</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1997</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-02-06 16:31:16 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-02-06 16:31:16 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000022.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Liberati-2002" MODIFIED="2008-02-07 15:54:02 +1000" MODIFIED_BY="[Empty name]" NAME="Liberati 2002" TYPE="COCHRANE_REVIEW">
<AU>Liberati A, D'Amico R, Pifferi S, Leonetti C, Torri V, Brazzi L, et al</AU>
<TI>Antibiotics for preventing respiratory tract infections in adults receiving intensive care</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-02-06 16:33:09 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-02-06 16:33:09 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000022.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Liberati-2004" MODIFIED="2008-02-06 16:38:01 +1000" MODIFIED_BY="[Empty name]" NAME="Liberati 2004" TYPE="COCHRANE_REVIEW">
<AU>Liberati A, D'Amico R, Pifferi,Torri V, Brazzi L</AU>
<TI>Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-02-06 16:38:01 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-02-06 16:38:01 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000022.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-SDD-Group-1993" NAME="SDD Group 1993" NOTES="&lt;p&gt;SDD Trialists' Collaborative Group. Meta-analysis of randomised controlled trials of selective decontamination of the digestive tract. Br Med J 1993;307:525-32.&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>SDD Trialists' Collaborative Group</AU>
<TI>Meta-analysis of randomised controlled trials of selective decontamination of the digestive tract</TI>
<SO>British Medical Journal</SO>
<YR>1993</YR>
<VL>307</VL>
<PG>525-32</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-07-28 19:07:42 +1000" MODIFIED_BY="Clare Dooley">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-07-28 19:07:42 +1000" MODIFIED_BY="Clare Dooley" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-07-28 18:52:49 +1000" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Abele_x002d_Horn-1997">
<CHAR_METHODS MODIFIED="2009-07-28 18:52:49 +1000" MODIFIED_BY="Clare Dooley">
<P>Randomised controlled study<BR/>Blinding: Open<BR/>Randomisation method: list block randomised assignments maintained by the main investigator<BR/>Accrual period: not available</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-07 16:23:16 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: intubation within 24 hrs of admission, expected ventilation for at least four days, first microbial culture within 36 hrs of admission<BR/>Exclusion criteria: transfer from other hospitals, evidence of infection, prior antibiotic therapy, ARDS, leucopenia, myelosuppression<BR/>Patients enrolled in the study: 125; 37 patients were excluded leaving 88 patients for analysis<BR/>Percentage of ventilated patients: 100%<BR/>ICU length of stay, mean: 19.3 days<BR/>Type of admission diagnosis: surgical unscheduled = 16% trauma = 84%<BR/>Severity score on admission: APACHE II mean = 17, ISS not available<BR/>Percentage of immunocompromised patients:not available<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated by protocol) in the first three days: not available<BR/>Stress ulcer prophylaxis applied: sucralfate 1 g x four to all patients<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:10:56 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, Treatment:<BR/>- polymyxin 100 mg, tobramycin 80 mg, amphotericin B 500 mg applied orally four times a day as a 2% paste during the ICU stay<BR/>- cefotaxime 2 g x 3 iv x three days</P>
<P>Group B, CTR:<BR/>- No prophylaxis</P>
<P>Antibiotic prophylaxis was performed only for abdominal, orthopedic and neurologic surgery<BR/>
<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-03-28 23:55:49 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory infections (acquired pneumonia):<BR/>Diagnosis was based on Clinical Pulmonary Infection Score as defined by Pugin 1991: new pulmonary infiltrate on X-ray, increasing amount of tracheal secretions containing &gt; 3 x 10<SUP>4</SUP> granulocytes/mcl and at least two of the following: temperature &gt; 38.5°C, WBC &gt; 12,000/mm<SUP>3</SUP> or &lt; 4,000/mm<SUP>3</SUP>, decrease in PaO<SUB>2</SUB> requiring an increase in FiO<SUB>2</SUB>. Besides a bacteriological confirmation is required: tracheal aspirates yielding bacteria &gt; 10<SUP>4</SUP> CFU/ml and granulocytes &gt; 10/field</P>
<P>Mortality: in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data about 37 excluded patients are not available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-02-13 09:35:19 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aerdts-1991">
<CHAR_METHODS MODIFIED="2008-02-13 09:28:53 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised study with three arms (one treatment arm versus two control arms)<BR/>Blinding: outcome assessor<BR/>Randomisation method: sealed envelopes, permuted block method.<BR/>Accrual period: May 86 to Sept 87<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-01-31 14:06:35 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: expected ventilation for at least five days, inclusion within 24 hrs of admission<BR/>Exclusion criteria: age &lt; 16 yrs, pregnancy, allergy to one of the component of the regimen<BR/>Patients enrolled in the study: 88<BR/>Percentage of ventilated patients: 100%<BR/>ICU length of stay, median: 16 days<BR/>Type of admission diagnosis: medical = 40% surgical scheduled = 6% surgical unscheduled = 20% trauma = 34%<BR/>Severity score on admission: APACHE II mean = 21.8, ISS not available<BR/>Percentage of immunocompromised patients: 4.6%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated by protocol) in the first three days: Treatment = 35% CTR = 80%<BR/>Stress ulcer prophylaxis applied: antiacids until enteral feeding was possible<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:29:32 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, CTR 1:<BR/>- No prophylaxis, infections of unknown origin were treated with ampicillin+gentamicin<BR/>Group B, CTR 2:<BR/>- No prophylaxis, infections of unknown origin were treated with cefotaxime+gentamicin and metronidazole if indicated.<BR/>Group C, Treatment:<BR/>- polymyxin E 200 mg, norfloxacin 50 mg, amphotericin B 500 mg applied enterally four times a day and, as a 2% paste, to the oropharynx until extubation<BR/>- cefotaxime 500 mg x 3 iv x five days. Infections of unknown origin were treated as group B</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-02-13 09:30:09 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory infections (acquired pneumonia and tracheobronchitis):<BR/>Diagnosis of tracheobronchitis was based on: positive culture of the tracheal aspirate and a gram stain showing many leukocytes as well as the causative organism, associated with two of the following: temperature &gt; 38°C, WBC &gt; 12000/mm<SUP>3</SUP>, purulent tracheal aspirate<BR/>Diagnosis of pneumonia was based on: a new and persistent pulmonary infiltrate on X-ray and criteria of tracheobronchitis</P>
<P>Mortality: in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-02-13 09:35:19 +1000" MODIFIED_BY="[Empty name]">
<P>The study presents two control groups that are considered as a whole in the meta-analysis<BR/>Personal contact with the main investigator provided data about 32 patients who were excluded from the published paper (16 early extubation, seven early deaths, five protocol violation, three other, one unknown); these data are considered in the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-03-28 23:54:47 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bergmans-2001">
<CHAR_METHODS>
<P>Randomised, placebo-controlled study.<BR/>Blinding: double blind.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-13 09:13:31 +1000" MODIFIED_BY="[Empty name]">
<P>Elegibility criteria: intubation within 24 hrs of admission and need for mechanical ventilation with an expected duration &gt; two hours<BR/>Esclusion criteria: age &lt; 16 yrs.<BR/>Patients enrolled in the study: 226<BR/>Percentage of ventilated patients: 100%<BR/>ICU length of stay, median treatment group: 13 days; median control A group: 15 days, median control B group: 12 days<BR/>Type of admission diagnosis: Medical = 35%, Surgery = 39%, Trauma = 19%, Neurology = 6%, Other = 1%.<BR/>Severity score on admission: APACHE II mean = 21.4, ISS not available<BR/>Percentage of immuncompromised patients: 2%<BR/>Percentage of patients treated with systematic antibiotic therapy at admission:<BR/>Treatment: 47% CTR = 42%<BR/>Stress ulcer prophylaxis applied: Treatment = 61%<BR/>Control = 76%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:13:33 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, Treatment:<BR/>Orabase with 2% gentamicin, 2% colistin and 2% vancomycin<BR/>Orabase was applied in the buccal cavities on a gloved finger every six hrs.<BR/>The application of Orabase was started within 24 h of intubation.<BR/>Application of treatment was limited to 21 days.</P>
<P>Group B, CTR1<BR/>no prophylaxis<BR/>- this group was studied in ICU in which there was the presence of patients receiving topical antimicrobial prophylaxis</P>
<P>Group C: CTR2<BR/>no prophylaxis<BR/>This control group was studied in ICU in which where no topical antimicrobial prophylaxis was used</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-03-28 23:54:47 +1000" MODIFIED_BY="[Empty name]">
<P>Ventilator-associated pneumonia (VAP); diagnosis of VAP was established on the basis of positive quantitative cultures from BAL (cutoff point &gt;= 10<SUP>4</SUP> colony-forming units [cfu]/ml) or PSB (cutoff point &gt;= 10<SUP>3</SUP> cfu/ml), or a positive blood culture unrelated to another source of infection, or a positive culture from pleural fluid in the absence of previous pleural instrumentation.</P>
<P>Mortality: in hospital</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-28 18:55:27 +1000" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Blair-1991">
<CHAR_METHODS MODIFIED="2008-01-31 12:43:11 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised study<BR/>Blinding: Open.<BR/>Randomisation method: sealed envelopes.<BR/>Accrual period: Sept. 1988 to Jan 1990<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-07 16:23:20 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: all admitted patients who do not fulfil the exclusion criteria<BR/>Exclusion criteria: patients discharged within 48 hrs of ICU admission; admission from CCU; patients expected to die after six hrs of ICU admission; patients with discharge anticipated within 48 hrs but remaining more than 48 hrs; drug overdose; security patients; age &lt; 18 yrs; patients not randomised within six hrs of admission; readmission to ICU; burns; miscellaneous</P>
<P>Patients enrolled in the study: 331<BR/>Percentage of ventilated patients: 93%<BR/>Length of stay in ICU, median: five days<BR/>Type of admission diagnosis: medical = 14% surgical scheduled = 33% surgical unscheduled = 13% trauma = 40%<BR/>Severity score on admission: APACHE II mean = 14.4, ISS mean = 24.8<BR/>Percentage of immunocompromised patients: 1.8%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: treatment = 42% CTR = 74%<BR/>Stress ulcer prophylaxis applied: all patients received ranitidine iv plus antiacid therapy if gastric pH was low<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:10:30 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, CTR:<BR/>- Standard antibiotic therapy (no prophylaxis)</P>
<P>Group B, Treatment:<BR/>- polymyxin 100 mg, tobramycin 80 mg, amphotericin B 500 mg applied enterally four times a day and, as a 2% gel, to the oropharynx<BR/>- cefotaxime 50 mg/kg/day iv x four days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-28 18:55:27 +1000" MODIFIED_BY="Clare Dooley">
<P>Respiratory infections (pneumonia acquired after 48 hrs). Diagnosis of infection was based on the fulfilment of Criteria I or Criteria II.<BR/>Criteria I: temperature &gt; 38.5°C on two separate occasion, WBC &gt; 12 x 10<SUP>9</SUP>/l or &lt; 4 x 10<SUP>9</SUP> and a new pulmonary infiltrate on X-ray.<BR/>Criteria II: temperature &gt; 37.5°C, a new pulmonary infiltrates on X-ray, purulent sputum and drop in PaO<SUB>2</SUB>
</P>
<P>Mortality: in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-02-13 09:35:21 +1000" MODIFIED_BY="[Empty name]">
<P>Personal contact with the main investigator provided data about 75 patients who were excluded from the published paper for short length of stay; these data are considered in the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-02-13 09:44:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boland-1991">
<CHAR_METHODS MODIFIED="2008-02-13 09:35:55 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled study<BR/>Blinding: double blind<BR/>Randomisation method: computer generated randomisation directed by the pharmacy department<BR/>Accrual period: Apr 89 to Mar 91</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-13 09:36:18 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: all multiple traumatised patients, intubated at the time of admission and likely to stay intubated at least five days<BR/>Exclusion criteria: patients who did not remain intubated for five days</P>
<P>Patients enrolled in the study: 64<BR/>Percentage of ventilated patients: 100%<BR/>Length of stay in ICU, median: eight days<BR/>Type of admission diagnosis: trauma = 100%<BR/>Severity score on admission: APACHE II mean = 16.8, ISS not available<BR/>Percentage of immunocompromised patients: 0%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: treatment = 0% CTR = 0%<BR/>Stress ulcer prophylaxis applied: H2-blockers or sucralfate (78%)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:14:24 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, CTR:<BR/>- Placebo</P>
<P>Group B, Treatment:<BR/>- polymyxin 100 mg, tobramycin 80 mg, nystatin 1,600,000 units applied enterally four times a day and, as a 2% paste plus 60,000 units of nystatin, to the oropharynx until extubation or discharge<BR/>- cefotaxime 1 g x 3 iv for the first three days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-01-31 13:33:50 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory infections (acquired pneumonia and tracheobronchitis).<BR/>Diagnosis of infection was based on:<BR/>positive sputum culture for bacteria, fever &gt; 38°C and leukocytosis (&gt; 10,000 WBC/mm<SUP>3</SUP> of blood)</P>
<P>Mortality: in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-02-13 09:44:59 +1000" MODIFIED_BY="[Empty name]">
<P>Personal contact with the main investigator provided data about 23 patients who were excluded from the published paper (20 early extubations, three early deaths); these data are considered in the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-03-29 00:02:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brun_x002d_Buisson-1989">
<CHAR_METHODS MODIFIED="2008-02-13 09:03:58 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised trial<BR/>Blinding: Open<BR/>Randomisation method: odd and even birth year technique<BR/>Accrual period: Apr 87 to May 87</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-07 16:17:36 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: patients with an admission SAPS &gt; 2 and staying in the ICU more than 48 hrs<BR/>Exclusion criteria: patients with severe neutropenia routinely receiving oral antibiotic prophylaxis<BR/>Patients enrolled in the study: 133<BR/>Percentage of ventilated patients: 59%<BR/>Length of stay in ICU, median: 3.5 days<BR/>Type of admission diagnosis: medical 75% surgical unscheduled 23% trauma 2%<BR/>Severity score on admission: SAPS mean = 10.4, ISS not available<BR/>Percentage of immunocompromised patients: 12.8%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: treatment = 41% CTR = 53%<BR/>Stress ulcer prophylaxis applied: none<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:21:47 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, Treatment:<BR/>- polymyxin E 50 mg, neomycin 1 g, nalidixic acid 1 g, applied orally and enterally four times a day until discharge<BR/>- Oropharyngeal disinfectant in intubated patients</P>
<P>Group B, CTR:<BR/>- Oropharyngeal disinfectant in intubated patients</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-03-29 00:02:17 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory infections (pneumonia acquired in the ICU or within 48 hrs from discharge)<BR/>Diagnosis of infection was based on:<BR/>purulent sputum or tracheal aspirate associated with a new and persistent pulmonary infiltrate on X-ray and the culture of at least 10<SUP>9</SUP> CFU/l from a protected wedged catheter sample of bronchial aspirate, temperature &gt; 38°C, WBC &gt; 10 x 10<SUP>9</SUP>
</P>
<P>Mortality: in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-03-28 23:51:14 +1000" MODIFIED_BY="[Empty name]">
<P>Setting: acute and intermediate areas of a medical ICU<BR/>Personal contact with the main investigator provided data about 47 patients who were excluded from the published paper (seven early deaths, one transferred, 39 other); these data are considered in the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-28 18:56:01 +1000" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Camus-2005">
<CHAR_METHODS MODIFIED="2008-02-07 16:13:30 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised trial<BR/>Blinding: double<BR/>Randomisation method: performed by computer<BR/>Accrual period: April 1996 to October 1998<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-28 18:56:01 +1000" MODIFIED_BY="Clare Dooley">
<P>Elegibility criteria: adults intubated for &lt; 48 hrs and likely to require mechanical ventilation for &gt; 48 hrs<BR/>Exclusion criteria: patients with SAPS II &gt; 80 and life expectancy of &lt; 48 hrs resulting from brain death of a palliative treatment, a polymorphonuclear count of &lt; 500 cells/mm<SUP>3</SUP>, severe diarrhoea and anyone who had received either a prior decontamination regimen or was already participating in another ongoing clinical trial.<BR/>Patients enrolled: 256<BR/>Pecentage of ventilated patients: not reported<BR/>Length of stay in ICU: not reported<BR/>Type of admission diagnosis: home/emergency department = 43%, hospital ward = 57%<BR/>Severity score on admission: median SAPS II = 46<BR/>Percentage of immunocompromised patients: 3.9%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in protocol) in the first three days: none<BR/>Stress ulcer prophylaxis applied: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group A - Treatment: solution containing 15 mg/ml polymyxin E and 10 mg/ml tobramycin<BR/>Group B - Control: placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Respiratory infections: acquired infections<BR/>Mortality: in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-01-31 15:09:30 +1000" MODIFIED_BY="[Empty name]">
<P>The study is a four arm, 2 x 2 factorial design. In this review we considered only two arms comparing SDD regimen versus placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-28 18:57:45 +1000" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Cerra-1992">
<CHAR_METHODS MODIFIED="2008-02-13 09:23:29 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled study<BR/>Blinding: double blind<BR/>Randomisation method: sealed envelopes<BR/>Accrual period: Sept 1988 to Jan 1990</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-13 09:51:29 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: admission within 48 hrs from surgery, trauma or other acute event, expected stay at least five days, hypermetabolism (VO<SUB>2</SUB> &gt; 140 ml/m<SUP>2</SUP> or urinary nitrogen excretion &gt; 10 g/day) without progressive MOSF (normal transaminases, stable bilirubin and creatinine)<BR/>Exclusion criteria: Cirrhosis, allergy to used drugs, chemo-radiotherapy, progressive MOSF, gastrointestinal leak or fistula</P>
<P>Patients enrolled in the study: 48<BR/>Percentage of ventilated patients: not available<BR/>ICU length of stay, median: not available<BR/>Type of admission diagnosis: surgical = 96% trauma = 4%<BR/>Severity score on admission: not available<BR/>Percentage of immunocompromised patients: not available<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: not available<BR/>Stress ulcer prophylaxis applied: not available</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:51:33 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, Treatment:<BR/>- norfloxacin 500 mg x 3, nystatin one million U x 4 applied enterally until discharge</P>
<P>Group B, CTR:<BR/>- Placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-28 18:57:45 +1000" MODIFIED_BY="Clare Dooley">
<P>Respiratory infections: not possible to evaluate</P>
<P>Mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-02-13 09:35:12 +1000" MODIFIED_BY="[Empty name]">
<P>Personal contact with the main investigator provided data about two patients who were excluded from the published paper for short length of stay); these data are considered in the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-28 18:58:30 +1000" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Cockerill-1992">
<CHAR_METHODS MODIFIED="2008-02-13 09:37:49 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised study. Intention-to-treat<BR/>Blinding: outcome assessor<BR/>Randomisation method: randomisation table at a remote site in the pharmacy<BR/>Accrual period: 1986 to 1989<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-13 09:37:57 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: all patients admitted to the mixed ICU if their condition suggested a prolonged stay (&gt; three days), age &gt; 18 yrs<BR/>Exclusion criteria: age &lt; 18 yrs, pregnancy, allergy to one of the component of the regimen, infections, antibiotic therapy 24 hrs before randomisation</P>
<P>Patients enrolled in the study: 150<BR/>Percentage of ventilated patients: 85%<BR/>ICU length of stay, median: 4.5 days<BR/>Type of admission diagnosis: medical = 18% surgical scheduled = 27% surgical unscheduled = 21% trauma = 34%<BR/>Severity score on admission: APACHE II mean = 19.4, ISS mean 24.3<BR/>Percentage of immunocompromised patients: 4%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: treatment = 75% CTR = 80%<BR/>Stress ulcer prophylaxis applied: H2-blockers (80%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:15:07 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, CTR:<BR/>- No prophylaxis</P>
<P>Group B, Treatment:<BR/>- gentamycin 80 mg, polymyxin B 100 mg, nystatin 2,000,000 units, applied enterally and as a 2% paste to the oropharynx four times a day during the ICU stay<BR/>- cefotaxime 1 g/8 hrs iv for the first three days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-28 18:58:30 +1000" MODIFIED_BY="Clare Dooley">
<P>Respiratory infections (only acquired infections)<BR/>Diagnosis of pneumonia was based on clinical and laboratory criteria:<BR/>a new or progressive pulmonary infiltrate, purulent secretions, isolation of a potential pathogen and fever with or without leukocytosis.<BR/>Diagnosis of tracheobronchitis was based on:<BR/>the presence of increased purulent endotracheal secretions requiring frequent suctioning and the presence of a potential pathogen</P>
<P>Mortality: in hospital</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-28 19:01:35 +1000" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-de-Jonge-2003">
<CHAR_METHODS MODIFIED="2008-02-11 15:18:03 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised study<BR/>Blinding: Open<BR/>Randomisation method:computer-generated random-number codes kept in sealed envelopes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-28 19:01:30 +1000" MODIFIED_BY="Clare Dooley">
<P>Eligibility criteria: adult patients admitted to ICU: with an expected stay of at least 72 hours and an expected duration of mechanical ventilation of at least 48 hours<BR/>Exclusion criteria:<BR/>previous admission in ICU within three months iper sensitivity to study medication, pregnancy and perceived imminent death</P>
<P>Number of patients enrolled in the study: 934</P>
<P>Percentage of ventilated patients: 85%</P>
<P>Length of stay in ICU: median SDD group = 6.8 days<BR/>control group = 8.5 days</P>
<P>Type of admission diagnosis:<BR/>medical: 41%<BR/>surgical urgent: 25%<BR/>surgical elective: 34%</P>
<P>Severity score at admission:<BR/>APACHE II mean = 18.7<BR/>SAPS II in SDD group mean = 17.9<BR/>SAPSII in control group mean = 17.1</P>
<P>Percentage of immunocompromised patients<BR/>SDD group = 2.4%<BR/>control group = 1.7%</P>
<P>Information on prescribed antibiotics per 1,000 patients available in the main publication</P>
<P>No stress ulcer prophylaxis by protocol<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:39:17 +1000" MODIFIED_BY="[Empty name]">
<P>SDD group: topical plus systemic treatment<BR/>Topical: oral paste containing 2% polymyxin E, 2% tobramycin, 2% amphotericin<BR/>500 mg amphotericin B through gastric tubes<BR/>Systemic: cefotaxime 1000 mg four times daily for four days</P>
<P>Control group:<BR/>No antibiotic prophylaxis; antibiotic treatment based on clinical needs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-28 19:01:35 +1000" MODIFIED_BY="Clare Dooley">
<P>Colonisation, antibiotic resistance<BR/>Mortality: in ICU and hospital</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-02-11 15:18:31 +1000" MODIFIED_BY="[Empty name]">
<P>Patients were allocated to either an SDD or a control unit to prevent cross-colonisation between SDD and ICU control patients. Standard care was the same in the two units</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-28 19:02:07 +1000" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Ferrer-1994">
<CHAR_METHODS MODIFIED="2008-02-13 09:26:19 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled study<BR/>Blinding: double blind<BR/>Randomisation method: computer generated table<BR/>Accrual period: Jan 91 to Mar 92</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-07 16:23:24 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: all mechanically ventilated patients expected to remain intubated for more than three days<BR/>Exclusion criteria: patients with HIV-related diseases or treated with antineoplastic chemotherapy as well as patients who received transplants, extubation or death within 72 hrs</P>
<P>Number of patients enrolled in the study: 101<BR/>Percentage of ventilated patients:100%<BR/>Length of stay in ICU, median: 7.5 days<BR/>Type of admission diagnosis: medical 66% surgical scheduled 6.9% surgical unscheduled 6.9% trauma = 19.8%<BR/>Severity score admission: SAPS mean = 12.1, ISS not available<BR/>Percentage of immunocompromised patients: 0%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: not available<BR/>treatment = 73% CTR = 74%<BR/>Stress ulcer prophylaxis applied: sucralfate except in patients with paralytic ileus or with upper gastrointestinal bleeding, who were treated with ranitidine</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:43:44 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, Treatment:<BR/>- polymyxin E 100 mg, tobramycin 80 mg, amphotericin B 500 mg applied enterally and, as a 2% paste, to the oropharynx four times a day until extubation or death<BR/>- cefotaxime 2 g/day iv for the first four days or others if required</P>
<P>Group B, CTR:<BR/>- Placebo<BR/>- cefotaxime 2 g/day iv for the first four days or others if required*</P>
<P>*patients infected on admission received adequate antibiotic treatment instead of cefotaxime</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-03-29 00:00:07 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory infections (pneumonia acquired after four days of mechanical ventilation)<BR/>Diagnosis of infection was based on clinical criteria plus brush or BAL confirmation.<BR/>Clinical criteria: new or progressive pulmonary X-ray infiltrate for at least 48 hrs, purulent tracheal secretions, temperature &gt; 38.5 °C and leukocytosis &gt;= 12 x 10<SUP>9</SUP> WBC/l or leukopenia &lt;= 4 x 10<SUP>9</SUP>
</P>
<P>Mortality: in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-28 19:02:07 +1000" MODIFIED_BY="Clare Dooley">
<P>Personal contact with the main investigator provided data about 21 patients who were excluded from the published paper (14 early extubations, six early deaths, one transfer); these data are considered in the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-03-29 00:00:45 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Finch-1991">
<CHAR_METHODS MODIFIED="2008-02-11 15:19:00 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised study<BR/>Blinding: Open<BR/>Randomisation method: sealed envelopes. Randomisation series made available to the hospital Pharmacy only<BR/>Accrual period: Aug 87 to Sept 89</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-01-31 13:51:26 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: all patients whose length of stay was &gt; 60 hrs, age &gt; 16 yrs<BR/>Exclusion criteria: none</P>
<P>Number of patients enrolled in the study: 49<BR/>Percentage of ventilated patients: not available<BR/>Length of stay in ICU: not available<BR/>Type of admission diagnosis: medical 59% surgical scheduled 27% surgical unscheduled 10% trauma = 4%<BR/>Severity score on admission: SAPS mean = 10.5, ISS not available<BR/>Percentage of immunocompromised patients: 22%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: treatment = 58% CTR = 68%<BR/>Stress ulcer prophylaxis applied: not available</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:14:53 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, Treatment:<BR/>- polymyxin B 100 mg, gentamycin 120 mg, amphotericin B 500 mg applied enterally and, as a 2% paste, to the oropharynx four times a day<BR/>- cefotaxime 1 g x 3 iv for the first four days</P>
<P>Group B, CTR:<BR/>- Conventional antibiotic therapy<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-03-29 00:00:45 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory infections (acquired pneumonia)<BR/>Diagnosis of pneumonia was based on:<BR/>tracheal aspirate with numerous leukocytes associated with any of the following: a single bacterial species with a growth density &gt; 10<SUP>5</SUP> CFU, diagnosis of septicaemia, clinical signs of pulmonary infections (fever, leukocytosis and appropriate radiological findings)</P>
<P>Mortality: in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-02-13 09:31:51 +1000" MODIFIED_BY="[Empty name]">
<P>Personal contact with the main investigator provided information about mortality on five patients who were excluded from the published paper (one early extubation, two early deaths, one transferring, one unknown); these data are considered in the analysis. Data about respiratory infections in patients excluded from published paper are not available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-28 19:03:04 +1000" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Gastinne-1992">
<CHAR_METHODS MODIFIED="2008-02-11 15:19:21 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled, multicenter (15 ICUs) study Intention to treat<BR/>Blinding: double blind<BR/>Randomisation method: a randomised list of consecutive treatment assignments, performed separately in each unit.<BR/>Accrual period: Feb 90 to Jun 90</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-28 19:03:04 +1000" MODIFIED_BY="Clare Dooley">
<P>Eligibility criteria: all patients &gt; 15 yrs who required mechanical ventilation and with intubation performed no more than 48 hrs before randomisation<BR/>Exclusion criteria: patients with ventilation for less than 24 hrs, drug or alcohol overdose, neutropenia (WBC &lt; 500/mm<SUP>3</SUP>), SAPS &gt; 24 or GCS &lt; 4, chronic degenerative central nervous system disease or spinal cord injury above level of C4, acute severe enteropathy, pregnancy, participation in another ongoing clinical trial, refusal of consent, patients with conditions in which survival was strongly related to status on admission</P>
<P>Number of patients enrolled in the study: 445<BR/>Percentage of ventilated patients: 100%<BR/>Length of stay in ICU, median: 12 days<BR/>Type of admission diagnosis: medical 72% surgical scheduled 3% surgical unscheduled 10% trauma = 15%<BR/>Severity score on admission: SAPS mean = 13.5, ISS not available GCS mean = 11.7<BR/>Percentage of immunocompromised patients: 18%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: treatment = 89% CTR = 84%<BR/>Stress ulcer prophylaxis applied: sucralfate (43% patients), H2-blockers (13% patients)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:09:13 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, CTR:<BR/>- Placebo</P>
<P>Group B, Treatment:<BR/>- tobramycin 80 mg, polymyxin E 100 mg, amphotericin B 100 mg applied enterally and, as a 2% paste, to the oropharynx four times a day throughout the period of ventilation<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-02-07 16:15:25 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory infections (pneumonia diagnosed within 48 hrs and acquired):<BR/>Diagnosis of infection was based on:<BR/>purulent tracheal aspirate, temperature &gt; 38.5°C, peripheral leukocytosis (&gt; 10,000 WBC/mm<SUP>3</SUP> of blood) and a new and persistent infiltrate on the chest film. Brushing was recommended but not mandatory.</P>
<P>Mortality: in hospital</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-28 19:04:14 +1000" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Gaussorgues-1991">
<CHAR_METHODS MODIFIED="2008-02-11 15:20:44 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised study. Intention to treat<BR/>Blinding: Open<BR/>Randomisation method: odd-even numbers<BR/>Accrual period: Sept 88 to Sept 89</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-13 09:52:17 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: all patients admitted to the ICU, who required mechanical ventilation and inotropic drugs for haemodynamic reasons<BR/>Exclusion criteria: neutropenia</P>
<P>Patients enrolled in the study: 118<BR/>Percentage of ventilated patients: 100%<BR/>ICU length of stay: not available<BR/>Type of admission diagnosis: medical = 83% surgical scheduled = 17% (all patients were infected on admission)<BR/>Severity score on admission: SAPS mean = 17.5<BR/>Percentage of immunocompromised patients: not available<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: treatment = 100% CTR = 100%<BR/>Stress ulcer prophylaxis applied: sucralfate 4 g to all patients<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:14:54 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, Treatment:<BR/>- polymyxin E 36 mg, gentamycin 80 mg, Vancomycin 50 mg, amphotericin B 500 mg applied enterally four times a day until extubation<BR/>- amphotericin B, Clorexidine applied orally four times a day<BR/>- systemic antibiotic therapy</P>
<P>Group B, CTR:<BR/>- amphotericin B, Clorexidine applied orally four times a day<BR/>- systemic antibiotic therapy<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-28 19:04:14 +1000" MODIFIED_BY="Clare Dooley">
<P>Respiratory infections: not possible to evaluate</P>
<P>Mortality: in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-02-11 15:20:57 +1000" MODIFIED_BY="[Empty name]">
<P>All patients were infected on admission<BR/>Data about respiratory infections are not provided</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-02-13 09:09:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Georges-1994">
<CHAR_METHODS MODIFIED="2008-02-11 15:21:01 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled study<BR/>Blinding: open<BR/>Randomisation method: sealed envelopes<BR/>Accrual period: Jun 1990 to April 1992</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-07 16:23:29 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: Polytrauma, expected mechanical ventilation for at least four days, age &gt; 18 years<BR/>Exclusion criteria: Hypersensitivity to the used agents, protocol violation, obesity, ventilation &lt; four days, patients on mechanical ventilation two days before admission, severe maxillo-facial lesions</P>
<P>Patients enrolled in the study: 138, but only 64 patients were analysed<BR/>Length of stay in ICU, mean: 33 days<BR/>Percentage of ventilated patients: 100%. Length of ventilation, mean: 16 days<BR/>Type of admission diagnosis: trauma 100%<BR/>Severity score on admission: APACHE II mean = 15, ISS = 41<BR/>Percentage of immunocompromised patients: 0%<BR/>Percentage of patients treated with systemic antibiotic therapy in the first 3 days: almost 100%<BR/>Stress ulcer prophylaxis: H2-blockers<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:09:21 +1000" MODIFIED_BY="[Empty name]">
<P>Group A:<BR/>Treatment: polymyxin E 75 mg, Netilmicin 150 mg, amphotericin B 400 mg applied enterally four times a day and, as a 2% paste, to the oropharynx until extubation<BR/>- Systemic antibiotic prophylaxis was free</P>
<P>Group B: CTR<BR/>- Placebo<BR/>- Systemic antibiotic prophylaxis was free</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-01-31 13:52:30 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory infections (acquired pneumonia)<BR/>Diagnosis of infection was based on:<BR/>Fever &gt; 38.5 °C, leukocytosis &gt; 12000/mm<SUP>3</SUP>, new infiltrates in the chest X-rays, purulent pulmonary secretions, positive bacteriologic findings (&gt; 10^3 CFU/ml) obtained through a protected catheter</P>
<P>Mortality: in ICU and hospital</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-02-11 15:21:18 +1000" MODIFIED_BY="[Empty name]">
<P>Antibiotic prophylaxis was free and almost all patients of both groups were treated with systemic antibiotics<BR/>74 potentially eligible patients were excluded from analysis; it is not evident if this happened before or after randomisation; these data are not available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-03-29 00:04:45 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hammond-1992">
<CHAR_METHODS MODIFIED="2008-02-11 15:21:22 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled study<BR/>Blinding: double blind<BR/>Randomisation method: computer generated random numbers.<BR/>Accrual period: Jan 89 to Dec 90<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-01-31 13:52:40 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: expected intubation for longer than 48 hrs and stay in ICU for at least five days<BR/>Exclusion criteria: hypersensitivity to the study drugs, patients with asthma, drug overdose and patients admitted electively after surgery</P>
<P>Number of patients enrolled in the study: 322<BR/>Percentage of ventilated patients: 100%<BR/>Length of stay in ICU, median: 11 days<BR/>Type of admission diagnosis: medical 55% surgical scheduled 3% surgical unscheduled 11% trauma = 31%<BR/>Severity score on admission: APACHE II mean = 13.9, ISS mean = 28.7<BR/>Percentage of immunocompromised patients: 0.8%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: treatment = 54% CTR = 58%<BR/>Stress ulcer prophylaxis applied: none, H2-blockers only to high risk patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:10:40 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, Treatment:<BR/>- polymyxin E 100 mg, tobramycin 80 mg, amphotericin B 500 mg applied enterally and, as a 2% gel, to the oropharynx four times a day until 48 hrs after extubation<BR/>- cefotaxime 1 g x 3 iv for the first three days to patients untreated on admission</P>
<P>Group B, CTR:<BR/>- Placebo<BR/>- cefotaxime 1 g x 3 iv for the first three days to patients untreated on admission<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-03-29 00:04:45 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory infections (infections acquired after 48 hrs)<BR/>Diagnosis of pneumonia was based on:<BR/>a new infiltrate on X-ray and purulent bronchial secretions with many leukocytes, temperature &gt; 38°C, WBC &gt; 10<SUP>10</SUP>/l, substantial number of organism on gram stain with a pure growth culture from tracheal aspirate, deterioration of gas exchange of &gt; 2 kPa<BR/>Diagnosis of bronchial infection was based on:<BR/>all the previous criteria except the X-ray changes</P>
<P>Mortality: in hospital</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-01-31 13:52:58 +1000" MODIFIED_BY="[Empty name]">
<P>Personal contact with the main investigator provided data on 82 patients who were excluded and separately considered in the published paper (78 short stay, three protocol violation, one unknown); these data are considered in the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-03-29 00:05:10 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jacobs-1992">
<CHAR_METHODS MODIFIED="2008-02-11 15:21:59 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised study<BR/>Blinding: open<BR/>Randomisation method: sealed envelopes.<BR/>Accrual period: Jul 89 to Aug 90</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-07 16:20:13 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: expected stay in ICU &gt; three days<BR/>Exclusion criteria: none</P>
<P>Patients enrolled in the study: 91<BR/>Percentage of ventilated patients: 100%<BR/>ICU length of stay, median: unknown<BR/>Type of admission diagnosis: medical = 25% surgical = 57% trauma = 18% (high percentage of neurologic and neurosurgical patients 52%)<BR/>Severity score on admission: APACHE II mean = 17.5, ISS not available<BR/>Percentage of immunocompromised patients: unknown<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: next to 100%<BR/>Stress ulcer prophylaxis applied: policy of maintenance a low gastric pH, H2-blockers only if peptic ulcer or steroid therapy (33%), sucralfate 4 g to all patients not on enteral feeding</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:10:41 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, Treatment:<BR/>- polymyxin E 100 mg, tobramycin 80 mg, amphotericin B 500 mg applied orally and enterally four times a day until extubation<BR/>- cefotaxime 50 mg/kg/day iv x four days</P>
<P>Group B, CTR:<BR/>- No prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-03-29 00:05:10 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory infections (acquired pneumonia)<BR/>Diagnosis of infection was based on:<BR/>alveolar infiltrates on two or more chest X-rays, moderate or copious purulent tracheal aspirate, rectal temperature &gt; 38.4°C, leucocytosis &gt; 13 x 10<SUP>9</SUP>/l, a heavy growth of organisms from tracheal aspirate with a high polymorphonuclear leucocytes/epithelial cell ratio</P>
<P>Mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-02-11 15:22:28 +1000" MODIFIED_BY="[Empty name]">
<P>Almost 100% of patients received systemic antibiotic therapy on admission<BR/>Personal contact with the main investigator provided data about 12 patients who were excluded from the published paper (11 short stay in ICU, one HIV+); these data are considered in the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-03-29 00:06:14 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kerver-1988">
<CHAR_METHODS MODIFIED="2008-02-11 15:22:58 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised study<BR/>Blinding: open<BR/>Randomisation method: odd/even numbers<BR/>Accrual period: Jan 85 to May 86</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-07 16:20:45 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: all patients admitted to the surgical ICU who required care &gt; five days<BR/>Exclusion criteria: none</P>
<P>Patients enrolled in the study: 96<BR/>Percentage of ventilated patients: 100%<BR/>ICU length of stay, not available<BR/>Type of admission diagnosis: surgical = 60% trauma = 28% other = 12%<BR/>Severity score on admission: APACHE II mean = 14.8, ISS not available<BR/>Percentage of immunocompromised patients: not available<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: about 85%<BR/>Stress ulcer prophylaxis applied: not available<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:10:42 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, Treatment:<BR/>- polymyxin E 200 mg, tobramycin 80 mg, amphotericin B 500 mg applied orally and enterally four times a day<BR/>- Oral disinfectant<BR/>- cefotaxime 50 to 70 mg/kg/day iv x five to seven days</P>
<P>Group B, CTR:<BR/>- Oral disinfectant</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-03-29 00:06:14 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory infections (primary pneumonia and pneumonia acquired after 48hs)<BR/>Diagnosis of infection was based on X-ray findings and the presence of three of the following criteria on the same day: rectal temperature &gt; 38.5°C for at least 12 hrs, WBC count &gt; 10 x 10<SUP>3</SUP> or &lt; 4 x 10<SUP>3</SUP>/mcl, at least 3% band forming granulocytes, unexplained decrease in platelet count &lt; 100,000/mcl, deterioration of renal function due to acute tubular necrosis, unexplained decrease in systolic blood pressure of &gt; 30 mmHg, progressive respiratory failure</P>
<P>Mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-28 19:05:07 +1000" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Korinek-1993">
<CHAR_METHODS MODIFIED="2008-02-11 15:23:19 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled, dual-centre study<BR/>Blinding: double blind<BR/>Randomisation method: randomisation performed by the hospital pharmacist on each unit separately<BR/>Accrual period: Mar 89 to Sep 90</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-13 09:27:44 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: all comatosed patients with emergency admission to two neurosurgical ICUs and intubated within 24 hrs for at least five days, age &gt; 16 yrs<BR/>Exclusion criteria: age &lt; 16 yrs, known immunosuppression, antibiotic treatment during the two weeks preceding ICU admission, serious injury of oropharyngeal mucosa or epistaxis, abnormal chest X-ray on admission, extubation or infection occurring within the first five days of neurosurgical care</P>
<P>Number of patients enrolled in the study: 191<BR/>Percentage of ventilated patients: 100%<BR/>Length of stay in ICU, mean: 26 days<BR/>Type of admission diagnosis: surgical scheduled 11% surgical unscheduled 39% trauma 50%<BR/>Severity score on admission: SAPS mean = 10.9, ISS not available<BR/>Percentage of immunocompromised patients: 0%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: treatment = 0% CTR = 0%<BR/>Stress ulcer prophylaxis applied: sucralfate (32%), antiacids (14%), H2-blockers (20%) until enteral feeding was started</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-28 19:05:07 +1000" MODIFIED_BY="Clare Dooley">
<P>Group A, Treatment:<BR/>- polymyxin E 100 mg, tobramycin 80 mg, amphotericin B 500 mg applied enterally and, as a 2% paste, to the oropharynx four times a day for 15 days<BR/>- Vancomicin x os</P>
<P>Group B, CTR:<BR/>- Placebo</P>
<P>The non-absorbable antibiotics were discontinued if any infection requiring a parenteral antibiotic treatment occurred and at the time of patient's extubation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-03-29 00:07:02 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory infections (pneumonia acquired after five days)<BR/>Diagnosis of infection was based on:<BR/>fever &gt; 38.5°C, leukocytosis &gt; 12,000 cells/mm<SUP>3</SUP>, purulent sputum, new and persistent infiltrates on chest X-ray and a culture of &gt; 10<SUP>3</SUP> CFU/ml obtained with either brush or plugged telescoping catheter</P>
<P>Mortality: in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Setting: neurosurgical ICU<BR/>Personal contact with the main investigator provided data about 68 patients who were excluded from the published paper (early extubation, early death, protocol violation, transferring, other); these data are considered in the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-02-13 09:52:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krueger-2002">
<CHAR_METHODS MODIFIED="2008-02-07 16:13:37 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind, placebo-controlled, double centre study<BR/>Randomisation method: computer-generated randomisation<BR/>Accrual period: Apr 89 to Mar 91</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-07 16:22:31 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: expected stay in ICU &gt; two days and at least one risk factor for infection<BR/>Exclusion criteria: patients expected to die within 48 hrs or randomisation was not achieved within 12 hrs after admission to ICU.<BR/>Patients enrolled in the study: 546, 19 patients were excluded leaving 527 patients for analysis<BR/>Percentage of ventilated patients: not available<BR/>ICU length of stay: 10 days for both groups<BR/>Type of admission diagnosis: surgical<BR/>Severity score on admission: APACHE II mean = 20, ISS not available<BR/>Percentage of immunocompromised patients: not available<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated by protocol) in the first three days: not available<BR/>Stress ulcer prophylaxis applied: sucralfate to all patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:17:23 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, Treatment:<BR/>- polymyxin B 50 mg, gentamycin 80 mg, applied nasally, orally and enterally four times a day during the ICU stay<BR/>- ciprofloxacin 400 mg x 2 iv x four days to uninfected patients</P>
<P>Group B, CTR:<BR/>- Placebo applied nasally, orally and enterally<BR/>- Placebo iv to uninfected patients</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-02-13 09:52:55 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory infections (acquired pneumonia)</P>
<P>Mortality in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Information about accrual period and severity score was reported on an abstract previously published</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-03-27 10:36:05 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Laggner-1994">
<CHAR_METHODS MODIFIED="2008-02-11 15:31:53 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled study<BR/>Blinding: double blind<BR/>Randomisation method: computer generated randomisation in time blocks. Open<BR/>Accrual period: Aug 87 to Nov 90<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-07 16:22:33 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: expected ventilation for five days, age &gt; 18 yrs and &lt; 80 yrs, acute onset of respiratory failure<BR/>Exclusion criteria: age &lt; 18 yrs and &gt; 80 yrs, bleeding of the nasopharynx and of the upper gastrointestinal tract on admission, stress ulcer prophylaxis with other drug therapy than sucralfate, mechanical ventilation for less than five days, patients on enteral nutrition or with known allergy to sucralfate or gentamicin</P>
<P>Number of patients enrolled in the study: 88, but only 67 patients were analysed<BR/>Percentage of ventilated patients: 100%<BR/>Length of stay in ICU, mean: 28.8 days<BR/>Type of admission diagnosis: medical 88% surgical scheduled 9% surgical unscheduled 1% trauma = 2%<BR/>Severity score on admission: APACHE II mean = 23, ISS not available<BR/>Percentage of immunocompromised patients: 15%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: 100%<BR/>Stress ulcer prophylaxis applied: sucralfate</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-27 10:36:05 +1000" MODIFIED_BY="Liz Dooley">
<P>Group A, Treatment:<BR/>- gentamycin 40 mg, amphotericin B 100 mg applied to the oropharynx four times a day until extubation<BR/>- Oropharyngeal disinfectant<BR/>- aminopenicillin and clavulanic acid or other appropriate regimens</P>
<P>Group B, CTR:<BR/>- Placebo<BR/>- Amphotericin B 100 mg<BR/>- Oropharyngeal disinfectant<BR/>- Aminopenicillin and clavulanic acid or other appropriate regimens<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-02-11 15:32:07 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory infections (acquired pneumonia):<BR/>Diagnosis of infection was based on:<BR/>appearance of a new infiltrate on the chest film with concomitant tracheal colonisation, fever &gt; 38°C and &gt; 15,000 or &lt; 5,000 WBC/mm<SUP>3</SUP> of blood</P>
<P>Mortality: in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-01-31 15:15:54 +1000" MODIFIED_BY="[Empty name]">
<P>Data about 21 patients who were excluded from the published paper (18 short mechanical ventilation, three early enteral nutrition) are not available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-28 19:05:59 +1000" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Lingnau-1997">
<CHAR_METHODS MODIFIED="2008-02-11 15:32:09 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled study with three arms (one control arm and two treatment arms). Intention to treat<BR/>Blinding: double blind<BR/>Randomisation method: continuous random numbers assigned to blinded study drugs or vehicle by Biometric department.<BR/>Accrual period: Aug 89 to Jan 94</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-07 16:27:03 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: non infected trauma patients, age &gt; 18 yrs, expected ventilation for at least two days, expected ICU stay for at least three days, ISS &gt; 16 and &lt; 74, inclusion within 24 hrs of admission<BR/>Exclusion criteria: isolated brain injury, prior antibiotic treatment, history of infection</P>
<P>Patients enrolled in the study: 357 Percentage of ventilated patients: 100%<BR/>ICU length of stay, mean: 20 days<BR/>Type of admission diagnosis: trauma = 100%<BR/>Severity score on admission: APACHE II mean = 15.6, ISS mean = 35.2<BR/>Percentage of immunocompromised patients: 0%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated by protocol) in the first three days: treatment 1 = 2% treatment 2 = 2% CTR = 6%<BR/>Stress ulcer prophylaxis applied: free<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:17:26 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, Treatment 1:<BR/>- polymyxin E 100 mg, tobramycin 80 mg, amphotericin B 500 mg applied orally and enterally four times a day during the ICU stay<BR/>- ciprofloxacin 200 mg x 2 iv, for four days</P>
<P>Group C, CTR:<BR/>- Placebo<BR/>- ciprofloxacin 200 mg x 2 iv, for four days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-28 19:05:44 +1000" MODIFIED_BY="Clare Dooley">
<P>Respiratory infections (acquired pneumonia):<BR/>Diagnosis of infection was based on:<BR/>concomitant occurrence of purulent sputum, positive cultures of bronchial secretions and deterioration of lung function</P>
<P>Mortality: in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-28 19:05:59 +1000" MODIFIED_BY="Clare Dooley">
<P>This three arm study has been split in two comparisons; the control group C has been used twice:<BR/>comparison Lingnau a (group A versus group C)<BR/>comparison Lingnau b (group B versus group C)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-28 19:06:13 +1000" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Lingnau-1997b">
<CHAR_METHODS>
<P>see Lingnau 1997</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-28 19:06:13 +1000" MODIFIED_BY="Clare Dooley">
<P>see Lingnau 1997<BR/>Only two groups of patients, group B and C, are considered in this comparison, totaling 267 patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:17:18 +1000" MODIFIED_BY="[Empty name]">
<P>Group B, Treatment 2:<BR/>- polymyxin E 100 mg, ciprofloxacin 50 mg, amphotericin B 500 mg applied orally and enterally four times a day during the ICU stay<BR/>- ciprofloxacin 200 mg x 2 iv, for four days</P>
<P>Group C, CTR:<BR/>- Placebo<BR/>- ciprofloxacin 200 mg x 2 iv, for four days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>see Lingnau 1997</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>see Lingnau 1997</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-28 19:06:28 +1000" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Palomar-1997">
<CHAR_METHODS MODIFIED="2008-02-13 09:30:41 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, multicentric (10 ICUs) study with three arms (one treatment arm and two control arms; one control arm was excluded from meta-analysis because it was the only one receiving sucralfate)<BR/>Blinding: open<BR/>Randomisation method: sealed envelopes.<BR/>Accrual period: Jul 89 to Aug 91</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-13 09:30:43 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: patients requiring mechanical ventilation for more than four days, not infected at the time of entry and not receiving antibiotic therapy<BR/>Exclusion criteria: ARDS, leukopenia, pregnancy</P>
<P>Number of patients enrolled in the study: 97<BR/>Percentage of ventilated patients: 100%<BR/>Length of stay in ICU, median 10 days<BR/>Type of admission diagnosis: medical 40% surgical 10% trauma 50%<BR/>Severity score on admission: APACHE II mean = 16.8, ISS not available<BR/>Percentage of immunocompromised patients: 0%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: treatment = 0% CTR = 6%<BR/>Stress ulcer prophylaxis applied: sucralfate to one control group (excluded from meta-analysis), antiacids or H2-blockers to the two other groups</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:18:31 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, CTR 1:<BR/>- No prophylaxis</P>
<P>Group B, Treatment:<BR/>- polymyxin E + B 100 mg, tobramycin 80 mg, amphotericin B 500 mg applied enterally and, as a 2% paste, to the oropharynx four times a day until extubation<BR/>- cefotaxime 1 g x 3 iv for the first four days</P>
<P>Group C*, CTR 2:<BR/>- cefotaxime 1 g x 3 iv for the first four days<BR/>- sucralfate</P>
<P>* This group was excluded from analysis because it was the only one receiving sucralfate</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-28 19:06:22 +1000" MODIFIED_BY="Clare Dooley">
<P>Respiratory infections (acquired infections)<BR/>Diagnosis of pneumonia was based on the CDC criteria of 1980 (clinical or radiologic suspicion with: purulent sputum, organism isolated from blood culture, isolation of pathogen from tracheal aspirate, brush or biopsy. Bacteriologic evaluation was performed with brush or BAL in 50% of patients)<BR/>Diagnosis of tracheobronchitis was based on the CDC criteria of 1980</P>
<P>Mortality: in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-28 19:06:28 +1000" MODIFIED_BY="Clare Dooley">
<P>Personal contact with the main investigator provided data about 16 patients who were excluded from the published paper (seven early extubations, five early deaths, three protocol violation, one other); these data are considered in the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-28 19:06:35 +1000" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Pneumatikos-2002">
<CHAR_METHODS MODIFIED="2008-02-11 15:32:38 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled<BR/>Blinding: outcome assessor<BR/>Randomisation method: not stated<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-28 19:06:35 +1000" MODIFIED_BY="Clare Dooley">
<P>Elegibility criteria: patients with multiple trauma admitted to the intensive care unit who required intubation and had an expected time for mechanical ventilation exceeding five days<BR/>Absence of cardiopulmonary disease, negative chest radiography, and a PaO<SUB>2</SUB>/FIO<SUB>2</SUB> ratio higher than 300 mmHg</P>
<P>Patients enrolled in the study: 61</P>
<P>Percentage of ventilated patients: 100%<BR/>ICU length of stay, median:<BR/>Treatment = 16 days<BR/>Control = 23 days<BR/>Type of admission diagnosis:<BR/>trauma = 100%</P>
<P>Severity score on admission: APACHE II<BR/>treatment = 18.1<BR/>control = 19.1<BR/>Percentage of immunocompromised patients: not stated<BR/>Percentage of patients treated with systemic antibiotic therapy:<BR/>not stated<BR/>Stress ulcer prophylaxis applied: H2 blockers or sucralfate<BR/>Treatment = 26%<BR/>Control = 19%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:08:00 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, treatment:<BR/>polymyxin 73 mg,<BR/>tobramycin 73 mg, amphotericin 500 ml in 500 ml 0.9 saline solution at an infusion rate of 2 ml/hr in the subglottic area for the entire period of the study</P>
<P>Group B CTR:<BR/>placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-02-07 16:32:04 +1000" MODIFIED_BY="[Empty name]">
<P>Ventilator associated pneumonia (VAP) defined as presence of new and persistent pulmonary infiltrates in addition to two of the following criteria: body temperature &gt; 38.3 °C, leukocytes/mm<SUP>3</SUP>) or leukopenia (&lt; 4000 leukocytes/mm<SUP>3</SUP>) and purulent tracheal secretions. The diagnosis of VAP was confirmed by quantitative cultures.</P>
<P>Mortality: not specified</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-28 19:06:47 +1000" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Pugin-1991">
<CHAR_METHODS MODIFIED="2008-02-11 15:32:52 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled study<BR/>Blinding: double blind<BR/>Randomisation method: sealed envelopes<BR/>Accrual period: Apr 89 to Nov 89</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-01-31 12:31:16 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: all adult patients admitted to the surgical ICU, at high risk of developing pneumonia and intubated for more than 48 hrs<BR/>Exclusion criteria: organ transplantation</P>
<P>Number of patients enrolled in the study: 79<BR/>Percentage of ventilated patients: 100%<BR/>Length of stay in ICU, mean 13.8 days<BR/>Type of admission diagnosis: medical 11% surgical scheduled 11% surgical unscheduled 22% trauma 56%<BR/>Severity score on admission: APACHE II mean = 15.2, ISS not available<BR/>Percentage of immunocompromised patients: not available<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: treatment = 46% CTR = 53%<BR/>Stress ulcer prophylaxis applied: sucralfate (61%), ranitidine (11%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:21:09 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, Treatment:<BR/>- polymyxin B sulfate 150 mg, neomycin sulfate 1 g, vancomycin hydrochloride 1 g applied as a solution to the retropharynx six times a day within 24 hrs after intubation until extubation or death</P>
<P>Group B, CTR:<BR/>- Placebo</P>
<P>Withdrawal from the study was possible at any time if the treating physicians estimated that there was any problem related to administration of the drugs or side effects</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-01-31 15:18:07 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory infections (pneumonia acquired after 48 hrs): Pneumonia are defined by the "clinical pulmonary infections score" (CPIS) greater or equal to seven during the course of intubation and that remained elevated (=7) for at least three days (i.e. for two consecutive measurements)</P>
<P>Mortality: in hospital</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-28 19:06:47 +1000" MODIFIED_BY="Clare Dooley">
<P>Personal contact with the main investigator provided data about 27 patients who were excluded from the published paper (20 early extubations, seven early deaths); these data are considered in the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-02-13 09:14:58 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Quinio-1995">
<CHAR_METHODS MODIFIED="2008-02-11 15:33:07 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled study. Intention to treat<BR/>Blinding: double blind<BR/>Randomisation method: randomisation made by the Pharmacy's Service according to computer generated random numbers.<BR/>Accrual period: Jan 91 to Jan 93<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-01-31 13:56:05 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: trauma patients intubated within 24 hrs and ventilated for more than 48 hrs, ICU stay &gt; five days and decontamination for more than four days<BR/>Exclusion criteria: age &lt; 16 yrs, antibiotic treatment in the week precedent to ICU admission, pregnancy</P>
<P>Number of patients enrolled in the study: 149<BR/>Percentage of ventilated patients: 100%<BR/>Length of stay in ICU, mean = 20.5 days<BR/>Type of admission diagnosis: medical 2% trauma 98%<BR/>Severity score on admission: SAPS mean = 11.2, ISS mean = 31.3<BR/>GCS mean 6.5<BR/>Percentage of immunocompromised patients: 0%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: treatment = 35% CTR = 26%<BR/>Stress ulcer prophylaxis applied: sucralfate until enteral feeding was effective, H2-blockers in high risk patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:14:58 +1000" MODIFIED_BY="[Empty name]">
<P>Group A,Treatment:<BR/>- polymyxin E 100 mg, gentamycin 80 mg, amphotericin B 500 mg applied enterally and in the nares and, as a 2% paste, to the oropharynx four times a day until extubation or starting of enteral nutrition</P>
<P>Group B, CTR:<BR/>- Placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-01-31 13:56:17 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory infections (pneumonia acquired after 48 hrs): Diagnosis of infection was based on:<BR/>purulent tracheal aspirate, fever &gt; 38.5°C, leukocytosis &gt; 10,000 WBC/mm<SUP>3</SUP>, new and persistent infiltrate on chest X-ray</P>
<P>Mortality: in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-02-13 09:44:36 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rocha-1992">
<CHAR_METHODS MODIFIED="2008-02-11 15:33:19 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled study<BR/>Blinding: double blind<BR/>Randomisation method: made by the Pharmacy's service according to computer generated random numbers<BR/>Accrual period: Sept 89 to Oct 90</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-01-31 13:56:28 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: expected mechanical ventilation for more than three days, stay in ICU more than five days<BR/>Exclusion criteria: infection or strong suspicion of this at the start of ventilation, antibiotic treatment in the previous seven days, neutropenia (WBC &lt; 500/mm<SUP>3</SUP>) and fever, pregnancy, history of hypersensitivity to the topical agents</P>
<P>Number of patients enrolled in the study: 151<BR/>Percentage of ventilated patients: 100%<BR/>Length of stay in ICU, median eight days<BR/>Type of admission diagnosis: medical 28% surgical scheduled 3% surgical unscheduled 1% trauma 68%<BR/>Severity score on admission: APACHE II mean = 16.3, ISS not available, GCS mean = nine<BR/>Percentage of immunocompromised patients: 0.7%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: treatment = 0% CTR = 0%<BR/>Stress ulcer prophylaxis applied: H2-blockers and antiacids</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:10:44 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, Treatment:<BR/>- polymyxin E 100 mg, tobramycin 80 mg, amphotericin B 500 mg applied enterally and, as a 2% paste, to the oropharynx four times a day<BR/>- cefotaxime 6 g/day iv for the first four days</P>
<P>Group B, CTR:<BR/>- Placebo<BR/>- No systemic prophylaxis<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-02-11 15:30:31 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory infections (acquired pneumonia):<BR/>Diagnosis of infection was based on:<BR/>purulent pulmonary secretions, new infiltrates in the chest X-ray and one of the following: fever/hypothermia, leukocytosis/leukopenia, positive physical examination, drop in arterial partial oxygen pressure. Bacteriologic diagnosis, even if performed (with brush in few patients), was not essential</P>
<P>Mortality: in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-02-13 09:44:36 +1000" MODIFIED_BY="[Empty name]">
<P>Personal contact with the main investigator provided mortality data about 50 patients who were excluded from the published paper (15 early extubations, 31 early deaths, two protocol violation, two other); these data are considered in the analysis. Data about respiratory infections in excluded patients are not available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-28 19:07:13 +1000" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Rodriguez_x002d_Rolda-1990">
<CHAR_METHODS MODIFIED="2008-02-11 15:33:32 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled, dual-center study<BR/>Blinding: double blind<BR/>Randomisation method: odd and even numbers<BR/>Accrual period: Jun 88 to Dec 88</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-01-31 12:32:36 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: patients intubated an mechanically ventilated for more than 72 hrs<BR/>Exclusion criteria: patients whose chest X-rays was difficult to interpret, with suspected inflammatory images during the first 72 hrs, patients ventilated for less time</P>
<P>Number of patients enrolled in the study: 31<BR/>Percentage of ventilated patients: 100%<BR/>Length of stay in ICU, median 13.5 days<BR/>Type of admission diagnosis: medical 39% surgical scheduled 16% surgical unscheduled 3% trauma 42%<BR/>Severity score on admission: APACHE II mean = 17.1, ISS not available<BR/>Percentage of immunocompromised patients: 0%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: treatment = 36% CTR = 35%<BR/>Stress ulcer prophylaxis applied: sucralfate or alkaline agents plus ranitidine according to a randomised open protocol</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:09:33 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, Treatment:<BR/>- polymyxin E, Tobramicin or Netilmicin, amphotericin B and antiseptic applied enterally and, as a 2% paste, to the oropharynx four times a day<BR/>- Antiseptic</P>
<P>Group B, CTR:<BR/>- Placebo<BR/>- Antiseptic<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-28 19:07:13 +1000" MODIFIED_BY="Clare Dooley">
<P>Respiratory infections (pneumonia acquired after 72 hrs): Diagnosis of infection was based on the presence of at least one in each category of criteria:<BR/>A) Clinical criteria: temperature &gt; 38°C, purulent bronchorrhoea, leukocytosis &gt; 15,000 WBC/mm<SUP>3</SUP>, increased alveolar-arterial oxygen gradient;<BR/>B) Radiologic criteria: new and persistent infiltrate;<BR/>C) Bacteriologic criteria: quantitative culture of tracheal aspirates &gt; 10<SUP>3</SUP> CFU/ml (in six patients either bronchoscopy or a telescoped catheter were used to obtain the sample)</P>
<P>Mortality: in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-02-13 09:32:13 +1000" MODIFIED_BY="[Empty name]">
<P>Personal contact with the main investigator provided data about three patients who were excluded from the published paper (two early deaths, one other); these data are considered in the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-02-13 09:44:39 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sanchez_x002d_Garcia-1992">
<CHAR_METHODS MODIFIED="2008-02-11 15:33:43 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled, multicentric (five ICUs) study<BR/>Blinding: double blind<BR/>Randomisation method: sealed envelopes.<BR/>Accrual period: not available</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-01-31 15:19:15 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: expected ventilation for longer than 48 hrs, age &gt; 16 yrs<BR/>Exclusion criteria: death or extubation before 48 hrs, pregnancy, allergy to study antibiotics, organ transplantation, absence or contraindication to nasogastric tube</P>
<P>Number of patients enrolled in the study: 271<BR/>Percentage of ventilated patients: 100%<BR/>Length of stay in ICU, median 13 days<BR/>Type of admission diagnosis: medical 70% surgical scheduled 3% surgical unscheduled 9% trauma 18%<BR/>Severity score on admission: APACHE II mean = 26.6, ISS not available<BR/>Percentage of immunocompromised patients: 4.4%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: treatment = 70% CTR = 69%<BR/>Stress ulcer prophylaxis applied: each group was randomised to receive either sucralfate or H2-blockers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:15:00 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, Treatment:<BR/>- polymyxin E 100 mg, gentamycin 80 mg, amphotericin B 500 mg applied orally and enterally four times a day until extubation<BR/>- Ceftriaxone 2 g/day iv x three days to uninfected patients</P>
<P>Group B, CTR:<BR/>- Placebo<BR/>- Systemic placebo to uninfected patients</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-01-31 12:33:51 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory infections (early and late acquired pneumonia):<BR/>Diagnosis of infection was based on:<BR/>new and persistent infiltrate on chest X-ray and three of the following: temperature &gt; 38.5°C, leukocytosis &gt; 12,000 WBC/mm<SUP>3</SUP> or leukopenia &lt; 3,000 WBC/mm<SUP>3</SUP>, purulent tracheal aspirate with growth of a potentially pathogenic micro-organism</P>
<P>Mortality: in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-02-13 09:44:39 +1000" MODIFIED_BY="[Empty name]">
<P>Personal contact with the main investigator provided data about 45 patients who were excluded from the published paper (12 early extubations, 12 early deaths, 17 protocol violation, two transferring, two other); these data are considered in the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-03-29 00:11:50 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stoutenbeek-1996">
<CHAR_METHODS MODIFIED="2008-01-31 12:34:02 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled study<BR/>Blinding: double blind.<BR/>Randomisation method: closed envelope method (the code was known by the pharmacist only).<BR/>Accrual period: Nov 84 to Aug 86<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-01-31 15:19:57 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: all patients admitted to the surgical ICU with blunt trauma and an HTI-ISS &gt; 18, age &gt; 18 yrs<BR/>Exclusion criteria: patients mechanically ventilated for less than five days or discharged from ICU within seven days and with an HTI-ISS &lt; 18 after 24 hrs</P>
<P>Number of patients enrolled in the study: 91<BR/>Percentage of ventilated patients: 100%<BR/>Length of stay in ICU, mean = 15 days<BR/>Type of admission diagnosis: trauma 100%<BR/>Severity score on admission: APACHE II mean = 10.6, HTI-ISS mean = 35.1<BR/>Percentage of immunocompromised patients: 0%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: treatment = 0% CTR = 0%<BR/>Stress ulcer prophylaxis applied: none except for patients with history of preexisting ulcer or on H2-blockers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:10:45 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, Treatment:<BR/>- polymyxin E 100 mg, tobramycin 80 mg, amphotericin 500 mg applied enterally and, as a 2% paste, to the oropharynx four times a day until ICU discharge<BR/>- cefotaxime 50 to 100 mg/kg/day iv for the first five days</P>
<P>Group B, CTR:<BR/>- Placebo<BR/>- cefotaxime 50 to 100 mg/kg/day iv for the first five days</P>
<P>The blinded medication was discontinued and topical prophylaxis was started when a patient developed MOSF not responding to conventional therapy. The code was not broken and the patient was further evaluated<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-03-29 00:11:50 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory infections (tracheobronchitis and pneumonia - early and late infections)<BR/>Diagnosis of infection was based on clinical criteria: temperature &gt; 38.5°C, WBC &gt; 12.5 x 10<SUP>9</SUP>/l or leukopenia &lt; 4 x 10^9/l, purulent secretions or X-ray changes and significant growth of bacteria</P>
<P>Mortality: in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-02-13 09:44:40 +1000" MODIFIED_BY="[Empty name]">
<P>Data about 32 patients who were initially excluded (25 early extubations, four early deaths, three other) are considered in the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-28 19:07:24 +1000" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Stoutenbeek-2007">
<CHAR_METHODS MODIFIED="2008-02-13 09:46:23 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, multicenter study. Intention to treat<BR/>Blinding: open<BR/>Randomisation method: randomisation lists prepared by the Biometrical Department and supplied with sealed envelopes<BR/>Accrual period: Oct 91 to Jun 94<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-13 09:53:18 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: patients admitted within 24 hrs after nonpenetrating blunt trauma with an HTI-ISS &gt;= 16, necessitating mechanical ventilation, age &gt; 18 yrs<BR/>Exclusion criteria: previous antibiotic use for more than three days at study entry, allergy to cefotaxime, referred patients from other hospital or secondary admissions with trauma occurred &gt; 24 hrs before</P>
<P>Number of patients enrolled in the study: 405, but 401 patients were analysed<BR/>Percentage of ventilated patients: 100%<BR/>Median length of ICU stay: SDD = 13 days, CTR = 12 days<BR/>Median duration of mechanical ventilation: SDD = nine days, CTR = eight days<BR/>Type of admission diagnosis: trauma 100%<BR/>Severity score on admission - APACHE II median: SDD = 15, CTR = 14 and HTI-ISS median: SDD = 34, CTR = 29<BR/>Percentage of immunocompromised patients: 0%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: treatment = 46% CTR = 88%<BR/>Stress ulcer prophylaxis applied: sucralfate, H2-blockers, omeprazole; no sucralfate</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:10:48 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, Treatment:<BR/>- polymyxin E, tobramycin, amphotericin B administered through the nasogastric tube and applied to the buccal mucosa four times a day until discharge<BR/>- cefotaxime 1 g every six hours for four days</P>
<P>Group B, CTR:<BR/>- Standard antibiotic prophylaxis used in each centres (no fluoroquinolones)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-02-13 09:46:55 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: Mortality from infection or multiple organ failure in ICU or up to two weeks after discharge</P>
<P>Secondary: incidence of infection, multiple organ failure and antibiotic usage</P>
<P>The maximum observation period was three months<BR/>Patients dying within 24 hours after injury or dying from craniocerebral trauma were excluded</P>
<P>Diagnosis of pneumonia was based on any of the following: presence of a new and progressive pulmonary infiltrate on chest X-ray for &gt;= 48 hrs, purulent tracheal aspirate, fever &gt; 38.5°C, leukocytosis &gt; 12,000/ml or leukopenia &lt; 4000/ml<BR/>Diagnosis of tracheobronchitis was based on the same criteria except for the radiographic changes<BR/>Mortality: in ICU or up to two weeks after discharge</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-28 19:07:24 +1000" MODIFIED_BY="Clare Dooley">
<P>four patients were excluded from the final analysis after randomisation: two because they did not fulfil the inclusion criteria, the data for one patient were not available and one was lost to follow-up after the 7th day</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-02-13 09:12:16 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ulrich-1989">
<CHAR_METHODS MODIFIED="2008-02-11 15:35:29 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled study<BR/>Blinding: open<BR/>Randomisation method: sealed envelopes containing a random code for clusters of four patients<BR/>Accrual period: Oct 86 to Sep 87</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-07 16:22:37 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: patients expected to stay in the ICU more than five days and ventilated more than 48 hrs<BR/>Exclusion criteria: patients who died within 24 hrs after randomisation</P>
<P>Number of patients enrolled in the study: 112<BR/>Percentage of ventilated patients: about 80%<BR/>Length of stay in ICU, median = 10 days<BR/>Type of admission diagnosis: medical 34% surgical scheduled 19% surgical unscheduled 31% trauma 16%<BR/>Severity score on admission: SAPS mean = 11.7, ISS mean = 36.9<BR/>Percentage of immunocompromised patients: 3%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: treatment = 83% CTR = 81%<BR/>Stress ulcer prophylaxis applied: not available</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:12:16 +1000" MODIFIED_BY="[Empty name]">
<P>Group A,Treatment:<BR/>- polymyxin E 100 mg, norfloxacin 50 mg, amphotericin B 500 mg, applied enterally and, as a 2% paste, to the oropharynx four times a day<BR/>- Trimethoprim 500 mg iv</P>
<P>Group B, CTR:<BR/>- Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Respiratory infections (acquired pneumonia): <BR/>Diagnosis of infection was based on clinical and radiologic signs of pulmonary infiltrations with fever and leukocytosis and a dense growth in cultures of sputum of tracheal aspirate</P>
<P>Mortality: in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Personal contact with the main investigator provided data about 12 patients who were excluded from the published paper (early death); these data are considered in the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-28 19:07:36 +1000" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Unertl-1987">
<CHAR_METHODS MODIFIED="2008-03-29 00:12:51 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised study<BR/>Blinding: outcome assessor<BR/>Randomisation method: blocked randomisation scheme and the sealed envelope technique. Blind<BR/>Accrual period: May 84 to Jan 85<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-07 16:35:18 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: all patients admitted to the ICU with: intubation within 24 hrs after the onset of an acute disease or surgery, expected ventilation &gt; six days, interval between intubation and first microbiologic culture &lt; 36 hrs<BR/>Exclusion criteria: Patients with infection, systemic antibiotic treatment, respiratory distress syndrome, leucopenia and myelosuppression on admission, renal failure</P>
<P>Number of patients enrolled in the study: 39<BR/>Percentage of ventilated patients: 100%<BR/>Length of stay in ICU: not available<BR/>Type of admission diagnosis: medical 52%, surgical 15%, trauma 33%<BR/>Severity score on admission: SAPS mean = 12.5, GCS (75% of patients have GCS &lt; 7)<BR/>Percentage of immunocompromised patients: not available<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: not available<BR/>Stress ulcer prophylaxis applied: H2-blockers to all patients and antiacids if pH &lt; 4</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:15:01 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, Treatment:<BR/>- polymyxin B 50 mg, gentamycin 80 mg, applied orally, nasally and enterally four times a day until extubation<BR/>- Amphoterycin B 300 mg applied orally four times a day</P>
<P>Group B, CTR:<BR/>- No prophylaxis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-28 19:07:36 +1000" MODIFIED_BY="Clare Dooley">
<P>Respiratory infections (acquired pneumonia):<BR/>Diagnosis of infection was based on:<BR/>new 'definite' infiltrate on chest X-ray together with increasing amounts of purulent tracheobronchial secretion containing &gt; 3 x 10<SUP>4</SUP> granulocytes/mcl and at least two of the following: new febrile spikes &gt; 38.5°C, blood leukocyte count &gt; 12000/mcl or &lt; 4000/mcl, decrease of PaO<SUB>2</SUB> requiring an increase of the FiO<SUB>2</SUB> of at least 15% to maintain oxygen tension.<BR/>'Definite' is an infiltrate confirmed by two blind independent radiologists and not reversible after chest physiotherapy</P>
<P>Mortality: in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-28 19:07:42 +1000" MODIFIED_BY="Clare Dooley" STUDY_ID="STD-Verwaest-1997">
<CHAR_METHODS MODIFIED="2008-02-11 15:36:05 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised study with three arms (one control arm and two treatment arms)<BR/>Blinding: open<BR/>Randomisation method: sealed envelopes with computer generated random numbers<BR/>Accrual period: Sept 89 to Mar 91<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-28 19:07:42 +1000" MODIFIED_BY="Clare Dooley">
<P>Eligibility criteria: expected ventilation &gt; 48 hrs<BR/>Exclusion criteria: age &lt; 18 yrs, pregnancy, recent organ transplantation, serious granulocytopenia (&lt;= 500 WBC/mm<SUP>3</SUP>), ventilation &lt; 48 hrs, death before 48 hrs, missing of essential data in the clinical or bacteriological dossier</P>
<P>Number of patients enrolled in the study: 660 (only two groups of patients, A and B, are considered in this comparison, totaling 440 patients)<BR/>Percentage of ventilated patients: 100%<BR/>Length of stay in ICU, mean = 19.6 days<BR/>Type of admission diagnosis: medical 10%, surgical 67% trauma 23%<BR/>Severity score on admission: APACHE II mean = 18.1, ISS not available<BR/>Percentage of immunocompromised patients: not available<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: treatment one = 34% treatment twp = 31% CTR = 34%<BR/>Stress ulcer prophylaxis applied: sucralfate 2 g x 4</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-07 16:36:24 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, CTR:<BR/>- No prophylaxis, antibiotic therapy was used only if an infection was suspected</P>
<P>Group B, Treatment 1:<BR/>- Ofloxacin 200 mg x 2, Amphoterycin B 500 mg x 4 applied enterally and, as a 2% paste, to the oropharynx four times a day until discharge<BR/>- Ofloxacin 200 mg iv x four days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-01-31 15:22:58 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory infections (pneumonia acquired after 48 hrs):<BR/>Diagnosis of infection was based on:<BR/>Fever &gt; 38.5°C, leukocytosis &gt; 10,000 cells/mcl, luxuriant growth of potentially pathogenic micro-organisms in culture of bronchial aspirate, new and persistent infiltrate on chest X-ray</P>
<P>Mortality: in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-02-13 09:32:23 +1000" MODIFIED_BY="[Empty name]">
<P>Personal contact with the main investigator provided mortality data about 82 patients who were excluded (33 early deaths, 49 other); these data are considered in the analysis.Data about respiratory infections in excluded patients are not available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-03-29 00:14:51 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wiener-1995">
<CHAR_METHODS MODIFIED="2008-02-11 15:36:23 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled study<BR/>Blinding: double blind<BR/>Randomisation method: random number table in blocks of six patients<BR/>Accrual period: eight months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-07 16:36:52 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: expected intubation for more than 48 hrs, inclusion within 18 hrs of intubation, age &gt; 18 yrs<BR/>Exclusion criteria: refusal to consent, allergy to one of the components of the regimen, active inflammatory bowel disease</P>
<P>Patients enrolled in the study: 121, but 60 patients were excluded leaving 61 patients for analysis<BR/>Percentage of ventilated patients: 100%<BR/>Length of stay in ICU, mean: 11.3 days<BR/>Type of admission diagnosis: not available<BR/>Severity score on admission: APACHE II mean = 27.2, ISS not available<BR/>Percentage of immunocompromised patients: &gt; 5%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: treatment = 93% CTR = 81%<BR/>Stress ulcer prophylaxis applied: H2-blockers to most patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:15:02 +1000" MODIFIED_BY="[Empty name]">
<P>Group A, Treatment:<BR/>- polymyxin E 100 mg, gentamycin 80 mg, nystatin 2,000,000 UI applied enterally four times a day and, as a 2% paste, to the oropharynx until extubation or tracheostomy</P>
<P>Group B, CTR:<BR/>- Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-03-29 00:14:51 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory infections (pneumonia acquired after 48 hrs):<BR/>Diagnosis of infection was based on the presence of the following: persistence of a new or progressive infiltrate on chest-film, fever &gt; 38.5°C and/or leukocytosis &gt; 12,000/mm<SUP>3</SUP>, growth of &gt; 10<SUP>3</SUP> bacteria from a quantitative culture of lower respiratory tract secretions obtained with a blind protected catheter</P>
<P>Mortality: in ICU</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>60 patients were excluded after randomisation; data are not available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-03-29 00:15:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Winter-1992">
<CHAR_METHODS MODIFIED="2008-01-31 12:38:13 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised study<BR/>Blinding: open.<BR/>Randomisation method: sealed envelopes based on a computer generated table of random numbers.<BR/>Accrual period: Jul 88 to May 90</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-02-07 16:37:04 +1000" MODIFIED_BY="[Empty name]">
<P>Eligibility criteria: patients likely to remain in the ICU for at least 48 hrs<BR/>Exclusion criteria: allergy to the antibiotics used, age &gt; 85 yrs, pregnancy</P>
<P>Patients enrolled in the study: 183<BR/>Percentage of ventilated patients: 92%<BR/>Length of stay in ICU, median = four days<BR/>Type of admission diagnosis: medical 40% surgical scheduled 10% surgical unscheduled 37% trauma 13%<BR/>Severity score on admission: APACHE II mean = 15.3, ISS mean = 26.2<BR/>Percentage of immunocompromised patients: 2.2%<BR/>Percentage of patients treated with systemic antibiotic therapy (not stated in the protocol) in the first three days: treatment = 47% CTR = 64%<BR/>Stress ulcer prophylaxis applied: all CTR patients received sucralfate; H2-blockers were used in patients of both groups with peptic ulcer or pancreatitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-13 09:09:37 +1000" MODIFIED_BY="[Empty name]">
<P>Group B, CTR:<BR/>- Conventional infections treatment and prophylaxis</P>
<P>Group C, Treatment:<BR/>- polymyxin E 100mg, tobramycin 80mg, amphotericin B 500 mg applied enterally and, as a 2% gel, to the oropharynx four times a day<BR/>- Ceftazidime 50mg/kg/day iv x three days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-03-29 00:15:22 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory infections (pneumonia acquired after 48 hrs): Diagnosis of infection was based on:<BR/>temperature &gt; 38.5°C two times in 24 hrs, WBC &lt; 4 or &gt; 12 x 10<SUP>9</SUP>/l, positive BAL, two of the following: new pulmonary infiltrates on chest X-ray, purulent sputum, increase of 15% in FiO<SUB>2</SUB> to maintain previous oxygenation</P>
<P>Mortality: in hospital<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Few patients were excluded after randomisation; data are not available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>APACHE Acute Physiology and Chronic Health Evaluation<BR/>ARDS Acute Respiratory Distress Syndrome<BR/>BAL Broncho-Alveolar-Lavage<BR/>CCU Coronary Care Unit<BR/>CDC Centre for Disease Control<BR/>CFU Colony Forming Unit<BR/>CI Confidence Interval<BR/>CTR Control group<BR/>GCS Glasgow Coma Score<BR/>hrs hours<BR/>HTI-ISS Hospital Trauma Index-Injury Severity Score<BR/>ICU Intensive Care Unit<BR/>ISS Injury Severity Score<BR/>iv intravenous<BR/>MOSF Multi-Organ-System-Failure<BR/>OR Odds Ratio<BR/>RCTs Randomised Controlled Trials<BR/>RD Risk Differences<BR/>RR Relative Risk<BR/>RTIs Respiratory Tract Infections<BR/>SAPS Symplified Acute Physiology Score<BR/>SDD Selective Decontamination of the Digestive Tract<BR/>VAP Ventilator Associated Pneumonia<BR/>VO2 Oxygen Consumption<BR/>yrs years<BR/>WBC White Blood Count<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-03-27 10:35:33 +1000" MODIFIED_BY="Liz Dooley" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Arnow-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study included a selected population of patients undergoing liver transplant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-02-07 16:43:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barret-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-02-07 16:43:13 +1000" MODIFIED_BY="[Empty name]">
<P>The study included only paediatric burns patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bion-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study included a selected population of patients undergoing liver transplant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bouter-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study included only patients undergoing cardiopulmonary by-pass</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-02-07 16:38:53 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-la-Cal-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-02-07 16:38:53 +1000" MODIFIED_BY="[Empty name]">
<P>The study included only critically ill burns patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-27 10:35:33 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-de-Smet-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-27 10:35:33 +1000" MODIFIED_BY="Liz Dooley">
<P>The study adopted a cluster design with type of treatments alternated for specific periods of time across participating hospitals. As a consequence patients were not properly randomised and the study could be affected by selection bias.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-02-13 09:53:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Flaherty-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-02-13 09:53:21 +1000" MODIFIED_BY="[Empty name]">
<P>The study included a selected population of cardio surgical patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Garbino-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study tested the effectiveness of fluconazole as both groups received SDD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hellinger-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study included only liver transplant patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hunefeld-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>After contacting the principal investigator it become apparent that it was not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-06 09:33:19 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Jacobs-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-06 09:33:19 +1000" MODIFIED_BY="Liz Dooley">
<P>This study, included in the previous version of this review as a personal contact with the principal investigator, has been excluded due to lack of feedback from the trial author. To date, this study has never been published</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-06 09:33:36 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Lenhart-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-06 09:33:36 +1000" MODIFIED_BY="Liz Dooley">
<P>This study, included in the previous version of this review as a congress proceeding, has been replaced by its published article (<LINK REF="STD-Krueger-2002" TYPE="STUDY">Krueger 2002</LINK>)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lipman-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>After contacting the principal investigator it become apparent that it was not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Luiten-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study included a selected population of patients affected by pancreatitis characterised by a low percentage of ICU admissions.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Martinez-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study compared the effect of two different prophylactic regimens without a control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-02-13 09:53:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martinez_x002d_Pellus-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-02-13 09:53:23 +1000" MODIFIED_BY="[Empty name]">
<P>The study included a selected population of cardio surgical patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nardi-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study tested the effectiveness of mupirocin as both groups received SDD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rayes-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study included only liver transplant patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rolando-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study included a selected population of patients with acute hepatic failure</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-02-07 16:41:56 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ruza-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-02-07 16:41:56 +1000" MODIFIED_BY="[Empty name]">
<P>The study included only paediatric burns patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schardey-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study included a selected population of patients undergoing gastric surgery and characterised by a low percentage of ICU admission</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-02-07 16:42:07 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-02-07 16:42:07 +1000" MODIFIED_BY="[Empty name]">
<P>The study included only paediatric, liver transplant patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-06 09:34:02 +1000" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Stoutenbeek-2">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-06 09:34:02 +1000" MODIFIED_BY="Liz Dooley">
<P>This unpublished study, included in the previous version of this review, has been replaced by its published article (<LINK REF="STD-Stoutenbeek-2007" TYPE="STUDY">Stoutenbeek 2007</LINK>)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tetteroo-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study included a selected population of patients undergoing oesophageal resection and characterised by a short length of stay in ICU</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-02-07 16:42:10 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zobel-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-02-07 16:42:10 +1000" MODIFIED_BY="[Empty name]">
<P>The study included only paediatric patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zwaveling-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study included only liver transplant patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-07-29 23:34:01 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-07-29 23:34:01 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Abele_x002d_Horn-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Aerdts-1991">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bergmans-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Blair-1991">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Boland-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Brun_x002d_Buisson-1989">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Camus-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Cerra-1992">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cockerill-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ferrer-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Finch-1991">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gastinne-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Gaussorgues-1991">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Georges-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hammond-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Jacobs-1992">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Kerver-1988">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Korinek-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Krueger-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Laggner-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lingnau-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lingnau-1997b">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Palomar-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pneumatikos-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Pugin-1991">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Quinio-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rocha-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Rodriguez_x002d_Rolda-1990">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Sanchez_x002d_Garcia-1992">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Stoutenbeek-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Stoutenbeek-2007">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Ulrich-1989">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Unertl-1987">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Verwaest-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wiener-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Winter-1992">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-de-Jonge-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-07-25 10:26:33 +1000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-07-25 09:39:37 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Topical plus systemic versus no prophylaxis</NAME>
<DICH_OUTCOME CHI2="15.545700253971583" CI_END="0.8665267369876117" CI_START="0.6525774325272966" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7519812452712047" ESTIMABLE="YES" EVENTS_1="496" EVENTS_2="614" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.062218032434151097" LOG_CI_START="-0.1853679490868074" LOG_EFFECT_SIZE="-0.12379299076047924" METHOD="MH" MODIFIED="2009-02-23 07:49:58 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="0.48509148433895943" P_Q="1.0" P_Z="8.134674982651322E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="17" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2025" TOTAL_2="2050" WEIGHT="100.00000000000001" Z="3.9403973632134117">
<NAME>Overall mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.7446599347135474" CI_START="0.36569353198544363" EFFECT_SIZE="1.1702127659574468" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.573412384069334" LOG_CI_START="-0.43688272095228137" LOG_EFFECT_SIZE="0.06826483155852639" ORDER="1" O_E="0.0" SE="0.5934523457311225" STUDY_ID="STD-Abele_x002d_Horn-1997" TOTAL_1="58" TOTAL_2="30" VAR="0.35218568665377176" WEIGHT="1.2092967106094308"/>
<DICH_DATA CI_END="2.287940017598692" CI_START="0.19425528686320684" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="0.35944463447091224" LOG_CI_START="-0.7116271525822747" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="39" O_E="0.0" SE="0.6291528696058958" STUDY_ID="STD-Aerdts-1991" TOTAL_1="28" TOTAL_2="60" VAR="0.3958333333333333" WEIGHT="1.482031713427728"/>
<DICH_DATA CI_END="1.3488211457155383" CI_START="0.4231410889989549" EFFECT_SIZE="0.7554744525547445" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="32" LOG_CI_END="0.1299543658479776" LOG_CI_START="-0.373514800574918" LOG_EFFECT_SIZE="-0.1217802173634702" ORDER="40" O_E="0.0" SE="0.29574028056937657" STUDY_ID="STD-Blair-1991" TOTAL_1="161" TOTAL_2="170" VAR="0.08746231355125357" WEIGHT="5.997775876832725"/>
<DICH_DATA CI_END="2.750140075418289" CI_START="0.07918788563693593" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4393548147146009" LOG_CI_START="-1.1013412527974495" LOG_EFFECT_SIZE="-0.3309932190414244" ORDER="41" O_E="0.0" SE="0.9050124966251124" STUDY_ID="STD-Boland-1991" TOTAL_1="32" TOTAL_2="32" VAR="0.819047619047619" WEIGHT="0.8490806691513025"/>
<DICH_DATA CI_END="1.4758152681157866" CI_START="0.27218079689436714" EFFECT_SIZE="0.6337890625" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.16903199904602084" LOG_CI_START="-0.5651425187249063" LOG_EFFECT_SIZE="-0.19805525983944272" ORDER="42" O_E="0.0" SE="0.43125774596111754" STUDY_ID="STD-Cockerill-1992" TOTAL_1="75" TOTAL_2="75" VAR="0.1859832434514638" WEIGHT="3.0914083740833203"/>
<DICH_DATA CI_END="0.9419229061649299" CI_START="0.5291735757540101" EFFECT_SIZE="0.7060033373433194" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="146" LOG_CI_END="-0.025984641577934012" LOG_CI_START="-0.2764018504080841" LOG_EFFECT_SIZE="-0.15119324599300907" ORDER="43" O_E="0.0" SE="0.14709630805200566" STUDY_ID="STD-de-Jonge-2003" TOTAL_1="466" TOTAL_2="468" VAR="0.021637323842530545" WEIGHT="24.987819858226885"/>
<DICH_DATA CI_END="7.897779386018733" CI_START="0.7913616846609111" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.8975049981302209" LOG_CI_START="-0.10162498078614562" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="44" O_E="0.0" SE="0.5868938953886337" STUDY_ID="STD-Finch-1991" TOTAL_1="24" TOTAL_2="25" VAR="0.34444444444444444" WEIGHT="0.8317524922298474"/>
<DICH_DATA CI_END="1.0627324410549521" CI_START="0.19191492277922798" EFFECT_SIZE="0.45161290322580644" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="23" LOG_CI_END="0.026423938088993383" LOG_CI_START="-0.7168912544010628" LOG_EFFECT_SIZE="-0.3452336581560347" ORDER="45" O_E="0.0" SE="0.4366270235382035" STUDY_ID="STD-Jacobs-1992" TOTAL_1="45" TOTAL_2="46" VAR="0.1906431576838309" WEIGHT="3.548099733948007"/>
<DICH_DATA CI_END="2.0407968368956793" CI_START="0.3568105186234178" EFFECT_SIZE="0.8533333333333334" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.3097997724736384" LOG_CI_START="-0.4475623512892641" LOG_EFFECT_SIZE="-0.06888128940781285" ORDER="46" O_E="0.0" SE="0.44487826050130463" STUDY_ID="STD-Kerver-1988" TOTAL_1="49" TOTAL_2="47" VAR="0.19791666666666666" WEIGHT="2.476485285024632"/>
<DICH_DATA CI_END="0.9122283619580175" CI_START="0.40616696330394897" EFFECT_SIZE="0.6087010954616588" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="75" LOG_CI_END="-0.039896429299223136" LOG_CI_START="-0.3912954040190561" LOG_EFFECT_SIZE="-0.21559591665913963" ORDER="47" O_E="0.0" SE="0.2064134972034083" STUDY_ID="STD-Krueger-2002" TOTAL_1="265" TOTAL_2="262" VAR="0.04260653182774144" WEIGHT="13.727072677740223"/>
<DICH_DATA CI_END="2.3317307496152946" CI_START="0.40537101015572424" EFFECT_SIZE="0.9722222222222222" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.36767839998603896" LOG_CI_START="-0.3921473128200622" LOG_EFFECT_SIZE="-0.012234456417011635" ORDER="48" O_E="0.0" SE="0.44632538490024204" STUDY_ID="STD-Palomar-1997" TOTAL_1="50" TOTAL_2="49" VAR="0.19920634920634922" WEIGHT="2.3053826653320213"/>
<DICH_DATA CI_END="1.0189574793666545" CI_START="0.27711447807661915" EFFECT_SIZE="0.5313829787234042" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="40" LOG_CI_END="0.008156061472842027" LOG_CI_START="-0.5573407835482371" LOG_EFFECT_SIZE="-0.2745923610376976" ORDER="49" O_E="0.0" SE="0.33217564601991056" STUDY_ID="STD-Rocha-1992" TOTAL_1="74" TOTAL_2="77" VAR="0.11034065980874491" WEIGHT="5.638045591185691"/>
<DICH_DATA CI_END="1.1927761794545892" CI_START="0.4536252643901103" EFFECT_SIZE="0.7355769230769231" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="65" LOG_CI_END="0.07655895737759512" LOG_CI_START="-0.34330276566792056" LOG_EFFECT_SIZE="-0.13337190414516273" ORDER="50" O_E="0.0" SE="0.2466288544659842" STUDY_ID="STD-Sanchez_x002d_Garcia-1992" TOTAL_1="131" TOTAL_2="140" VAR="0.06082579185520362" WEIGHT="8.689238828215052"/>
<DICH_DATA CI_END="1.5090163852666119" CI_START="0.5812382953597286" EFFECT_SIZE="0.9365351629502573" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="44" LOG_CI_END="0.17869395547621283" LOG_CI_START="-0.23564577958476657" LOG_EFFECT_SIZE="-0.028475912054276853" ORDER="51" O_E="0.0" SE="0.24338521138958621" STUDY_ID="STD-Stoutenbeek-2007" TOTAL_1="201" TOTAL_2="200" VAR="0.05923636112315357" WEIGHT="7.900473298596857"/>
<DICH_DATA CI_END="1.029835736720453" CI_START="0.22826752352611648" EFFECT_SIZE="0.48484848484848486" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="33" LOG_CI_END="0.012767958370225096" LOG_CI_START="-0.6415558728141504" LOG_EFFECT_SIZE="-0.31439395722196267" ORDER="52" O_E="0.0" SE="0.3843530573929037" STUDY_ID="STD-Ulrich-1989" TOTAL_1="55" TOTAL_2="57" VAR="0.14772727272727273" WEIGHT="4.403089755741755"/>
<DICH_DATA CI_END="1.9569277922450594" CI_START="0.7637544189990784" EFFECT_SIZE="1.222543352601156" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="40" LOG_CI_END="0.29157480112653844" LOG_CI_START="-0.117046263962007" LOG_EFFECT_SIZE="0.0872642685822657" ORDER="53" O_E="0.0" SE="0.24002603633990555" STUDY_ID="STD-Verwaest-1997" TOTAL_1="220" TOTAL_2="220" VAR="0.05761249812104566" WEIGHT="7.121985733972137"/>
<DICH_DATA CI_END="1.339355470494049" CI_START="0.40847242284131835" EFFECT_SIZE="0.7396551724137931" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="40" LOG_CI_END="0.12689585586625518" LOG_CI_START="-0.3888372586226812" LOG_EFFECT_SIZE="-0.13097070137821304" ORDER="54" O_E="0.0" SE="0.30294418437089093" STUDY_ID="STD-Winter-1992" TOTAL_1="91" TOTAL_2="92" VAR="0.09177517884414436" WEIGHT="5.740960735682395"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.545700253971587" CI_END="0.8665267369876118" CI_START="0.6525774325272968" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7519812452712048" ESTIMABLE="YES" EVENTS_1="496" EVENTS_2="614" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.06221803243415104" LOG_CI_START="-0.18536794908680723" LOG_EFFECT_SIZE="-0.12379299076047917" METHOD="MH" MODIFIED="2009-02-21 22:34:15 +1000" MODIFIED_BY="Clare Dooley" NO="2" P_CHI2="0.4850914843389593" P_Q="0.4285998298765483" P_Z="8.134674982651391E-5" Q="0.6266151774964569" RANDOM="NO" SCALE="23.502270613739245" SORT_BY="USER" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2025" TOTAL_2="2050" WEIGHT="100.00000000000001" Z="3.9403973632134095">
<NAME>Mortality according to quality of allocation concealment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.58446526726881" CI_END="0.9033799362641575" CI_START="0.6604339134867636" DF="9" EFFECT_SIZE="0.7724135852458581" ESTIMABLE="YES" EVENTS_1="403" EVENTS_2="497" I2="22.3097502356976" ID="CMP-001.02.01" LOG_CI_END="-0.04412955918809001" LOG_CI_START="-0.18017063367998584" LOG_EFFECT_SIZE="-0.11215009643403795" MODIFIED="2008-07-30 00:25:17 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.23776137958550836" P_Z="0.001231310249712096" STUDIES="10" TAU2="0.0" TOTAL_1="1642" TOTAL_2="1694" WEIGHT="80.88220097066561" Z="3.2315262238906044">
<NAME>Adequate</NAME>
<DICH_DATA CI_END="2.287940017598692" CI_START="0.19425528686320684" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="0.35944463447091224" LOG_CI_START="-0.7116271525822747" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="55" O_E="0.0" SE="0.6291528696058958" STUDY_ID="STD-Aerdts-1991" TOTAL_1="28" TOTAL_2="60" VAR="0.3958333333333333" WEIGHT="1.482031713427728"/>
<DICH_DATA CI_END="1.3488211457155383" CI_START="0.4231410889989549" EFFECT_SIZE="0.7554744525547445" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="32" LOG_CI_END="0.1299543658479776" LOG_CI_START="-0.373514800574918" LOG_EFFECT_SIZE="-0.1217802173634702" ORDER="56" O_E="0.0" SE="0.29574028056937657" STUDY_ID="STD-Blair-1991" TOTAL_1="161" TOTAL_2="170" VAR="0.08746231355125357" WEIGHT="5.997775876832725"/>
<DICH_DATA CI_END="0.9419229061649299" CI_START="0.5291735757540101" EFFECT_SIZE="0.7060033373433194" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="146" LOG_CI_END="-0.025984641577934012" LOG_CI_START="-0.2764018504080841" LOG_EFFECT_SIZE="-0.15119324599300907" ORDER="57" O_E="0.0" SE="0.14709630805200566" STUDY_ID="STD-de-Jonge-2003" TOTAL_1="466" TOTAL_2="468" VAR="0.021637323842530545" WEIGHT="24.987819858226885"/>
<DICH_DATA CI_END="7.897779386018733" CI_START="0.7913616846609111" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.8975049981302209" LOG_CI_START="-0.10162498078614562" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="58" O_E="0.0" SE="0.5868938953886337" STUDY_ID="STD-Finch-1991" TOTAL_1="24" TOTAL_2="25" VAR="0.34444444444444444" WEIGHT="0.8317524922298474"/>
<DICH_DATA CI_END="1.1927761794545892" CI_START="0.4536252643901103" EFFECT_SIZE="0.7355769230769231" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="65" LOG_CI_END="0.07655895737759512" LOG_CI_START="-0.34330276566792056" LOG_EFFECT_SIZE="-0.13337190414516273" MODIFIED="2008-07-30 00:22:29 +1000" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.2466288544659842" STUDY_ID="STD-Sanchez_x002d_Garcia-1992" TOTAL_1="131" TOTAL_2="140" VAR="0.06082579185520362" WEIGHT="8.689238828215052"/>
<DICH_DATA CI_END="1.5090163852666119" CI_START="0.5812382953597286" EFFECT_SIZE="0.9365351629502573" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="44" LOG_CI_END="0.17869395547621283" LOG_CI_START="-0.23564577958476657" LOG_EFFECT_SIZE="-0.028475912054276853" MODIFIED="2008-07-30 00:22:29 +1000" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.24338521138958621" STUDY_ID="STD-Stoutenbeek-2007" TOTAL_1="201" TOTAL_2="200" VAR="0.05923636112315357" WEIGHT="7.900473298596857"/>
<DICH_DATA CI_END="1.029835736720453" CI_START="0.22826752352611648" EFFECT_SIZE="0.48484848484848486" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="33" LOG_CI_END="0.012767958370225096" LOG_CI_START="-0.6415558728141504" LOG_EFFECT_SIZE="-0.31439395722196267" MODIFIED="2008-07-30 00:22:28 +1000" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.3843530573929037" STUDY_ID="STD-Ulrich-1989" TOTAL_1="55" TOTAL_2="57" VAR="0.14772727272727273" WEIGHT="4.403089755741755"/>
<DICH_DATA CI_END="1.9569277922450594" CI_START="0.7637544189990784" EFFECT_SIZE="1.222543352601156" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="40" LOG_CI_END="0.29157480112653844" LOG_CI_START="-0.117046263962007" LOG_EFFECT_SIZE="0.0872642685822657" MODIFIED="2008-07-30 00:22:28 +1000" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.24002603633990555" STUDY_ID="STD-Verwaest-1997" TOTAL_1="220" TOTAL_2="220" VAR="0.05761249812104566" WEIGHT="7.121985733972137"/>
<DICH_DATA CI_END="1.339355470494049" CI_START="0.40847242284131835" EFFECT_SIZE="0.7396551724137931" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="40" LOG_CI_END="0.12689585586625518" LOG_CI_START="-0.3888372586226812" LOG_EFFECT_SIZE="-0.13097070137821304" MODIFIED="2008-07-30 00:22:25 +1000" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.30294418437089093" STUDY_ID="STD-Winter-1992" TOTAL_1="91" TOTAL_2="92" VAR="0.09177517884414436" WEIGHT="5.740960735682395"/>
<DICH_DATA CI_END="0.9122283619580175" CI_START="0.40616696330394897" EFFECT_SIZE="0.6087010954616588" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="75" LOG_CI_END="-0.039896429299223136" LOG_CI_START="-0.3912954040190561" LOG_EFFECT_SIZE="-0.21559591665913963" MODIFIED="2008-07-30 00:22:21 +1000" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.2064134972034083" STUDY_ID="STD-Krueger-2002" TOTAL_1="265" TOTAL_2="262" VAR="0.04260653182774144" WEIGHT="13.727072677740223"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.3521753031941395" CI_END="0.9292840105766115" CI_START="0.4766468214085342" DF="6" EFFECT_SIZE="0.665537579575426" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="117" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-0.03185153533263681" LOG_CI_START="-0.32180329879064923" LOG_EFFECT_SIZE="-0.176827417061643" MODIFIED="2008-11-19 23:59:33 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.763521844177692" P_Z="0.016822123414298246" STUDIES="7" TAU2="0.0" TOTAL_1="383" TOTAL_2="356" WEIGHT="19.117799029334403" Z="2.3905725889489275">
<NAME>Not adequate</NAME>
<DICH_DATA CI_END="3.7446599347135474" CI_START="0.36569353198544363" EFFECT_SIZE="1.1702127659574468" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.573412384069334" LOG_CI_START="-0.43688272095228137" LOG_EFFECT_SIZE="0.06826483155852639" ORDER="1" O_E="0.0" SE="0.5934523457311225" STUDY_ID="STD-Abele_x002d_Horn-1997" TOTAL_1="58" TOTAL_2="30" VAR="0.35218568665377176" WEIGHT="1.2092967106094308"/>
<DICH_DATA CI_END="2.750140075418289" CI_START="0.07918788563693593" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4393548147146009" LOG_CI_START="-1.1013412527974495" LOG_EFFECT_SIZE="-0.3309932190414244" MODIFIED="2008-07-30 00:24:14 +1000" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.9050124966251124" STUDY_ID="STD-Boland-1991" TOTAL_1="32" TOTAL_2="32" VAR="0.819047619047619" WEIGHT="0.8490806691513025"/>
<DICH_DATA CI_END="1.4758152681157866" CI_START="0.27218079689436714" EFFECT_SIZE="0.6337890625" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.16903199904602084" LOG_CI_START="-0.5651425187249063" LOG_EFFECT_SIZE="-0.19805525983944272" MODIFIED="2008-07-30 00:24:16 +1000" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.43125774596111754" STUDY_ID="STD-Cockerill-1992" TOTAL_1="75" TOTAL_2="75" VAR="0.1859832434514638" WEIGHT="3.0914083740833203"/>
<DICH_DATA CI_END="1.0627324410549521" CI_START="0.19191492277922798" EFFECT_SIZE="0.45161290322580644" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="23" LOG_CI_END="0.026423938088993383" LOG_CI_START="-0.7168912544010628" LOG_EFFECT_SIZE="-0.3452336581560347" MODIFIED="2008-11-19 23:59:18 +1000" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="0.4366270235382035" STUDY_ID="STD-Jacobs-1992" TOTAL_1="45" TOTAL_2="46" VAR="0.1906431576838309" WEIGHT="3.548099733948007"/>
<DICH_DATA CI_END="2.0407968368956793" CI_START="0.3568105186234178" EFFECT_SIZE="0.8533333333333334" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.3097997724736384" LOG_CI_START="-0.4475623512892641" LOG_EFFECT_SIZE="-0.06888128940781285" MODIFIED="2008-07-30 00:24:19 +1000" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.44487826050130463" STUDY_ID="STD-Kerver-1988" TOTAL_1="49" TOTAL_2="47" VAR="0.19791666666666666" WEIGHT="2.476485285024632"/>
<DICH_DATA CI_END="2.3317307496152946" CI_START="0.40537101015572424" EFFECT_SIZE="0.9722222222222222" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.36767839998603896" LOG_CI_START="-0.3921473128200622" LOG_EFFECT_SIZE="-0.012234456417011635" MODIFIED="2008-11-19 23:59:33 +1000" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="0.44632538490024204" STUDY_ID="STD-Palomar-1997" TOTAL_1="50" TOTAL_2="49" VAR="0.19920634920634922" WEIGHT="2.3053826653320213"/>
<DICH_DATA CI_END="1.0189574793666545" CI_START="0.27711447807661915" EFFECT_SIZE="0.5313829787234042" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="40" LOG_CI_END="0.008156061472842027" LOG_CI_START="-0.5573407835482371" LOG_EFFECT_SIZE="-0.2745923610376976" MODIFIED="2008-07-30 00:25:35 +1000" MODIFIED_BY="[Empty name]" ORDER="221" O_E="0.0" SE="0.33217564601991056" STUDY_ID="STD-Rocha-1992" TOTAL_1="74" TOTAL_2="77" VAR="0.11034065980874491" WEIGHT="5.638045591185691"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.545700253971585" CI_END="0.8665267369876117" CI_START="0.6525774325272966" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7519812452712047" ESTIMABLE="YES" EVENTS_1="496" EVENTS_2="614" I2="0.0" I2_Q="55.36467122657675" ID="CMP-001.03" LOG_CI_END="-0.062218032434151097" LOG_CI_START="-0.1853679490868074" LOG_EFFECT_SIZE="-0.12379299076047924" METHOD="MH" MODIFIED="2009-01-06 08:10:09 +1000" MODIFIED_BY="Liz Dooley" NO="3" P_CHI2="0.4850914843389593" P_Q="0.13444822615140584" P_Z="8.134674982651322E-5" Q="2.240377807176408" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2025" TOTAL_2="2050" WEIGHT="100.0" Z="3.9403973632134117">
<NAME>Mortality according to blinding of the studies</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7944595657431892" CI_END="0.8273113260790292" CI_START="0.4760822859333958" DF="3" EFFECT_SIZE="0.6275892504642613" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="184" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.08233103004231715" LOG_CI_START="-0.3223179774511338" LOG_EFFECT_SIZE="-0.20232450374672545" MODIFIED="2008-02-13 09:58:03 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8507918176230137" P_Z="9.506028151325984E-4" STUDIES="4" TAU2="0.0" TOTAL_1="502" TOTAL_2="511" WEIGHT="28.903437766292264" Z="3.3047525693803856">
<NAME>Double-blind</NAME>
<DICH_DATA CI_END="2.750140075418289" CI_START="0.07918788563693593" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4393548147146009" LOG_CI_START="-1.1013412527974495" LOG_EFFECT_SIZE="-0.3309932190414244" ORDER="72" O_E="0.0" SE="0.9050124966251124" STUDY_ID="STD-Boland-1991" TOTAL_1="32" TOTAL_2="32" VAR="0.819047619047619" WEIGHT="0.8490806691513024"/>
<DICH_DATA CI_END="0.9122283619580175" CI_START="0.40616696330394897" EFFECT_SIZE="0.6087010954616588" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="75" LOG_CI_END="-0.039896429299223136" LOG_CI_START="-0.3912954040190561" LOG_EFFECT_SIZE="-0.21559591665913963" ORDER="73" O_E="0.0" SE="0.2064134972034083" STUDY_ID="STD-Krueger-2002" TOTAL_1="265" TOTAL_2="262" VAR="0.04260653182774144" WEIGHT="13.727072677740221"/>
<DICH_DATA CI_END="1.0189574793666545" CI_START="0.27711447807661915" EFFECT_SIZE="0.5313829787234042" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="40" LOG_CI_END="0.008156061472842027" LOG_CI_START="-0.5573407835482371" LOG_EFFECT_SIZE="-0.2745923610376976" ORDER="74" O_E="0.0" SE="0.33217564601991056" STUDY_ID="STD-Rocha-1992" TOTAL_1="74" TOTAL_2="77" VAR="0.11034065980874491" WEIGHT="5.63804559118569"/>
<DICH_DATA CI_END="1.1927761794545892" CI_START="0.4536252643901103" EFFECT_SIZE="0.7355769230769231" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="65" LOG_CI_END="0.07655895737759512" LOG_CI_START="-0.34330276566792056" LOG_EFFECT_SIZE="-0.13337190414516273" ORDER="75" O_E="0.0" SE="0.2466288544659842" STUDY_ID="STD-Sanchez_x002d_Garcia-1992" TOTAL_1="131" TOTAL_2="140" VAR="0.06082579185520362" WEIGHT="8.68923882821505"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.546609470451934" CI_END="0.9468775845900558" CI_START="0.6802236977575494" DF="12" EFFECT_SIZE="0.8025512892728941" ESTIMABLE="YES" EVENTS_1="364" EVENTS_2="430" I2="4.356630942719893" ID="CMP-001.03.02" LOG_CI_END="-0.023706164368975477" LOG_CI_START="-0.1673482421091755" LOG_EFFECT_SIZE="-0.09552720323907549" MODIFIED="2008-02-13 09:58:34 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4028370679880776" P_Z="0.009136748183633253" STUDIES="13" TAU2="0.0" TOTAL_1="1523" TOTAL_2="1539" WEIGHT="71.09656223370774" Z="2.6068945929766008">
<NAME>Open</NAME>
<DICH_DATA CI_END="3.7446599347135474" CI_START="0.36569353198544363" EFFECT_SIZE="1.1702127659574468" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.573412384069334" LOG_CI_START="-0.43688272095228137" LOG_EFFECT_SIZE="0.06826483155852639" ORDER="1" O_E="0.0" SE="0.5934523457311225" STUDY_ID="STD-Abele_x002d_Horn-1997" TOTAL_1="58" TOTAL_2="30" VAR="0.35218568665377176" WEIGHT="1.2092967106094306"/>
<DICH_DATA CI_END="2.287940017598692" CI_START="0.19425528686320684" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="0.35944463447091224" LOG_CI_START="-0.7116271525822747" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="77" O_E="0.0" SE="0.6291528696058958" STUDY_ID="STD-Aerdts-1991" TOTAL_1="28" TOTAL_2="60" VAR="0.3958333333333333" WEIGHT="1.4820317134277279"/>
<DICH_DATA CI_END="1.3488211457155383" CI_START="0.4231410889989549" EFFECT_SIZE="0.7554744525547445" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="32" LOG_CI_END="0.1299543658479776" LOG_CI_START="-0.373514800574918" LOG_EFFECT_SIZE="-0.1217802173634702" ORDER="78" O_E="0.0" SE="0.29574028056937657" STUDY_ID="STD-Blair-1991" TOTAL_1="161" TOTAL_2="170" VAR="0.08746231355125357" WEIGHT="5.9977758768327245"/>
<DICH_DATA CI_END="1.4758152681157866" CI_START="0.27218079689436714" EFFECT_SIZE="0.6337890625" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.16903199904602084" LOG_CI_START="-0.5651425187249063" LOG_EFFECT_SIZE="-0.19805525983944272" ORDER="79" O_E="0.0" SE="0.43125774596111754" STUDY_ID="STD-Cockerill-1992" TOTAL_1="75" TOTAL_2="75" VAR="0.1859832434514638" WEIGHT="3.09140837408332"/>
<DICH_DATA CI_END="0.9419229061649299" CI_START="0.5291735757540101" EFFECT_SIZE="0.7060033373433194" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="146" LOG_CI_END="-0.025984641577934012" LOG_CI_START="-0.2764018504080841" LOG_EFFECT_SIZE="-0.15119324599300907" ORDER="80" O_E="0.0" SE="0.14709630805200566" STUDY_ID="STD-de-Jonge-2003" TOTAL_1="466" TOTAL_2="468" VAR="0.021637323842530545" WEIGHT="24.98781985822688"/>
<DICH_DATA CI_END="7.897779386018733" CI_START="0.7913616846609111" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.8975049981302209" LOG_CI_START="-0.10162498078614562" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="81" O_E="0.0" SE="0.5868938953886337" STUDY_ID="STD-Finch-1991" TOTAL_1="24" TOTAL_2="25" VAR="0.34444444444444444" WEIGHT="0.8317524922298473"/>
<DICH_DATA CI_END="1.0627324410549521" CI_START="0.19191492277922798" EFFECT_SIZE="0.45161290322580644" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="23" LOG_CI_END="0.026423938088993383" LOG_CI_START="-0.7168912544010628" LOG_EFFECT_SIZE="-0.3452336581560347" ORDER="82" O_E="0.0" SE="0.4366270235382035" STUDY_ID="STD-Jacobs-1992" TOTAL_1="45" TOTAL_2="46" VAR="0.1906431576838309" WEIGHT="3.5480997339480065"/>
<DICH_DATA CI_END="2.0407968368956793" CI_START="0.3568105186234178" EFFECT_SIZE="0.8533333333333334" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.3097997724736384" LOG_CI_START="-0.4475623512892641" LOG_EFFECT_SIZE="-0.06888128940781285" ORDER="83" O_E="0.0" SE="0.44487826050130463" STUDY_ID="STD-Kerver-1988" TOTAL_1="49" TOTAL_2="47" VAR="0.19791666666666666" WEIGHT="2.476485285024632"/>
<DICH_DATA CI_END="2.3317307496152946" CI_START="0.40537101015572424" EFFECT_SIZE="0.9722222222222222" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.36767839998603896" LOG_CI_START="-0.3921473128200622" LOG_EFFECT_SIZE="-0.012234456417011635" ORDER="84" O_E="0.0" SE="0.44632538490024204" STUDY_ID="STD-Palomar-1997" TOTAL_1="50" TOTAL_2="49" VAR="0.19920634920634922" WEIGHT="2.305382665332021"/>
<DICH_DATA CI_END="1.5090163852666119" CI_START="0.5812382953597286" EFFECT_SIZE="0.9365351629502573" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="44" LOG_CI_END="0.17869395547621283" LOG_CI_START="-0.23564577958476657" LOG_EFFECT_SIZE="-0.028475912054276853" ORDER="85" O_E="0.0" SE="0.24338521138958621" STUDY_ID="STD-Stoutenbeek-2007" TOTAL_1="201" TOTAL_2="200" VAR="0.05923636112315357" WEIGHT="7.900473298596856"/>
<DICH_DATA CI_END="1.029835736720453" CI_START="0.22826752352611648" EFFECT_SIZE="0.48484848484848486" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="33" LOG_CI_END="0.012767958370225096" LOG_CI_START="-0.6415558728141504" LOG_EFFECT_SIZE="-0.31439395722196267" ORDER="86" O_E="0.0" SE="0.3843530573929037" STUDY_ID="STD-Ulrich-1989" TOTAL_1="55" TOTAL_2="57" VAR="0.14772727272727273" WEIGHT="4.403089755741754"/>
<DICH_DATA CI_END="1.9569277922450594" CI_START="0.7637544189990784" EFFECT_SIZE="1.222543352601156" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="40" LOG_CI_END="0.29157480112653844" LOG_CI_START="-0.117046263962007" LOG_EFFECT_SIZE="0.0872642685822657" ORDER="87" O_E="0.0" SE="0.24002603633990555" STUDY_ID="STD-Verwaest-1997" TOTAL_1="220" TOTAL_2="220" VAR="0.05761249812104566" WEIGHT="7.121985733972136"/>
<DICH_DATA CI_END="1.339355470494049" CI_START="0.40847242284131835" EFFECT_SIZE="0.7396551724137931" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="40" LOG_CI_END="0.12689585586625518" LOG_CI_START="-0.3888372586226812" LOG_EFFECT_SIZE="-0.13097070137821304" ORDER="88" O_E="0.0" SE="0.30294418437089093" STUDY_ID="STD-Winter-1992" TOTAL_1="91" TOTAL_2="92" VAR="0.09177517884414436" WEIGHT="5.740960735682394"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="33.76590219016857" CI_END="0.379090918034332" CI_START="0.2042401670122455" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="OR" EFFECT_SIZE="0.2782545460763533" ESTIMABLE="YES" EVENTS_1="287" EVENTS_2="603" I2="55.57648684900986" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.4212566199386951" LOG_CI_START="-0.6898588430703015" LOG_EFFECT_SIZE="-0.5555577315044984" METHOD="MH" MODIFIED="2009-07-25 09:37:05 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0036726191998374125" P_Q="1.0" P_Z="5.158684054051375E-16" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="16" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.18065170334880176" TOTALS="YES" TOTAL_1="1501" TOTAL_2="1523" WEIGHT="100.00000000000001" Z="8.107700170062088">
<NAME>RTIs</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.2505540244440661" CI_START="0.030853234654228925" EFFECT_SIZE="0.08792270531400966" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="-0.6010986171489486" LOG_CI_START="-1.5106992977947373" LOG_EFFECT_SIZE="-1.055898957471843" ORDER="1" O_E="0.0" SE="0.5343039424073224" STUDY_ID="STD-Abele_x002d_Horn-1997" TOTAL_1="58" TOTAL_2="30" VAR="0.2854807028720072" WEIGHT="5.340539271255943"/>
<DICH_DATA CI_END="0.3103697328595148" CI_START="0.005050338655409076" EFFECT_SIZE="0.03959131545338442" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="29" LOG_CI_END="-0.5081206375846462" LOG_CI_START="-2.2966794988626953" LOG_EFFECT_SIZE="-1.4024000682236706" ORDER="90" O_E="0.0" SE="1.0506083286238768" STUDY_ID="STD-Aerdts-1991" TOTAL_1="28" TOTAL_2="60" VAR="1.1037778601738557" WEIGHT="1.938135411800917"/>
<DICH_DATA CI_END="0.5577599085734664" CI_START="0.14032121297778935" EFFECT_SIZE="0.2797598021900389" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="38" LOG_CI_END="-0.2535527057585015" LOG_CI_START="-0.8528766697927175" LOG_EFFECT_SIZE="-0.5532146877756094" ORDER="91" O_E="0.0" SE="0.3520458631751668" STUDY_ID="STD-Blair-1991" TOTAL_1="161" TOTAL_2="170" VAR="0.12393628977874827" WEIGHT="8.173002472834808"/>
<DICH_DATA CI_END="1.8373826106476403" CI_START="0.25632805060705594" EFFECT_SIZE="0.6862745098039216" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" LOG_CI_END="0.2641996018098267" LOG_CI_START="-0.5912038653051481" LOG_EFFECT_SIZE="-0.16350213174766073" ORDER="92" O_E="0.0" SE="0.5024682308987886" STUDY_ID="STD-Boland-1991" TOTAL_1="32" TOTAL_2="32" VAR="0.25247432306255835" WEIGHT="5.747515201644704"/>
<DICH_DATA CI_END="0.963853169438941" CI_START="0.09076345350795924" EFFECT_SIZE="0.29577464788732394" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.015989120204314807" LOG_CI_START="-1.0420889877659971" LOG_EFFECT_SIZE="-0.529039053985156" ORDER="93" O_E="0.0" SE="0.6027361414819943" STUDY_ID="STD-Cockerill-1992" TOTAL_1="75" TOTAL_2="75" VAR="0.3632908562486027" WEIGHT="4.5765832753917435"/>
<DICH_DATA CI_END="2.475465108838378" CI_START="0.1489103795741114" EFFECT_SIZE="0.6071428571428571" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.39365680942098763" LOG_CI_START="-0.8270750293488781" LOG_EFFECT_SIZE="-0.21670910996394532" ORDER="94" O_E="0.0" SE="0.7170639248134768" STUDY_ID="STD-Finch-1991" TOTAL_1="20" TOTAL_2="24" VAR="0.5141806722689075" WEIGHT="3.582732337154225"/>
<DICH_DATA CI_END="1.985902722706102" CI_START="0.005423905030457442" EFFECT_SIZE="0.10378510378510379" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2979579712355713" LOG_CI_START="-2.265687923327823" LOG_EFFECT_SIZE="-0.9838649760461257" ORDER="95" O_E="0.0" SE="1.5058982887183816" STUDY_ID="STD-Jacobs-1992" TOTAL_1="45" TOTAL_2="46" VAR="2.26772965596495" WEIGHT="1.0167527258600773"/>
<DICH_DATA CI_END="0.17696698533121802" CI_START="0.019438331339088954" EFFECT_SIZE="0.05865102639296188" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="31" LOG_CI_END="-0.7521077473434803" LOG_CI_START="-1.7113410193135528" LOG_EFFECT_SIZE="-1.2317243833285165" ORDER="96" O_E="0.0" SE="0.5634583722364961" STUDY_ID="STD-Kerver-1988" TOTAL_1="49" TOTAL_2="47" VAR="0.3174853372434018" WEIGHT="4.997416811381402"/>
<DICH_DATA CI_END="0.5850225663034238" CI_START="0.09845774046624653" EFFECT_SIZE="0.24" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="25" LOG_CI_END="-0.23282738138442857" LOG_CI_START="-1.0067501351923593" LOG_EFFECT_SIZE="-0.619788758288394" ORDER="97" O_E="0.0" SE="0.4546060565661952" STUDY_ID="STD-Palomar-1997" TOTAL_1="50" TOTAL_2="49" VAR="0.20666666666666667" WEIGHT="6.427266594475853"/>
<DICH_DATA CI_END="0.5327528671134043" CI_START="0.07735106189720055" EFFECT_SIZE="0.203" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="25" LOG_CI_END="-0.2734742043670595" LOG_CI_START="-1.1115337198065147" LOG_EFFECT_SIZE="-0.6925039620867871" ORDER="98" O_E="0.0" SE="0.49228030783064286" STUDY_ID="STD-Rocha-1992" TOTAL_1="47" TOTAL_2="54" VAR="0.24233990147783252" WEIGHT="5.8852194526355985"/>
<DICH_DATA CI_END="0.7252562687742867" CI_START="0.25610352099553974" EFFECT_SIZE="0.43097643097643096" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="60" LOG_CI_END="-0.13950850867170986" LOG_CI_START="-0.5915844506669782" LOG_EFFECT_SIZE="-0.365546479669344" ORDER="99" O_E="0.0" SE="0.26555164614002447" STUDY_ID="STD-Sanchez_x002d_Garcia-1992" TOTAL_1="131" TOTAL_2="140" VAR="0.07051767676767677" WEIGHT="9.911233685701704"/>
<DICH_DATA CI_END="0.6707305048432612" CI_START="0.29662361264882736" EFFECT_SIZE="0.4460431654676259" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="100" LOG_CI_END="-0.17345194148425758" LOG_CI_START="-0.5277942800274247" LOG_EFFECT_SIZE="-0.3506231107558412" ORDER="100" O_E="0.0" SE="0.20814244368312068" STUDY_ID="STD-Stoutenbeek-2007" TOTAL_1="201" TOTAL_2="200" VAR="0.04332327686238106" WEIGHT="11.1146272618488"/>
<DICH_DATA CI_END="0.4491197579077952" CI_START="0.06731752430453788" EFFECT_SIZE="0.17387820512820512" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="26" LOG_CI_END="-0.3476378388104043" LOG_CI_START="-1.1718718641853472" LOG_EFFECT_SIZE="-0.7597548514978757" ORDER="101" O_E="0.0" SE="0.48415914652946884" STUDY_ID="STD-Ulrich-1989" TOTAL_1="55" TOTAL_2="57" VAR="0.2344100791681437" WEIGHT="5.997657519638357"/>
<DICH_DATA CI_END="0.8208376058169056" CI_START="0.26497928122369097" EFFECT_SIZE="0.46637426900584794" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="40" LOG_CI_END="-0.08574275502874151" LOG_CI_START="-0.5767880822971287" LOG_EFFECT_SIZE="-0.33126541866293513" ORDER="102" O_E="0.0" SE="0.2884424559510227" STUDY_ID="STD-Verwaest-1997" TOTAL_1="193" TOTAL_2="185" VAR="0.08319905039505766" WEIGHT="9.434873259615214"/>
<DICH_DATA CI_END="0.5331170223859775" CI_START="0.042430612346863975" EFFECT_SIZE="0.15040106951871657" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="17" LOG_CI_END="-0.27317745026386936" LOG_CI_START="-1.3723207005702909" LOG_EFFECT_SIZE="-0.8227490754170801" ORDER="103" O_E="0.0" SE="0.6456421860768298" STUDY_ID="STD-Winter-1992" TOTAL_1="91" TOTAL_2="92" VAR="0.4168538324420677" WEIGHT="4.1663185893872"/>
<DICH_DATA CI_END="0.5641013147248746" CI_START="0.27887624767490915" EFFECT_SIZE="0.39662886677466636" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="149" LOG_CI_END="-0.24864288808334084" LOG_CI_START="-0.5545884736973802" LOG_EFFECT_SIZE="-0.4016156808903604" ORDER="104" O_E="0.0" SE="0.17971395144476027" STUDY_ID="STD-Krueger-2002" TOTAL_1="265" TOTAL_2="262" VAR="0.032297104343889646" WEIGHT="11.690126129373468"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="33.76590219016855" CI_END="0.3790909180343322" CI_START="0.20424016701224562" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="OR" EFFECT_SIZE="0.2782545460763535" ESTIMABLE="YES" EVENTS_1="287" EVENTS_2="603" I2="55.57648684900985" I2_Q="67.80844677101672" ID="CMP-001.05" LOG_CI_END="-0.4212566199386949" LOG_CI_START="-0.6898588430703013" LOG_EFFECT_SIZE="-0.555557731504498" METHOD="MH" MODIFIED="2009-07-25 09:38:00 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0036726191998375235" P_Q="0.07798519792065028" P_Z="5.158684054051375E-16" Q="3.106404940721101" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.18065170334880162" TOTALS="YES" TOTAL_1="1501" TOTAL_2="1523" WEIGHT="100.0" Z="8.107700170062088">
<NAME>RTIs according to quality of allocation concealment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.028317244611959" CI_END="0.4721855788514727" CI_START="0.27422009034159844" DF="8" EFFECT_SIZE="0.3598371466242067" ESTIMABLE="YES" EVENTS_1="234" EVENTS_2="466" I2="33.49028099850317" ID="CMP-001.05.01" LOG_CI_END="-0.32588728096095027" LOG_CI_START="-0.5619007304186029" LOG_EFFECT_SIZE="-0.4438940056897765" MODIFIED="2008-11-20 00:11:05 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.14994500685619072" P_Z="1.673332077727676E-13" STUDIES="9" TAU2="0.051582815966008784" TOTAL_1="1145" TOTAL_2="1190" WEIGHT="66.00870666735469" Z="7.372599028609893">
<NAME>Adequate</NAME>
<DICH_DATA CI_END="0.3103697328595148" CI_START="0.005050338655409076" EFFECT_SIZE="0.03959131545338442" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="29" LOG_CI_END="-0.5081206375846462" LOG_CI_START="-2.2966794988626953" LOG_EFFECT_SIZE="-1.4024000682236706" ORDER="105" O_E="0.0" SE="1.0506083286238768" STUDY_ID="STD-Aerdts-1991" TOTAL_1="28" TOTAL_2="60" VAR="1.1037778601738557" WEIGHT="1.9381354118009164"/>
<DICH_DATA CI_END="0.5577599085734664" CI_START="0.14032121297778935" EFFECT_SIZE="0.2797598021900389" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="38" LOG_CI_END="-0.2535527057585015" LOG_CI_START="-0.8528766697927175" LOG_EFFECT_SIZE="-0.5532146877756094" ORDER="106" O_E="0.0" SE="0.3520458631751668" STUDY_ID="STD-Blair-1991" TOTAL_1="161" TOTAL_2="170" VAR="0.12393628977874827" WEIGHT="8.173002472834806"/>
<DICH_DATA CI_END="2.475465108838378" CI_START="0.1489103795741114" EFFECT_SIZE="0.6071428571428571" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.39365680942098763" LOG_CI_START="-0.8270750293488781" LOG_EFFECT_SIZE="-0.21670910996394532" ORDER="107" O_E="0.0" SE="0.7170639248134768" STUDY_ID="STD-Finch-1991" TOTAL_1="20" TOTAL_2="24" VAR="0.5141806722689075" WEIGHT="3.5827323371542237"/>
<DICH_DATA CI_END="0.7252562687742867" CI_START="0.25610352099553974" EFFECT_SIZE="0.43097643097643096" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="60" LOG_CI_END="-0.13950850867170986" LOG_CI_START="-0.5915844506669782" LOG_EFFECT_SIZE="-0.365546479669344" ORDER="110" O_E="0.0" SE="0.26555164614002447" STUDY_ID="STD-Sanchez_x002d_Garcia-1992" TOTAL_1="131" TOTAL_2="140" VAR="0.07051767676767677" WEIGHT="9.911233685701706"/>
<DICH_DATA CI_END="0.6707305048432612" CI_START="0.29662361264882736" EFFECT_SIZE="0.4460431654676259" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="100" LOG_CI_END="-0.17345194148425758" LOG_CI_START="-0.5277942800274247" LOG_EFFECT_SIZE="-0.3506231107558412" ORDER="111" O_E="0.0" SE="0.20814244368312068" STUDY_ID="STD-Stoutenbeek-2007" TOTAL_1="201" TOTAL_2="200" VAR="0.04332327686238106" WEIGHT="11.114627261848801"/>
<DICH_DATA CI_END="0.4491197579077952" CI_START="0.06731752430453788" EFFECT_SIZE="0.17387820512820512" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="26" LOG_CI_END="-0.3476378388104043" LOG_CI_START="-1.1718718641853472" LOG_EFFECT_SIZE="-0.7597548514978757" ORDER="112" O_E="0.0" SE="0.48415914652946884" STUDY_ID="STD-Ulrich-1989" TOTAL_1="55" TOTAL_2="57" VAR="0.2344100791681437" WEIGHT="5.997657519638356"/>
<DICH_DATA CI_END="0.8208376058169056" CI_START="0.26497928122369097" EFFECT_SIZE="0.46637426900584794" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="40" LOG_CI_END="-0.08574275502874151" LOG_CI_START="-0.5767880822971287" LOG_EFFECT_SIZE="-0.33126541866293513" ORDER="113" O_E="0.0" SE="0.2884424559510227" STUDY_ID="STD-Verwaest-1997" TOTAL_1="193" TOTAL_2="185" VAR="0.08319905039505766" WEIGHT="9.434873259615213"/>
<DICH_DATA CI_END="0.5331170223859775" CI_START="0.042430612346863975" EFFECT_SIZE="0.15040106951871657" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="17" LOG_CI_END="-0.27317745026386936" LOG_CI_START="-1.3723207005702909" LOG_EFFECT_SIZE="-0.8227490754170801" ORDER="114" O_E="0.0" SE="0.6456421860768298" STUDY_ID="STD-Winter-1992" TOTAL_1="91" TOTAL_2="92" VAR="0.4168538324420677" WEIGHT="4.166318589387198"/>
<DICH_DATA CI_END="0.5641013147248746" CI_START="0.27887624767490915" EFFECT_SIZE="0.39662886677466636" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="149" LOG_CI_END="-0.24864288808334084" LOG_CI_START="-0.5545884736973802" LOG_EFFECT_SIZE="-0.4016156808903604" ORDER="115" O_E="0.0" SE="0.17971395144476027" STUDY_ID="STD-Krueger-2002" TOTAL_1="265" TOTAL_2="262" VAR="0.032297104343889646" WEIGHT="11.690126129373473"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.904149846168401" CI_END="0.36587751096485377" CI_START="0.09950619409520339" DF="6" EFFECT_SIZE="0.19080639040959463" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="137" I2="56.847415581806075" ID="CMP-001.05.02" LOG_CI_END="-0.43666428404721686" LOG_CI_START="-1.0021498843031231" LOG_EFFECT_SIZE="-0.7194070841751701" MODIFIED="2008-11-20 00:12:15 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.03072540807914681" P_Z="6.13536628415519E-7" STUDIES="7" TAU2="0.4161916331194106" TOTAL_1="356" TOTAL_2="333" WEIGHT="33.991293332645306" Z="4.986906738449991">
<NAME>Not adequate</NAME>
<DICH_DATA CI_END="0.2505540244440661" CI_START="0.030853234654228925" EFFECT_SIZE="0.08792270531400966" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="-0.6010986171489486" LOG_CI_START="-1.5106992977947373" LOG_EFFECT_SIZE="-1.055898957471843" ORDER="1" O_E="0.0" SE="0.5343039424073224" STUDY_ID="STD-Abele_x002d_Horn-1997" TOTAL_1="58" TOTAL_2="30" VAR="0.2854807028720072" WEIGHT="5.340539271255941"/>
<DICH_DATA CI_END="0.17696698533121802" CI_START="0.019438331339088954" EFFECT_SIZE="0.05865102639296188" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="31" LOG_CI_END="-0.7521077473434803" LOG_CI_START="-1.7113410193135528" LOG_EFFECT_SIZE="-1.2317243833285165" ORDER="117" O_E="0.0" SE="0.5634583722364961" STUDY_ID="STD-Kerver-1988" TOTAL_1="49" TOTAL_2="47" VAR="0.3174853372434018" WEIGHT="4.997416811381401"/>
<DICH_DATA CI_END="1.8373826106476403" CI_START="0.25632805060705594" EFFECT_SIZE="0.6862745098039216" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" LOG_CI_END="0.2641996018098267" LOG_CI_START="-0.5912038653051481" LOG_EFFECT_SIZE="-0.16350213174766073" ORDER="118" O_E="0.0" SE="0.5024682308987886" STUDY_ID="STD-Boland-1991" TOTAL_1="32" TOTAL_2="32" VAR="0.25247432306255835" WEIGHT="5.747515201644703"/>
<DICH_DATA CI_END="0.963853169438941" CI_START="0.09076345350795924" EFFECT_SIZE="0.29577464788732394" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.015989120204314807" LOG_CI_START="-1.0420889877659971" LOG_EFFECT_SIZE="-0.529039053985156" ORDER="119" O_E="0.0" SE="0.6027361414819943" STUDY_ID="STD-Cockerill-1992" TOTAL_1="75" TOTAL_2="75" VAR="0.3632908562486027" WEIGHT="4.576583275391742"/>
<DICH_DATA CI_END="0.5327528671134043" CI_START="0.07735106189720055" EFFECT_SIZE="0.203" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="25" LOG_CI_END="-0.2734742043670595" LOG_CI_START="-1.1115337198065147" LOG_EFFECT_SIZE="-0.6925039620867871" ORDER="120" O_E="0.0" SE="0.49228030783064286" STUDY_ID="STD-Rocha-1992" TOTAL_1="47" TOTAL_2="54" VAR="0.24233990147783252" WEIGHT="5.885219452635598"/>
<DICH_DATA CI_END="1.985902722706102" CI_START="0.005423905030457442" EFFECT_SIZE="0.10378510378510379" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2979579712355713" LOG_CI_START="-2.265687923327823" LOG_EFFECT_SIZE="-0.9838649760461257" MODIFIED="2008-11-20 00:12:05 +1000" MODIFIED_BY="[Empty name]" ORDER="217" O_E="0.0" SE="1.5058982887183816" STUDY_ID="STD-Jacobs-1992" TOTAL_1="45" TOTAL_2="46" VAR="2.26772965596495" WEIGHT="1.0167527258600766"/>
<DICH_DATA CI_END="0.5850225663034238" CI_START="0.09845774046624653" EFFECT_SIZE="0.24" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="25" LOG_CI_END="-0.23282738138442857" LOG_CI_START="-1.0067501351923593" LOG_EFFECT_SIZE="-0.619788758288394" MODIFIED="2008-11-20 00:12:15 +1000" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.4546060565661952" STUDY_ID="STD-Palomar-1997" TOTAL_1="50" TOTAL_2="49" VAR="0.20666666666666667" WEIGHT="6.42726659447585"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="33.76590219016855" CI_END="0.37909091803433215" CI_START="0.2042401670122456" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="OR" EFFECT_SIZE="0.2782545460763534" ESTIMABLE="YES" EVENTS_1="287" EVENTS_2="603" I2="55.57648684900985" I2_Q="79.73018747112803" ID="CMP-001.06" LOG_CI_END="-0.42125661993869495" LOG_CI_START="-0.6898588430703013" LOG_EFFECT_SIZE="-0.5555577315044982" METHOD="MH" MODIFIED="2009-07-25 09:39:37 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0036726191998375235" P_Q="0.026341903207549255" P_Z="5.158684054051375E-16" Q="4.933444739933423" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.18065170334880162" TOTALS="YES" TOTAL_1="1501" TOTAL_2="1523" WEIGHT="100.0" Z="8.107700170062088">
<NAME>RTIs according to blinding of the studies</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.1343399284758426" CI_END="0.5311679444164862" CI_START="0.3026864787984331" DF="3" EFFECT_SIZE="0.4009705160557669" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="251" I2="4.286067610451208" ID="CMP-001.06.01" LOG_CI_END="-0.27476814219256845" LOG_CI_START="-0.5190069788266592" LOG_EFFECT_SIZE="-0.3968875605096139" MODIFIED="2008-02-13 09:59:05 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3713730894273921" P_Z="1.8918338400541168E-10" STUDIES="4" TAU2="0.004357686352913679" TOTAL_1="475" TOTAL_2="488" WEIGHT="33.234094469355476" Z="6.369874138208433">
<NAME>Double-blind</NAME>
<DICH_DATA CI_END="1.8373826106476403" CI_START="0.25632805060705594" EFFECT_SIZE="0.6862745098039216" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" LOG_CI_END="0.2641996018098267" LOG_CI_START="-0.5912038653051481" LOG_EFFECT_SIZE="-0.16350213174766073" ORDER="121" O_E="0.0" SE="0.5024682308987886" STUDY_ID="STD-Boland-1991" TOTAL_1="32" TOTAL_2="32" VAR="0.25247432306255835" WEIGHT="5.747515201644703"/>
<DICH_DATA CI_END="0.5327528671134043" CI_START="0.07735106189720055" EFFECT_SIZE="0.203" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="25" LOG_CI_END="-0.2734742043670595" LOG_CI_START="-1.1115337198065147" LOG_EFFECT_SIZE="-0.6925039620867871" ORDER="122" O_E="0.0" SE="0.49228030783064286" STUDY_ID="STD-Rocha-1992" TOTAL_1="47" TOTAL_2="54" VAR="0.24233990147783252" WEIGHT="5.885219452635598"/>
<DICH_DATA CI_END="0.7252562687742867" CI_START="0.25610352099553974" EFFECT_SIZE="0.43097643097643096" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="60" LOG_CI_END="-0.13950850867170986" LOG_CI_START="-0.5915844506669782" LOG_EFFECT_SIZE="-0.365546479669344" ORDER="123" O_E="0.0" SE="0.26555164614002447" STUDY_ID="STD-Sanchez_x002d_Garcia-1992" TOTAL_1="131" TOTAL_2="140" VAR="0.07051767676767677" WEIGHT="9.911233685701706"/>
<DICH_DATA CI_END="0.5641013147248746" CI_START="0.27887624767490915" EFFECT_SIZE="0.39662886677466636" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="149" LOG_CI_END="-0.24864288808334084" LOG_CI_START="-0.5545884736973802" LOG_EFFECT_SIZE="-0.4016156808903604" ORDER="124" O_E="0.0" SE="0.17971395144476027" STUDY_ID="STD-Krueger-2002" TOTAL_1="265" TOTAL_2="262" VAR="0.032297104343889646" WEIGHT="11.690126129373473"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="27.70671394327869" CI_END="0.3444558735124647" CI_START="0.14389148398412355" DF="11" EFFECT_SIZE="0.2226303366721528" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="352" I2="60.2984315551846" ID="CMP-001.06.02" LOG_CI_END="-0.46286640544716556" LOG_CI_START="-0.8419649084132547" LOG_EFFECT_SIZE="-0.6524156569302101" MODIFIED="2008-02-13 09:59:13 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.003589402127053831" P_Z="1.5191068886195236E-11" STUDIES="12" TAU2="0.30300992107517316" TOTAL_1="1026" TOTAL_2="1035" WEIGHT="66.76590553064452" Z="6.746062991694979">
<NAME>Open</NAME>
<DICH_DATA CI_END="0.2505540244440661" CI_START="0.030853234654228925" EFFECT_SIZE="0.08792270531400966" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="-0.6010986171489486" LOG_CI_START="-1.5106992977947373" LOG_EFFECT_SIZE="-1.055898957471843" ORDER="1" O_E="0.0" SE="0.5343039424073224" STUDY_ID="STD-Abele_x002d_Horn-1997" TOTAL_1="58" TOTAL_2="30" VAR="0.2854807028720072" WEIGHT="5.340539271255941"/>
<DICH_DATA CI_END="0.3103697328595148" CI_START="0.005050338655409076" EFFECT_SIZE="0.03959131545338442" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="29" LOG_CI_END="-0.5081206375846462" LOG_CI_START="-2.2966794988626953" LOG_EFFECT_SIZE="-1.4024000682236706" ORDER="126" O_E="0.0" SE="1.0506083286238768" STUDY_ID="STD-Aerdts-1991" TOTAL_1="28" TOTAL_2="60" VAR="1.1037778601738557" WEIGHT="1.9381354118009164"/>
<DICH_DATA CI_END="0.5577599085734664" CI_START="0.14032121297778935" EFFECT_SIZE="0.2797598021900389" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="38" LOG_CI_END="-0.2535527057585015" LOG_CI_START="-0.8528766697927175" LOG_EFFECT_SIZE="-0.5532146877756094" ORDER="127" O_E="0.0" SE="0.3520458631751668" STUDY_ID="STD-Blair-1991" TOTAL_1="161" TOTAL_2="170" VAR="0.12393628977874827" WEIGHT="8.173002472834806"/>
<DICH_DATA CI_END="0.963853169438941" CI_START="0.09076345350795924" EFFECT_SIZE="0.29577464788732394" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.015989120204314807" LOG_CI_START="-1.0420889877659971" LOG_EFFECT_SIZE="-0.529039053985156" ORDER="128" O_E="0.0" SE="0.6027361414819943" STUDY_ID="STD-Cockerill-1992" TOTAL_1="75" TOTAL_2="75" VAR="0.3632908562486027" WEIGHT="4.576583275391742"/>
<DICH_DATA CI_END="2.475465108838378" CI_START="0.1489103795741114" EFFECT_SIZE="0.6071428571428571" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.39365680942098763" LOG_CI_START="-0.8270750293488781" LOG_EFFECT_SIZE="-0.21670910996394532" ORDER="129" O_E="0.0" SE="0.7170639248134768" STUDY_ID="STD-Finch-1991" TOTAL_1="20" TOTAL_2="24" VAR="0.5141806722689075" WEIGHT="3.5827323371542237"/>
<DICH_DATA CI_END="1.985902722706102" CI_START="0.005423905030457442" EFFECT_SIZE="0.10378510378510379" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2979579712355713" LOG_CI_START="-2.265687923327823" LOG_EFFECT_SIZE="-0.9838649760461257" ORDER="130" O_E="0.0" SE="1.5058982887183816" STUDY_ID="STD-Jacobs-1992" TOTAL_1="45" TOTAL_2="46" VAR="2.26772965596495" WEIGHT="1.0167527258600766"/>
<DICH_DATA CI_END="0.17696698533121802" CI_START="0.019438331339088954" EFFECT_SIZE="0.05865102639296188" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="31" LOG_CI_END="-0.7521077473434803" LOG_CI_START="-1.7113410193135528" LOG_EFFECT_SIZE="-1.2317243833285165" ORDER="131" O_E="0.0" SE="0.5634583722364961" STUDY_ID="STD-Kerver-1988" TOTAL_1="49" TOTAL_2="47" VAR="0.3174853372434018" WEIGHT="4.997416811381401"/>
<DICH_DATA CI_END="0.5850225663034238" CI_START="0.09845774046624653" EFFECT_SIZE="0.24" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="25" LOG_CI_END="-0.23282738138442857" LOG_CI_START="-1.0067501351923593" LOG_EFFECT_SIZE="-0.619788758288394" ORDER="132" O_E="0.0" SE="0.4546060565661952" STUDY_ID="STD-Palomar-1997" TOTAL_1="50" TOTAL_2="49" VAR="0.20666666666666667" WEIGHT="6.42726659447585"/>
<DICH_DATA CI_END="0.6707305048432612" CI_START="0.29662361264882736" EFFECT_SIZE="0.4460431654676259" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="100" LOG_CI_END="-0.17345194148425758" LOG_CI_START="-0.5277942800274247" LOG_EFFECT_SIZE="-0.3506231107558412" ORDER="133" O_E="0.0" SE="0.20814244368312068" STUDY_ID="STD-Stoutenbeek-2007" TOTAL_1="201" TOTAL_2="200" VAR="0.04332327686238106" WEIGHT="11.114627261848801"/>
<DICH_DATA CI_END="0.4491197579077952" CI_START="0.06731752430453788" EFFECT_SIZE="0.17387820512820512" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="26" LOG_CI_END="-0.3476378388104043" LOG_CI_START="-1.1718718641853472" LOG_EFFECT_SIZE="-0.7597548514978757" ORDER="134" O_E="0.0" SE="0.48415914652946884" STUDY_ID="STD-Ulrich-1989" TOTAL_1="55" TOTAL_2="57" VAR="0.2344100791681437" WEIGHT="5.997657519638356"/>
<DICH_DATA CI_END="0.8208376058169056" CI_START="0.26497928122369097" EFFECT_SIZE="0.46637426900584794" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="40" LOG_CI_END="-0.08574275502874151" LOG_CI_START="-0.5767880822971287" LOG_EFFECT_SIZE="-0.33126541866293513" ORDER="135" O_E="0.0" SE="0.2884424559510227" STUDY_ID="STD-Verwaest-1997" TOTAL_1="193" TOTAL_2="185" VAR="0.08319905039505766" WEIGHT="9.434873259615213"/>
<DICH_DATA CI_END="0.5331170223859775" CI_START="0.042430612346863975" EFFECT_SIZE="0.15040106951871657" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="17" LOG_CI_END="-0.27317745026386936" LOG_CI_START="-1.3723207005702909" LOG_EFFECT_SIZE="-0.8227490754170801" ORDER="136" O_E="0.0" SE="0.6456421860768298" STUDY_ID="STD-Winter-1992" TOTAL_1="91" TOTAL_2="92" VAR="0.4168538324420677" WEIGHT="4.166318589387198"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-07-25 10:26:33 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Topical versus control</NAME>
<DICH_OUTCOME CHI2="12.630321249939316" CI_END="1.1564043019573726" CI_START="0.8215132020247454" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9746801531457342" ESTIMABLE="YES" EVENTS_1="361" EVENTS_2="408" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.06310969862718574" LOG_CI_START="-0.08538545289790747" LOG_EFFECT_SIZE="-0.011137877135360845" METHOD="MH" MODIFIED="2009-02-23 07:50:11 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="0.8569467084679921" P_Q="0.9735527209800335" P_Z="0.7687470894838666" Q="0.001099109703065516" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1396" TOTAL_2="1620" WEIGHT="100.00000000000001" Z="0.2940141523186435">
<NAME>Overall mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.320288782666189" CI_END="1.3178550628316885" CI_START="0.7268314599574154" DF="6" EFFECT_SIZE="0.9787024672137224" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="130" I2="18.036020461276323" ID="CMP-002.01.01" LOG_CI_END="0.1198676493523393" LOG_CI_START="-0.13856628308357954" LOG_EFFECT_SIZE="-0.009349316865620134" MODIFIED="2008-02-13 10:00:08 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.29223991682788886" P_Z="0.8872296794384422" STUDIES="7" TAU2="0.0" TOTAL_1="534" TOTAL_2="699" WEIGHT="32.95887705826166" Z="0.14181051353395366">
<NAME>Topical plus systemic versus systemic</NAME>
<DICH_DATA CI_END="2.5382887829805623" CI_START="0.45225712352772124" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.4045410305720316" LOG_CI_START="-0.3446145838171452" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="137" O_E="0.0" SE="0.4400577162723017" STUDY_ID="STD-Ferrer-1994" TOTAL_1="51" TOTAL_2="50" VAR="0.19365079365079363" WEIGHT="3.747049816413018"/>
<DICH_DATA CI_END="2.05817758962199" CI_START="0.4858667226007754" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" LOG_CI_END="0.31348284509374424" LOG_CI_START="-0.31348284509374424" LOG_EFFECT_SIZE="0.0" ORDER="138" O_E="0.0" SE="0.3682827499463503" STUDY_ID="STD-Gaussorgues-1991" TOTAL_1="59" TOTAL_2="59" VAR="0.135632183908046" WEIGHT="5.536273664383439"/>
<DICH_DATA CI_END="1.9057013551241238" CI_START="0.6411196454598078" EFFECT_SIZE="1.1053427419354838" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="31" LOG_CI_END="0.2800548427955801" LOG_CI_START="-0.19306091507685405" LOG_EFFECT_SIZE="0.043496963859363" ORDER="139" O_E="0.0" SE="0.27791053813503996" STUDY_ID="STD-Hammond-1992" TOTAL_1="162" TOTAL_2="160" VAR="0.07723426720650751" WEIGHT="9.253288356651217"/>
<DICH_DATA CI_END="1.4950733468268482" CI_START="0.1919570009909387" EFFECT_SIZE="0.5357142857142857" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.17466249924291438" LOG_CI_START="-0.7167960438159904" LOG_EFFECT_SIZE="-0.27106677228653797" ORDER="140" O_E="0.0" SE="0.5236471609837574" STUDY_ID="STD-Laggner-1994" TOTAL_1="33" TOTAL_2="34" VAR="0.2742063492063492" WEIGHT="3.7656918553006453"/>
<DICH_DATA CI_END="2.44918126125483" CI_START="0.4465151262124346" EFFECT_SIZE="1.0457516339869282" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.38902092797880333" LOG_CI_START="-0.35016382430215126" LOG_EFFECT_SIZE="0.019428551838326" ORDER="141" O_E="0.0" SE="0.43420078251336847" STUDY_ID="STD-Lingnau-1997" TOTAL_1="90" TOTAL_2="177" VAR="0.1885303195352215" WEIGHT="3.8726030506307096"/>
<DICH_DATA CI_END="3.4373548064773924" CI_START="0.7345527925819908" EFFECT_SIZE="1.5889992360580596" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" LOG_CI_END="0.5362243626703443" LOG_CI_START="-0.1339769858463328" LOG_EFFECT_SIZE="0.20112368841200576" ORDER="142" O_E="0.0" SE="0.39367958966887606" STUDY_ID="STD-Lingnau-1997b" TOTAL_1="90" TOTAL_2="177" VAR="0.15498361932185464" WEIGHT="3.6813633938094403"/>
<DICH_DATA CI_END="0.905755529414" CI_START="0.03611030374777444" EFFECT_SIZE="0.18085106382978725" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.042989006024688754" LOG_CI_START="-1.4423688584181606" LOG_EFFECT_SIZE="-0.7426789322214247" ORDER="143" O_E="0.0" SE="0.8220026523379126" STUDY_ID="STD-Stoutenbeek-1996" TOTAL_1="49" TOTAL_2="42" VAR="0.6756883604505632" WEIGHT="3.1026069210731904"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.301157529612041" CI_END="1.1986612815959707" CI_START="0.7893393647752529" DF="12" EFFECT_SIZE="0.9727026958920459" ESTIMABLE="YES" EVENTS_1="250" EVENTS_2="278" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.07869647724719504" LOG_CI_START="-0.10273623815703715" LOG_EFFECT_SIZE="-0.012019880454921071" MODIFIED="2008-07-29 23:34:01 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.947156348464248" P_Z="0.7950994898831903" STUDIES="13" TAU2="0.0" TOTAL_1="862" TOTAL_2="921" WEIGHT="67.04112294173835" Z="0.2596944298345952">
<NAME>Topical versus no prophylaxis</NAME>
<DICH_DATA CI_END="1.2437442574177962" CI_START="0.40948468193657594" EFFECT_SIZE="0.7136485280999108" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="59" LOG_CI_END="0.09473108854572515" LOG_CI_START="-0.38776233975178437" LOG_EFFECT_SIZE="-0.14651562560302958" ORDER="144" O_E="0.0" SE="0.28341902816294645" STUDY_ID="STD-Bergmans-2001" TOTAL_1="87" TOTAL_2="139" VAR="0.08032634552482902" WEIGHT="11.173744396968456"/>
<DICH_DATA CI_END="2.210142940292002" CI_START="0.4256617025693126" EFFECT_SIZE="0.9699346405228758" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.3444203624509802" LOG_CI_START="-0.3709354222001613" LOG_EFFECT_SIZE="-0.013257529874590538" ORDER="145" O_E="0.0" SE="0.42020352897232416" STUDY_ID="STD-Brun_x002d_Buisson-1989" TOTAL_1="65" TOTAL_2="68" VAR="0.17657100576079487" WEIGHT="4.319068565239764"/>
<DICH_DATA CI_END="1.5473418615767363" CI_START="0.5045211196035045" EFFECT_SIZE="0.8835534213685474" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="34" LOG_CI_END="0.18958627504016115" LOG_CI_START="-0.2971206491787386" LOG_EFFECT_SIZE="-0.053767187069288735" ORDER="157" O_E="0.0" SE="0.2858940565243123" STUDY_ID="STD-Camus-2005" TOTAL_1="130" TOTAL_2="126" VAR="0.0817354115559267" WEIGHT="9.773392305440119"/>
<DICH_DATA CI_END="4.395153081922656" CI_START="0.4512704656262258" EFFECT_SIZE="1.4083333333333334" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.6429740060256017" LOG_CI_START="-0.34556308889350423" LOG_EFFECT_SIZE="0.14870545856604875" ORDER="146" O_E="0.0" SE="0.5806715828930215" STUDY_ID="STD-Cerra-1992" TOTAL_1="25" TOTAL_2="23" VAR="0.33717948717948715" WEIGHT="1.8772422195323157"/>
<DICH_DATA CI_END="1.7046641959053193" CI_START="0.7929083886799282" EFFECT_SIZE="1.1626016260162602" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="82" LOG_CI_END="0.23163883949932243" LOG_CI_START="-0.10077698744799464" LOG_EFFECT_SIZE="0.06543092602566387" ORDER="147" O_E="0.0" SE="0.19526270223373549" STUDY_ID="STD-Gastinne-1992" TOTAL_1="220" TOTAL_2="225" VAR="0.038127522883620445" WEIGHT="18.26451216558902"/>
<DICH_DATA CI_END="2.7548653711542483" CI_START="0.13067789220101353" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.4401003799596892" LOG_CI_START="-0.8837978791924019" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="148" O_E="0.0" SE="0.7776643908280131" STUDY_ID="STD-Georges-1994" TOTAL_1="31" TOTAL_2="33" VAR="0.6047619047619047" WEIGHT="1.6425869420907762"/>
<DICH_DATA CI_END="2.7698956081845445" CI_START="0.6717534152854143" EFFECT_SIZE="1.3640699523052464" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.44246340168404286" LOG_CI_START="-0.17279011687716972" LOG_EFFECT_SIZE="0.1348366424034365" ORDER="150" O_E="0.0" SE="0.3614029623568912" STUDY_ID="STD-Korinek-1993" TOTAL_1="96" TOTAL_2="95" VAR="0.1306121012003365" WEIGHT="4.945697826537494"/>
<DICH_DATA CI_END="2.266780075801115" CI_START="0.17613412978734566" EFFECT_SIZE="0.6318681318681318" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.35540938669062466" LOG_CI_START="-0.754156481953551" LOG_EFFECT_SIZE="-0.19937354763146312" ORDER="151" O_E="0.0" SE="0.6517644836812194" STUDY_ID="STD-Pneumatikos-2002" TOTAL_1="31" TOTAL_2="30" VAR="0.4247969421882465" WEIGHT="2.2403808783926653"/>
<DICH_DATA CI_END="2.6458409367378852" CI_START="0.35857280190356156" EFFECT_SIZE="0.974025974025974" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.422563731622661" LOG_CI_START="-0.44542265518422464" LOG_EFFECT_SIZE="-0.011429461780781828" ORDER="152" O_E="0.0" SE="0.5098595002122741" STUDY_ID="STD-Pugin-1991" TOTAL_1="38" TOTAL_2="41" VAR="0.25995670995671" WEIGHT="2.927547360080776"/>
<DICH_DATA CI_END="2.9300356849026024" CI_START="0.4762234022233019" EFFECT_SIZE="1.18125" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.4668729096585168" LOG_CI_START="-0.3221892666238781" LOG_EFFECT_SIZE="0.07234182151731933" ORDER="153" O_E="0.0" SE="0.46349902826904527" STUDY_ID="STD-Quinio-1995" TOTAL_1="76" TOTAL_2="73" VAR="0.21483134920634922" WEIGHT="3.225328914095791"/>
<DICH_DATA CI_END="3.413269838436535" CI_START="0.18453905260272507" EFFECT_SIZE="0.7936507936507936" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.5331706230901324" LOG_CI_START="-0.7339117133252583" LOG_EFFECT_SIZE="-0.10037054511756292" ORDER="154" O_E="0.0" SE="0.7442904365691219" STUDY_ID="STD-Rodriguez_x002d_Rolda-1990" TOTAL_1="14" TOTAL_2="17" VAR="0.553968253968254" WEIGHT="1.5260162558778825"/>
<DICH_DATA CI_END="3.3760928873525207" CI_START="0.20569470912544024" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.5284143869789978" LOG_CI_START="-0.6867768790742474" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="155" O_E="0.0" SE="0.7138093649734567" STUDY_ID="STD-Unertl-1987" TOTAL_1="19" TOTAL_2="20" VAR="0.5095238095238095" WEIGHT="1.6173163737509182"/>
<DICH_DATA CI_END="1.7186089470706398" CI_START="0.22190063611641403" EFFECT_SIZE="0.6175438596491228" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.2351770683975112" LOG_CI_START="-0.653841452786232" LOG_EFFECT_SIZE="-0.20933219219436036" ORDER="156" O_E="0.0" SE="0.5222138800559843" STUDY_ID="STD-Wiener-1995" TOTAL_1="30" TOTAL_2="31" VAR="0.272707336523126" WEIGHT="3.5082887381423604"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.630321249939316" CI_END="1.1564043019573724" CI_START="0.8215132020247452" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="OR" EFFECT_SIZE="0.974680153145734" ESTIMABLE="YES" EVENTS_1="361" EVENTS_2="408" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.06310969862718566" LOG_CI_START="-0.08538545289790758" LOG_EFFECT_SIZE="-0.011137877135360944" METHOD="MH" MODIFIED="2009-01-06 08:12:15 +1000" MODIFIED_BY="Liz Dooley" NO="2" P_CHI2="0.8569467084679921" P_Q="0.3321428236052829" P_Z="0.7687470894838646" Q="0.9405257873486097" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1396" TOTAL_2="1620" WEIGHT="100.00000000000001" Z="0.2940141523186461">
<NAME>Mortality according to quality of allocation concealment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.203524796858668" CI_END="1.5161863867954788" CI_START="0.2731756483891164" DF="1" EFFECT_SIZE="0.6435722176194422" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" I2="76.21044127663268" ID="CMP-002.02.01" LOG_CI_END="0.18075259297223942" LOG_CI_START="-0.5635580174414365" LOG_EFFECT_SIZE="-0.1914027122345985" MODIFIED="2008-07-30 00:29:14 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04034018728636013" P_Z="0.31344173778169504" STUDIES="2" TAU2="0.0" TOTAL_1="74" TOTAL_2="65" WEIGHT="4.979849140605506" Z="1.0080265342841181">
<NAME>Adequate</NAME>
<DICH_DATA CI_END="4.395153081922656" CI_START="0.4512704656262258" EFFECT_SIZE="1.4083333333333334" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.6429740060256017" LOG_CI_START="-0.34556308889350423" LOG_EFFECT_SIZE="0.14870545856604875" ORDER="158" O_E="0.0" SE="0.5806715828930215" STUDY_ID="STD-Cerra-1992" TOTAL_1="25" TOTAL_2="23" VAR="0.33717948717948715" WEIGHT="1.8772422195323157"/>
<DICH_DATA CI_END="0.905755529414" CI_START="0.03611030374777444" EFFECT_SIZE="0.18085106382978725" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.042989006024688754" LOG_CI_START="-1.4423688584181606" LOG_EFFECT_SIZE="-0.7426789322214247" ORDER="162" O_E="0.0" SE="0.8220026523379126" STUDY_ID="STD-Stoutenbeek-1996" TOTAL_1="49" TOTAL_2="42" VAR="0.6756883604505632" WEIGHT="3.1026069210731904"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.981642868478562" CI_END="1.1812718617668627" CI_START="0.8331100160211107" DF="17" EFFECT_SIZE="0.9920329730819829" ESTIMABLE="YES" EVENTS_1="346" EVENTS_2="390" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.07234985906809682" LOG_CI_START="-0.07929764421625132" LOG_EFFECT_SIZE="-0.0034738925740772533" MODIFIED="2008-11-19 23:48:12 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9669376245083632" P_Z="0.928448962914986" STUDIES="18" TAU2="0.0" TOTAL_1="1322" TOTAL_2="1555" WEIGHT="95.0201508593945" Z="0.08979645802128154">
<NAME>Not adequate</NAME>
<DICH_DATA CI_END="1.2437442574177962" CI_START="0.40948468193657594" EFFECT_SIZE="0.7136485280999108" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="59" LOG_CI_END="0.09473108854572515" LOG_CI_START="-0.38776233975178437" LOG_EFFECT_SIZE="-0.14651562560302958" ORDER="173" O_E="0.0" SE="0.28341902816294645" STUDY_ID="STD-Bergmans-2001" TOTAL_1="87" TOTAL_2="139" VAR="0.08032634552482902" WEIGHT="11.173744396968456"/>
<DICH_DATA CI_END="2.210142940292002" CI_START="0.4256617025693126" EFFECT_SIZE="0.9699346405228758" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.3444203624509802" LOG_CI_START="-0.3709354222001613" LOG_EFFECT_SIZE="-0.013257529874590538" ORDER="164" O_E="0.0" SE="0.42020352897232416" STUDY_ID="STD-Brun_x002d_Buisson-1989" TOTAL_1="65" TOTAL_2="68" VAR="0.17657100576079487" WEIGHT="4.319068565239764"/>
<DICH_DATA CI_END="1.5473418615767363" CI_START="0.5045211196035045" EFFECT_SIZE="0.8835534213685474" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="34" LOG_CI_END="0.18958627504016115" LOG_CI_START="-0.2971206491787386" LOG_EFFECT_SIZE="-0.053767187069288735" ORDER="178" O_E="0.0" SE="0.2858940565243123" STUDY_ID="STD-Camus-2005" TOTAL_1="130" TOTAL_2="126" VAR="0.0817354115559267" WEIGHT="9.773392305440119"/>
<DICH_DATA CI_END="2.5382887829805623" CI_START="0.45225712352772124" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.4045410305720316" LOG_CI_START="-0.3446145838171452" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="165" O_E="0.0" SE="0.4400577162723017" STUDY_ID="STD-Ferrer-1994" TOTAL_1="51" TOTAL_2="50" VAR="0.19365079365079363" WEIGHT="3.747049816413018"/>
<DICH_DATA CI_END="1.7046641959053193" CI_START="0.7929083886799282" EFFECT_SIZE="1.1626016260162602" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="82" LOG_CI_END="0.23163883949932243" LOG_CI_START="-0.10077698744799464" LOG_EFFECT_SIZE="0.06543092602566387" ORDER="166" O_E="0.0" SE="0.19526270223373549" STUDY_ID="STD-Gastinne-1992" TOTAL_1="220" TOTAL_2="225" VAR="0.038127522883620445" WEIGHT="18.26451216558902"/>
<DICH_DATA CI_END="2.05817758962199" CI_START="0.4858667226007754" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" LOG_CI_END="0.31348284509374424" LOG_CI_START="-0.31348284509374424" LOG_EFFECT_SIZE="0.0" ORDER="167" O_E="0.0" SE="0.3682827499463503" STUDY_ID="STD-Gaussorgues-1991" TOTAL_1="59" TOTAL_2="59" VAR="0.135632183908046" WEIGHT="5.536273664383439"/>
<DICH_DATA CI_END="2.7548653711542483" CI_START="0.13067789220101353" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.4401003799596892" LOG_CI_START="-0.8837978791924019" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2008-11-19 23:47:33 +1000" MODIFIED_BY="[Empty name]" ORDER="222" O_E="0.0" SE="0.7776643908280131" STUDY_ID="STD-Georges-1994" TOTAL_1="31" TOTAL_2="33" VAR="0.6047619047619047" WEIGHT="1.6425869420907762"/>
<DICH_DATA CI_END="1.9057013551241238" CI_START="0.6411196454598078" EFFECT_SIZE="1.1053427419354838" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="31" LOG_CI_END="0.2800548427955801" LOG_CI_START="-0.19306091507685405" LOG_EFFECT_SIZE="0.043496963859363" ORDER="168" O_E="0.0" SE="0.27791053813503996" STUDY_ID="STD-Hammond-1992" TOTAL_1="162" TOTAL_2="160" VAR="0.07723426720650751" WEIGHT="9.253288356651217"/>
<DICH_DATA CI_END="2.7698956081845445" CI_START="0.6717534152854143" EFFECT_SIZE="1.3640699523052464" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.44246340168404286" LOG_CI_START="-0.17279011687716972" LOG_EFFECT_SIZE="0.1348366424034365" ORDER="174" O_E="0.0" SE="0.3614029623568912" STUDY_ID="STD-Korinek-1993" TOTAL_1="96" TOTAL_2="95" VAR="0.1306121012003365" WEIGHT="4.945697826537494"/>
<DICH_DATA CI_END="1.4950733468268482" CI_START="0.1919570009909387" EFFECT_SIZE="0.5357142857142857" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.17466249924291438" LOG_CI_START="-0.7167960438159904" LOG_EFFECT_SIZE="-0.27106677228653797" ORDER="169" O_E="0.0" SE="0.5236471609837574" STUDY_ID="STD-Laggner-1994" TOTAL_1="33" TOTAL_2="34" VAR="0.2742063492063492" WEIGHT="3.7656918553006453"/>
<DICH_DATA CI_END="2.44918126125483" CI_START="0.4465151262124346" EFFECT_SIZE="1.0457516339869282" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.38902092797880333" LOG_CI_START="-0.35016382430215126" LOG_EFFECT_SIZE="0.019428551838326" ORDER="175" O_E="0.0" SE="0.43420078251336847" STUDY_ID="STD-Lingnau-1997" TOTAL_1="90" TOTAL_2="177" VAR="0.1885303195352215" WEIGHT="3.8726030506307096"/>
<DICH_DATA CI_END="3.4373548064773924" CI_START="0.7345527925819908" EFFECT_SIZE="1.5889992360580596" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" LOG_CI_END="0.5362243626703443" LOG_CI_START="-0.1339769858463328" LOG_EFFECT_SIZE="0.20112368841200576" ORDER="176" O_E="0.0" SE="0.39367958966887606" STUDY_ID="STD-Lingnau-1997b" TOTAL_1="90" TOTAL_2="177" VAR="0.15498361932185464" WEIGHT="3.6813633938094403"/>
<DICH_DATA CI_END="2.266780075801115" CI_START="0.17613412978734566" EFFECT_SIZE="0.6318681318681318" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.35540938669062466" LOG_CI_START="-0.754156481953551" LOG_EFFECT_SIZE="-0.19937354763146312" ORDER="170" O_E="0.0" SE="0.6517644836812194" STUDY_ID="STD-Pneumatikos-2002" TOTAL_1="31" TOTAL_2="30" VAR="0.4247969421882465" WEIGHT="2.2403808783926653"/>
<DICH_DATA CI_END="2.6458409367378852" CI_START="0.35857280190356156" EFFECT_SIZE="0.974025974025974" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.422563731622661" LOG_CI_START="-0.44542265518422464" LOG_EFFECT_SIZE="-0.011429461780781828" MODIFIED="2008-11-19 23:47:48 +1000" MODIFIED_BY="[Empty name]" ORDER="223" O_E="0.0" SE="0.5098595002122741" STUDY_ID="STD-Pugin-1991" TOTAL_1="38" TOTAL_2="41" VAR="0.25995670995671" WEIGHT="2.927547360080776"/>
<DICH_DATA CI_END="2.9300356849026024" CI_START="0.4762234022233019" EFFECT_SIZE="1.18125" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.4668729096585168" LOG_CI_START="-0.3221892666238781" LOG_EFFECT_SIZE="0.07234182151731933" ORDER="177" O_E="0.0" SE="0.46349902826904527" STUDY_ID="STD-Quinio-1995" TOTAL_1="76" TOTAL_2="73" VAR="0.21483134920634922" WEIGHT="3.225328914095791"/>
<DICH_DATA CI_END="3.413269838436535" CI_START="0.18453905260272507" EFFECT_SIZE="0.7936507936507936" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.5331706230901324" LOG_CI_START="-0.7339117133252583" LOG_EFFECT_SIZE="-0.10037054511756292" ORDER="171" O_E="0.0" SE="0.7442904365691219" STUDY_ID="STD-Rodriguez_x002d_Rolda-1990" TOTAL_1="14" TOTAL_2="17" VAR="0.553968253968254" WEIGHT="1.5260162558778825"/>
<DICH_DATA CI_END="3.3760928873525207" CI_START="0.20569470912544024" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.5284143869789978" LOG_CI_START="-0.6867768790742474" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2008-11-19 23:48:12 +1000" MODIFIED_BY="[Empty name]" ORDER="224" O_E="0.0" SE="0.7138093649734567" STUDY_ID="STD-Unertl-1987" TOTAL_1="19" TOTAL_2="20" VAR="0.5095238095238095" WEIGHT="1.6173163737509182"/>
<DICH_DATA CI_END="1.7186089470706398" CI_START="0.22190063611641403" EFFECT_SIZE="0.6175438596491228" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.2351770683975112" LOG_CI_START="-0.653841452786232" LOG_EFFECT_SIZE="-0.20933219219436036" ORDER="172" O_E="0.0" SE="0.5222138800559843" STUDY_ID="STD-Wiener-1995" TOTAL_1="30" TOTAL_2="31" VAR="0.272707336523126" WEIGHT="3.5082887381423604"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.933091060264934" CI_END="1.159043033014885" CI_START="0.8232319675633456" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9768117917794766" ESTIMABLE="YES" EVENTS_1="360" EVENTS_2="406" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.06409956077287712" LOG_CI_START="-0.08447777349003546" LOG_EFFECT_SIZE="-0.010189106358579164" METHOD="MH" MODIFIED="2009-01-06 08:12:30 +1000" MODIFIED_BY="Liz Dooley" NO="3" P_CHI2="0.8884653714189831" P_Q="0.6117525315265502" P_Z="0.788068181487224" Q="0.2576308391528301" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1396" TOTAL_2="1620" WEIGHT="100.0" Z="0.2688200269110379">
<NAME>Mortality according to blinding of the studies</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.964844542008827" CI_END="1.1971629298752477" CI_START="0.8267720621593996" DF="14" EFFECT_SIZE="0.9948773111664309" ESTIMABLE="YES" EVENTS_1="304" EVENTS_2="344" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.07815326045692858" LOG_CI_START="-0.0826142072443223" LOG_EFFECT_SIZE="-0.002230473393696851" MODIFIED="2008-02-13 10:00:30 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6887955993737649" P_Z="0.9566286459470043" STUDIES="15" TAU2="0.0" TOTAL_1="1191" TOTAL_2="1410" WEIGHT="84.61015669964226" Z="0.054384728236739434">
<NAME>Double-blind</NAME>
<DICH_DATA CI_END="1.3208908887813042" CI_START="0.43401410814051533" EFFECT_SIZE="0.7571560480147738" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="57" LOG_CI_END="0.12086694452043276" LOG_CI_START="-0.36249615300364013" LOG_EFFECT_SIZE="-0.12081460424160367" ORDER="179" O_E="0.0" SE="0.28392987617156185" STUDY_ID="STD-Bergmans-2001" TOTAL_1="87" TOTAL_2="139" VAR="0.08061617458279845" WEIGHT="10.819027793389784"/>
<DICH_DATA CI_END="3.744982507673742" CI_START="0.3845144795868432" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.5734497935071778" LOG_CI_START="-0.4150873014119282" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="180" O_E="0.0" SE="0.5806715828930215" STUDY_ID="STD-Cerra-1992" TOTAL_1="25" TOTAL_2="23" VAR="0.33717948717948715" WEIGHT="2.038210709511849"/>
<DICH_DATA CI_END="2.5382887829805623" CI_START="0.45225712352772124" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.4045410305720316" LOG_CI_START="-0.3446145838171452" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="181" O_E="0.0" SE="0.4400577162723017" STUDY_ID="STD-Ferrer-1994" TOTAL_1="51" TOTAL_2="50" VAR="0.19365079365079363" WEIGHT="3.755399351447879"/>
<DICH_DATA CI_END="1.7046641959053193" CI_START="0.7929083886799282" EFFECT_SIZE="1.1626016260162602" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="82" LOG_CI_END="0.23163883949932243" LOG_CI_START="-0.10077698744799464" LOG_EFFECT_SIZE="0.06543092602566387" ORDER="182" O_E="0.0" SE="0.19526270223373549" STUDY_ID="STD-Gastinne-1992" TOTAL_1="220" TOTAL_2="225" VAR="0.038127522883620445" WEIGHT="18.305210899711327"/>
<DICH_DATA CI_END="1.9057013551241238" CI_START="0.6411196454598078" EFFECT_SIZE="1.1053427419354838" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="31" LOG_CI_END="0.2800548427955801" LOG_CI_START="-0.19306091507685405" LOG_EFFECT_SIZE="0.043496963859363" ORDER="183" O_E="0.0" SE="0.27791053813503996" STUDY_ID="STD-Hammond-1992" TOTAL_1="162" TOTAL_2="160" VAR="0.07723426720650751" WEIGHT="9.273907419409097"/>
<DICH_DATA CI_END="2.7698956081845445" CI_START="0.6717534152854143" EFFECT_SIZE="1.3640699523052464" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.44246340168404286" LOG_CI_START="-0.17279011687716972" LOG_EFFECT_SIZE="0.1348366424034365" ORDER="184" O_E="0.0" SE="0.3614029623568912" STUDY_ID="STD-Korinek-1993" TOTAL_1="96" TOTAL_2="95" VAR="0.1306121012003365" WEIGHT="4.956718303792328"/>
<DICH_DATA CI_END="1.4950733468268482" CI_START="0.1919570009909387" EFFECT_SIZE="0.5357142857142857" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.17466249924291438" LOG_CI_START="-0.7167960438159904" LOG_EFFECT_SIZE="-0.27106677228653797" ORDER="185" O_E="0.0" SE="0.5236471609837574" STUDY_ID="STD-Laggner-1994" TOTAL_1="33" TOTAL_2="34" VAR="0.2742063492063492" WEIGHT="3.774082930310804"/>
<DICH_DATA CI_END="2.44918126125483" CI_START="0.4465151262124346" EFFECT_SIZE="1.0457516339869282" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.38902092797880333" LOG_CI_START="-0.35016382430215126" LOG_EFFECT_SIZE="0.019428551838326" ORDER="186" O_E="0.0" SE="0.43420078251336847" STUDY_ID="STD-Lingnau-1997" TOTAL_1="90" TOTAL_2="177" VAR="0.1885303195352215" WEIGHT="3.8812323553988812"/>
<DICH_DATA CI_END="3.4373548064773924" CI_START="0.7345527925819908" EFFECT_SIZE="1.5889992360580596" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" LOG_CI_END="0.5362243626703443" LOG_CI_START="-0.1339769858463328" LOG_EFFECT_SIZE="0.20112368841200576" ORDER="187" O_E="0.0" SE="0.39367958966887606" STUDY_ID="STD-Lingnau-1997b" TOTAL_1="90" TOTAL_2="177" VAR="0.15498361932185464" WEIGHT="3.6895665600705416"/>
<DICH_DATA CI_END="2.6458409367378852" CI_START="0.35857280190356156" EFFECT_SIZE="0.974025974025974" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.422563731622661" LOG_CI_START="-0.44542265518422464" LOG_EFFECT_SIZE="-0.011429461780781828" ORDER="188" O_E="0.0" SE="0.5098595002122741" STUDY_ID="STD-Pugin-1991" TOTAL_1="38" TOTAL_2="41" VAR="0.25995670995671" WEIGHT="2.9340708013070276"/>
<DICH_DATA CI_END="2.9300356849026024" CI_START="0.4762234022233019" EFFECT_SIZE="1.18125" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.4668729096585168" LOG_CI_START="-0.3221892666238781" LOG_EFFECT_SIZE="0.07234182151731933" ORDER="189" O_E="0.0" SE="0.46349902826904527" STUDY_ID="STD-Quinio-1995" TOTAL_1="76" TOTAL_2="73" VAR="0.21483134920634922" WEIGHT="3.232515900681673"/>
<DICH_DATA CI_END="3.413269838436535" CI_START="0.18453905260272507" EFFECT_SIZE="0.7936507936507936" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.5331706230901324" LOG_CI_START="-0.7339117133252583" LOG_EFFECT_SIZE="-0.10037054511756292" ORDER="190" O_E="0.0" SE="0.7442904365691219" STUDY_ID="STD-Rodriguez_x002d_Rolda-1990" TOTAL_1="14" TOTAL_2="17" VAR="0.553968253968254" WEIGHT="1.5294166713557895"/>
<DICH_DATA CI_END="0.905755529414" CI_START="0.03611030374777444" EFFECT_SIZE="0.18085106382978725" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.042989006024688754" LOG_CI_START="-1.4423688584181606" LOG_EFFECT_SIZE="-0.7426789322214247" ORDER="191" O_E="0.0" SE="0.8220026523379126" STUDY_ID="STD-Stoutenbeek-1996" TOTAL_1="49" TOTAL_2="42" VAR="0.6756883604505632" WEIGHT="3.1095204467683732"/>
<DICH_DATA CI_END="1.7186089470706398" CI_START="0.22190063611641403" EFFECT_SIZE="0.6175438596491228" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.2351770683975112" LOG_CI_START="-0.653841452786232" LOG_EFFECT_SIZE="-0.20933219219436036" ORDER="192" O_E="0.0" SE="0.5222138800559843" STUDY_ID="STD-Wiener-1995" TOTAL_1="30" TOTAL_2="31" VAR="0.272707336523126" WEIGHT="3.516106242890554"/>
<DICH_DATA CI_END="1.5473418615767363" CI_START="0.5045211196035045" EFFECT_SIZE="0.8835534213685474" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="34" LOG_CI_END="0.18958627504016115" LOG_CI_START="-0.2971206491787386" LOG_EFFECT_SIZE="-0.053767187069288735" ORDER="193" O_E="0.0" SE="0.2858940565243123" STUDY_ID="STD-Camus-2005" TOTAL_1="130" TOTAL_2="126" VAR="0.0817354115559267" WEIGHT="9.795170313596367"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6807756195744653" CI_END="1.3735548036375316" CI_START="0.5605826740470743" DF="4" EFFECT_SIZE="0.8774913246142845" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="62" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.13784599207295783" LOG_CI_START="-0.25136032912662315" LOG_EFFECT_SIZE="-0.05675716852683263" MODIFIED="2008-07-29 23:34:01 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9536783497831234" P_Z="0.5675691822833779" STUDIES="5" TAU2="0.0" TOTAL_1="205" TOTAL_2="210" WEIGHT="15.389843300357745" Z="0.5716351462853991">
<NAME>Open</NAME>
<DICH_DATA CI_END="2.7548653711542483" CI_START="0.13067789220101353" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.4401003799596892" LOG_CI_START="-0.8837978791924019" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="3" O_E="0.0" SE="0.7776643908280131" STUDY_ID="STD-Georges-1994" TOTAL_1="31" TOTAL_2="33" VAR="0.6047619047619047" WEIGHT="1.646247111528801"/>
<DICH_DATA CI_END="2.210142940292002" CI_START="0.4256617025693126" EFFECT_SIZE="0.9699346405228758" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.3444203624509802" LOG_CI_START="-0.3709354222001613" LOG_EFFECT_SIZE="-0.013257529874590538" ORDER="194" O_E="0.0" SE="0.42020352897232416" STUDY_ID="STD-Brun_x002d_Buisson-1989" TOTAL_1="65" TOTAL_2="68" VAR="0.17657100576079487" WEIGHT="4.328692727199254"/>
<DICH_DATA CI_END="2.05817758962199" CI_START="0.4858667226007754" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" LOG_CI_END="0.31348284509374424" LOG_CI_START="-0.31348284509374424" LOG_EFFECT_SIZE="0.0" ORDER="195" O_E="0.0" SE="0.3682827499463503" STUDY_ID="STD-Gaussorgues-1991" TOTAL_1="59" TOTAL_2="59" VAR="0.135632183908046" WEIGHT="5.548610119244773"/>
<DICH_DATA CI_END="3.3760928873525207" CI_START="0.20569470912544024" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.5284143869789978" LOG_CI_START="-0.6867768790742474" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="198" O_E="0.0" SE="0.7138093649734567" STUDY_ID="STD-Unertl-1987" TOTAL_1="19" TOTAL_2="20" VAR="0.5095238095238095" WEIGHT="1.6209202328898964"/>
<DICH_DATA CI_END="2.266780075801115" CI_START="0.17613412978734566" EFFECT_SIZE="0.6318681318681318" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.35540938669062466" LOG_CI_START="-0.754156481953551" LOG_EFFECT_SIZE="-0.19937354763146312" ORDER="199" O_E="0.0" SE="0.6517644836812194" STUDY_ID="STD-Pneumatikos-2002" TOTAL_1="31" TOTAL_2="30" VAR="0.4247969421882465" WEIGHT="2.245373109495021"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="51.609294711447866" CI_END="0.6326912333159046" CI_START="0.3073416966302425" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_MEASURE="OR" EFFECT_SIZE="0.44096756920480074" ESTIMABLE="YES" EVENTS_1="260" EVENTS_2="483" I2="67.0601970148042" I2_Q="86.88289004299554" ID="CMP-002.04" LOG_CI_END="-0.19880818316200585" LOG_CI_START="-0.5123785156043864" LOG_EFFECT_SIZE="-0.35559334938319614" METHOD="MH" MODIFIED="2009-07-25 10:23:23 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="2.3682000545477422E-5" P_Q="0.00576089549195169" P_Z="8.77873789867079E-6" Q="7.623630535063143" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.342629521427183" TOTALS="YES" TOTAL_1="1312" TOTAL_2="1538" WEIGHT="99.99999999999999" Z="4.445255726232324">
<NAME>RTIs</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.420674481732435" CI_END="1.1302498397815997" CI_START="0.557088341937137" DF="5" EFFECT_SIZE="0.7935042591055489" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="195" I2="22.12656140370329" ID="CMP-002.04.01" LOG_CI_END="0.053174454142985605" LOG_CI_START="-0.25407592982874094" LOG_EFFECT_SIZE="-0.10045073784287767" MODIFIED="2008-02-13 10:00:45 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2674094327701869" P_Z="0.19999720552673603" STUDIES="6" TAU2="0.04225488756673603" TOTAL_1="475" TOTAL_2="640" WEIGHT="35.12907778518827" Z="1.2815595271030287">
<NAME>Topical plus systemic versus systemic</NAME>
<DICH_DATA CI_END="1.5975128891721608" CI_START="0.19915453483947404" EFFECT_SIZE="0.5640495867768595" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.2034443708515732" LOG_CI_START="-0.700809800058886" LOG_EFFECT_SIZE="-0.24868271460365646" ORDER="1" O_E="0.0" SE="0.5311633761231399" STUDY_ID="STD-Ferrer-1994" TOTAL_1="51" TOTAL_2="50" VAR="0.28213453213453216" WEIGHT="5.430366017355325"/>
<DICH_DATA CI_END="1.4158408660902455" CI_START="0.441640237525855" EFFECT_SIZE="0.7907542579075426" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="30" LOG_CI_END="0.1510144434225211" LOG_CI_START="-0.3549313652169108" LOG_EFFECT_SIZE="-0.1019584608971948" ORDER="201" O_E="0.0" SE="0.2971950724669467" STUDY_ID="STD-Hammond-1992" TOTAL_1="162" TOTAL_2="160" VAR="0.08832491109863372" WEIGHT="7.872520223175701"/>
<DICH_DATA CI_END="2.217475353924042" CI_START="0.024772153849553735" EFFECT_SIZE="0.234375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3458588015751184" LOG_CI_START="-1.6060362314315304" LOG_EFFECT_SIZE="-0.630088714928206" ORDER="202" O_E="0.0" SE="1.1465528044243463" STUDY_ID="STD-Laggner-1994" TOTAL_1="33" TOTAL_2="34" VAR="1.3145833333333334" WEIGHT="2.0472309731250413"/>
<DICH_DATA CI_END="1.8261037950853203" CI_START="0.6518235992244097" EFFECT_SIZE="1.0910075839653304" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="71" LOG_CI_END="0.26152545904257407" LOG_CI_START="-0.18586991998716226" LOG_EFFECT_SIZE="0.037827769527705925" ORDER="203" O_E="0.0" SE="0.2628022602849106" STUDY_ID="STD-Lingnau-1997" TOTAL_1="90" TOTAL_2="177" VAR="0.06906502801085791" WEIGHT="8.240812247715448"/>
<DICH_DATA CI_END="1.5268916306076445" CI_START="0.5381069466440779" EFFECT_SIZE="0.9064386317907445" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="71" LOG_CI_END="0.18380821459457922" LOG_CI_START="-0.2691314014310799" LOG_EFFECT_SIZE="-0.04266159341825034" ORDER="204" O_E="0.0" SE="0.2660589725407314" STUDY_ID="STD-Lingnau-1997b" TOTAL_1="90" TOTAL_2="177" VAR="0.07078737686942968" WEIGHT="8.20647994628549"/>
<DICH_DATA CI_END="0.905755529414" CI_START="0.03611030374777444" EFFECT_SIZE="0.18085106382978725" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.042989006024688754" LOG_CI_START="-1.4423688584181606" LOG_EFFECT_SIZE="-0.7426789322214247" ORDER="205" O_E="0.0" SE="0.8220026523379126" STUDY_ID="STD-Stoutenbeek-1996" TOTAL_1="49" TOTAL_2="42" VAR="0.6756883604505632" WEIGHT="3.33166837753126"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="36.06907745421337" CI_END="0.5530325128566476" CI_START="0.20850635732300138" DF="11" EFFECT_SIZE="0.3395744318068213" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="288" I2="69.50296271379948" ID="CMP-002.04.02" LOG_CI_END="-0.2572493357130921" LOG_CI_START="-0.6808806989242366" LOG_EFFECT_SIZE="-0.46906501731866435" MODIFIED="2008-07-29 23:34:01 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.6481771665166622E-4" P_Z="1.4226711582218324E-5" STUDIES="12" TAU2="0.44471883247486516" TOTAL_1="837" TOTAL_2="898" WEIGHT="64.87092221481171" Z="4.340332752436086">
<NAME>Topical versus no prophylaxis</NAME>
<DICH_DATA CI_END="0.671930208140419" CI_START="0.13997394460039791" EFFECT_SIZE="0.3066801619433198" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="38" LOG_CI_END="-0.1726758337818444" LOG_CI_START="-0.853952798388802" LOG_EFFECT_SIZE="-0.5133143160853232" ORDER="206" O_E="0.0" SE="0.40018546138549066" STUDY_ID="STD-Bergmans-2001" TOTAL_1="87" TOTAL_2="139" VAR="0.16014840350431803" WEIGHT="6.747904625663359"/>
<DICH_DATA CI_END="2.0891650904476964" CI_START="0.11966502845709831" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.31997276024718874" LOG_CI_START="-0.9220327515751512" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="207" O_E="0.0" SE="0.7295601856708801" STUDY_ID="STD-Brun_x002d_Buisson-1989" TOTAL_1="65" TOTAL_2="68" VAR="0.532258064516129" WEIGHT="3.8778667566401253"/>
<DICH_DATA CI_END="1.3533142348536038" CI_START="0.4492821493403727" EFFECT_SIZE="0.7797563261480788" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="33" LOG_CI_END="0.13139864997362607" LOG_CI_START="-0.34748083624111786" LOG_EFFECT_SIZE="-0.10804109313374592" ORDER="208" O_E="0.0" SE="0.2812961806942281" STUDY_ID="STD-Gastinne-1992" TOTAL_1="220" TOTAL_2="225" VAR="0.07912754127315984" WEIGHT="8.044198391378693"/>
<DICH_DATA CI_END="0.6229021368690192" CI_START="0.050738208140471794" EFFECT_SIZE="0.17777777777777778" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="15" LOG_CI_END="-0.20558017927382535" LOG_CI_START="-1.2946648742929747" LOG_EFFECT_SIZE="-0.7501225267834001" ORDER="209" O_E="0.0" SE="0.6397337409104347" STUDY_ID="STD-Georges-1994" TOTAL_1="31" TOTAL_2="33" VAR="0.4092592592592592" WEIGHT="4.512233155320276"/>
<DICH_DATA CI_END="0.7842094649382524" CI_START="0.21699676833675877" EFFECT_SIZE="0.41251778093883357" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="37" LOG_CI_END="-0.10556792033006301" LOG_CI_START="-0.6635467339116726" LOG_EFFECT_SIZE="-0.3845573271208679" ORDER="211" O_E="0.0" SE="0.3277595171375104" STUDY_ID="STD-Korinek-1993" TOTAL_1="96" TOTAL_2="95" VAR="0.10742630107421397" WEIGHT="7.538392607544077"/>
<DICH_DATA CI_END="0.5564677792688406" CI_START="0.050882611857369246" EFFECT_SIZE="0.16826923076923078" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" LOG_CI_END="-0.2545599772247965" LOG_CI_START="-1.2934306040001753" LOG_EFFECT_SIZE="-0.7739952906124858" ORDER="212" O_E="0.0" SE="0.610237748660397" STUDY_ID="STD-Pneumatikos-2002" TOTAL_1="31" TOTAL_2="30" VAR="0.3723901098901099" WEIGHT="4.744901170162665"/>
<DICH_DATA CI_END="0.2789118286048895" CI_START="0.02489835041841142" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="24" LOG_CI_END="-0.5545330669856574" LOG_CI_START="-1.6038294251095921" LOG_EFFECT_SIZE="-1.0791812460476249" ORDER="213" O_E="0.0" SE="0.6163618748627414" STUDY_ID="STD-Pugin-1991" TOTAL_1="38" TOTAL_2="41" VAR="0.37990196078431376" WEIGHT="4.695570461431607"/>
<DICH_DATA CI_END="0.614021813661682" CI_START="0.15351209051596904" EFFECT_SIZE="0.30701754385964913" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="38" LOG_CI_END="-0.21181619989365566" LOG_CI_START="-0.8138574140787381" LOG_EFFECT_SIZE="-0.5128368069861969" ORDER="214" O_E="0.0" SE="0.35364198936439095" STUDY_ID="STD-Quinio-1995" TOTAL_1="76" TOTAL_2="73" VAR="0.12506265664160401" WEIGHT="7.2541249232261285"/>
<DICH_DATA CI_END="0.40376398770443706" CI_START="0.00436016420127471" EFFECT_SIZE="0.04195804195804196" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.3938724190196639" LOG_CI_START="-2.3604971551431726" LOG_EFFECT_SIZE="-1.3771847870814182" ORDER="215" O_E="0.0" SE="1.155205104948396" STUDY_ID="STD-Rodriguez_x002d_Rolda-1990" TOTAL_1="14" TOTAL_2="17" VAR="1.3344988344988344" WEIGHT="2.0229205912229897"/>
<DICH_DATA CI_END="0.6115464173133797" CI_START="0.007539211293396412" EFFECT_SIZE="0.06790123456790123" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.21357057375769592" LOG_CI_START="-2.122674085011116" LOG_EFFECT_SIZE="-1.1681223293844059" ORDER="216" O_E="0.0" SE="1.1214168527250505" STUDY_ID="STD-Unertl-1987" TOTAL_1="19" TOTAL_2="20" VAR="1.2575757575757576" WEIGHT="2.1201639126204044"/>
<DICH_DATA CI_END="3.2723302284791824" CI_START="0.33400516766290156" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.5148571242075897" LOG_CI_START="-0.47624681381681633" LOG_EFFECT_SIZE="0.019305155195386624" ORDER="217" O_E="0.0" SE="0.582179359239153" STUDY_ID="STD-Wiener-1995" TOTAL_1="30" TOTAL_2="31" VAR="0.3389328063241107" WEIGHT="4.9778242534624315"/>
<DICH_DATA CI_END="1.5591177368390494" CI_START="0.5764814772919735" EFFECT_SIZE="0.948051948051948" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="53" LOG_CI_END="0.1928789121925828" LOG_CI_START="-0.23921464229663475" LOG_EFFECT_SIZE="-0.02316786505202598" ORDER="218" O_E="0.0" SE="0.2538138928045568" STUDY_ID="STD-Camus-2005" TOTAL_1="130" TOTAL_2="126" VAR="0.06442149218060306" WEIGHT="8.334821366138971"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="51.60929471144787" CI_END="0.6326912333159046" CI_START="0.30734169663024247" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_MEASURE="OR" EFFECT_SIZE="0.4409675692048007" ESTIMABLE="YES" EVENTS_1="260" EVENTS_2="483" I2="67.06019701480422" I2_Q="16.78959534083589" ID="CMP-002.05" LOG_CI_END="-0.19880818316200585" LOG_CI_START="-0.5123785156043864" LOG_EFFECT_SIZE="-0.3555933493831962" METHOD="MH" MODIFIED="2009-07-25 10:25:28 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="2.3682000545255377E-5" P_Q="0.27296770740890985" P_Z="8.77873789867079E-6" Q="1.201772788025816" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3426295214271831" TOTALS="YES" TOTAL_1="1312" TOTAL_2="1538" WEIGHT="99.99999999999999" Z="4.445255726232324">
<NAME>RTIs according to quality of allocation concealment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.905755529414" CI_START="0.03611030374777444" DF="0" EFFECT_SIZE="0.18085106382978727" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="-0.042989006024688754" LOG_CI_START="-1.4423688584181606" LOG_EFFECT_SIZE="-0.7426789322214247" MODIFIED="2008-11-20 00:07:01 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.03749029526388022" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="42" WEIGHT="3.331668377531261" Z="2.0803843313035926">
<NAME>Adequate</NAME>
<DICH_DATA CI_END="0.905755529414" CI_START="0.03611030374777444" EFFECT_SIZE="0.18085106382978725" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.042989006024688754" LOG_CI_START="-1.4423688584181606" LOG_EFFECT_SIZE="-0.7426789322214247" ORDER="222" O_E="0.0" SE="0.8220026523379126" STUDY_ID="STD-Stoutenbeek-1996" TOTAL_1="49" TOTAL_2="42" VAR="0.6756883604505632" WEIGHT="3.331668377531261"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="49.48656766433195" CI_END="0.6564027528048149" CI_START="0.31624725618834704" DF="16" EFFECT_SIZE="0.45561559403624513" ESTIMABLE="YES" EVENTS_1="258" EVENTS_2="475" I2="67.66799405340008" ID="CMP-002.05.02" LOG_CI_END="-0.1828296062822077" LOG_CI_START="-0.4999732338079979" LOG_EFFECT_SIZE="-0.3414014200451028" MODIFIED="2008-11-20 00:08:39 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.7666647744784E-5" P_Z="2.4456601385994583E-5" STUDIES="17" TAU2="0.3368566030648582" TOTAL_1="1263" TOTAL_2="1496" WEIGHT="96.66833162246873" Z="4.219756788301339">
<NAME>Not adequate</NAME>
<DICH_DATA CI_END="1.5975128891721608" CI_START="0.19915453483947404" EFFECT_SIZE="0.5640495867768595" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.2034443708515732" LOG_CI_START="-0.700809800058886" LOG_EFFECT_SIZE="-0.24868271460365646" ORDER="2" O_E="0.0" SE="0.5311633761231399" STUDY_ID="STD-Ferrer-1994" TOTAL_1="51" TOTAL_2="50" VAR="0.28213453213453216" WEIGHT="5.430366017355325"/>
<DICH_DATA CI_END="0.6229021368690192" CI_START="0.050738208140471794" EFFECT_SIZE="0.17777777777777778" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="15" LOG_CI_END="-0.20558017927382535" LOG_CI_START="-1.2946648742929747" LOG_EFFECT_SIZE="-0.7501225267834001" MODIFIED="2008-11-20 00:08:17 +1000" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="0.6397337409104347" STUDY_ID="STD-Georges-1994" TOTAL_1="31" TOTAL_2="33" VAR="0.4092592592592592" WEIGHT="4.512233155320277"/>
<DICH_DATA CI_END="0.2789118286048895" CI_START="0.02489835041841142" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="24" LOG_CI_END="-0.5545330669856574" LOG_CI_START="-1.6038294251095921" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2008-11-20 00:08:30 +1000" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.6163618748627414" STUDY_ID="STD-Pugin-1991" TOTAL_1="38" TOTAL_2="41" VAR="0.37990196078431376" WEIGHT="4.695570461431607"/>
<DICH_DATA CI_END="0.6115464173133797" CI_START="0.007539211293396412" EFFECT_SIZE="0.06790123456790123" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.21357057375769592" LOG_CI_START="-2.122674085011116" LOG_EFFECT_SIZE="-1.1681223293844059" MODIFIED="2008-11-20 00:08:39 +1000" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.0" SE="1.1214168527250505" STUDY_ID="STD-Unertl-1987" TOTAL_1="19" TOTAL_2="20" VAR="1.2575757575757576" WEIGHT="2.120163912620405"/>
<DICH_DATA CI_END="2.0891650904476964" CI_START="0.11966502845709831" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.31997276024718874" LOG_CI_START="-0.9220327515751512" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="224" O_E="0.0" SE="0.7295601856708801" STUDY_ID="STD-Brun_x002d_Buisson-1989" TOTAL_1="65" TOTAL_2="68" VAR="0.532258064516129" WEIGHT="3.877866756640126"/>
<DICH_DATA CI_END="1.3533142348536038" CI_START="0.4492821493403727" EFFECT_SIZE="0.7797563261480788" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="33" LOG_CI_END="0.13139864997362607" LOG_CI_START="-0.34748083624111786" LOG_EFFECT_SIZE="-0.10804109313374592" ORDER="226" O_E="0.0" SE="0.2812961806942281" STUDY_ID="STD-Gastinne-1992" TOTAL_1="220" TOTAL_2="225" VAR="0.07912754127315984" WEIGHT="8.044198391378693"/>
<DICH_DATA CI_END="1.4158408660902455" CI_START="0.441640237525855" EFFECT_SIZE="0.7907542579075426" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="30" LOG_CI_END="0.1510144434225211" LOG_CI_START="-0.3549313652169108" LOG_EFFECT_SIZE="-0.1019584608971948" ORDER="227" O_E="0.0" SE="0.2971950724669467" STUDY_ID="STD-Hammond-1992" TOTAL_1="162" TOTAL_2="160" VAR="0.08832491109863372" WEIGHT="7.872520223175702"/>
<DICH_DATA CI_END="2.217475353924042" CI_START="0.024772153849553735" EFFECT_SIZE="0.234375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3458588015751184" LOG_CI_START="-1.6060362314315304" LOG_EFFECT_SIZE="-0.630088714928206" ORDER="228" O_E="0.0" SE="1.1465528044243463" STUDY_ID="STD-Laggner-1994" TOTAL_1="33" TOTAL_2="34" VAR="1.3145833333333334" WEIGHT="2.0472309731250418"/>
<DICH_DATA CI_END="0.5564677792688406" CI_START="0.050882611857369246" EFFECT_SIZE="0.16826923076923078" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" LOG_CI_END="-0.2545599772247965" LOG_CI_START="-1.2934306040001753" LOG_EFFECT_SIZE="-0.7739952906124858" ORDER="229" O_E="0.0" SE="0.610237748660397" STUDY_ID="STD-Pneumatikos-2002" TOTAL_1="31" TOTAL_2="30" VAR="0.3723901098901099" WEIGHT="4.744901170162666"/>
<DICH_DATA CI_END="0.40376398770443706" CI_START="0.00436016420127471" EFFECT_SIZE="0.04195804195804196" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.3938724190196639" LOG_CI_START="-2.3604971551431726" LOG_EFFECT_SIZE="-1.3771847870814182" ORDER="230" O_E="0.0" SE="1.155205104948396" STUDY_ID="STD-Rodriguez_x002d_Rolda-1990" TOTAL_1="14" TOTAL_2="17" VAR="1.3344988344988344" WEIGHT="2.02292059122299"/>
<DICH_DATA CI_END="3.2723302284791824" CI_START="0.33400516766290156" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.5148571242075897" LOG_CI_START="-0.47624681381681633" LOG_EFFECT_SIZE="0.019305155195386624" ORDER="231" O_E="0.0" SE="0.582179359239153" STUDY_ID="STD-Wiener-1995" TOTAL_1="30" TOTAL_2="31" VAR="0.3389328063241107" WEIGHT="4.9778242534624315"/>
<DICH_DATA CI_END="0.671930208140419" CI_START="0.13997394460039791" EFFECT_SIZE="0.3066801619433198" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="38" LOG_CI_END="-0.1726758337818444" LOG_CI_START="-0.853952798388802" LOG_EFFECT_SIZE="-0.5133143160853232" ORDER="232" O_E="0.0" SE="0.40018546138549066" STUDY_ID="STD-Bergmans-2001" TOTAL_1="87" TOTAL_2="139" VAR="0.16014840350431803" WEIGHT="6.747904625663357"/>
<DICH_DATA CI_END="0.7842094649382524" CI_START="0.21699676833675877" EFFECT_SIZE="0.41251778093883357" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="37" LOG_CI_END="-0.10556792033006301" LOG_CI_START="-0.6635467339116726" LOG_EFFECT_SIZE="-0.3845573271208679" ORDER="233" O_E="0.0" SE="0.3277595171375104" STUDY_ID="STD-Korinek-1993" TOTAL_1="96" TOTAL_2="95" VAR="0.10742630107421397" WEIGHT="7.538392607544076"/>
<DICH_DATA CI_END="1.8261037950853203" CI_START="0.6518235992244097" EFFECT_SIZE="1.0910075839653304" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="71" LOG_CI_END="0.26152545904257407" LOG_CI_START="-0.18586991998716226" LOG_EFFECT_SIZE="0.037827769527705925" ORDER="234" O_E="0.0" SE="0.2628022602849106" STUDY_ID="STD-Lingnau-1997" TOTAL_1="90" TOTAL_2="177" VAR="0.06906502801085791" WEIGHT="8.240812247715446"/>
<DICH_DATA CI_END="1.5268916306076445" CI_START="0.5381069466440779" EFFECT_SIZE="0.9064386317907445" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="71" LOG_CI_END="0.18380821459457922" LOG_CI_START="-0.2691314014310799" LOG_EFFECT_SIZE="-0.04266159341825034" ORDER="235" O_E="0.0" SE="0.2660589725407314" STUDY_ID="STD-Lingnau-1997b" TOTAL_1="90" TOTAL_2="177" VAR="0.07078737686942968" WEIGHT="8.206479946285492"/>
<DICH_DATA CI_END="0.614021813661682" CI_START="0.15351209051596904" EFFECT_SIZE="0.30701754385964913" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="38" LOG_CI_END="-0.21181619989365566" LOG_CI_START="-0.8138574140787381" LOG_EFFECT_SIZE="-0.5128368069861969" ORDER="236" O_E="0.0" SE="0.35364198936439095" STUDY_ID="STD-Quinio-1995" TOTAL_1="76" TOTAL_2="73" VAR="0.12506265664160401" WEIGHT="7.254124923226128"/>
<DICH_DATA CI_END="1.5591177368390494" CI_START="0.5764814772919735" EFFECT_SIZE="0.948051948051948" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="53" LOG_CI_END="0.1928789121925828" LOG_CI_START="-0.23921464229663475" LOG_EFFECT_SIZE="-0.02316786505202598" ORDER="237" O_E="0.0" SE="0.2538138928045568" STUDY_ID="STD-Camus-2005" TOTAL_1="130" TOTAL_2="126" VAR="0.06442149218060306" WEIGHT="8.334821366138971"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="51.60929471144785" CI_END="0.6326912333159045" CI_START="0.30734169663024247" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_MEASURE="OR" EFFECT_SIZE="0.4409675692048006" ESTIMABLE="YES" EVENTS_1="260" EVENTS_2="483" I2="67.06019701480419" I2_Q="81.43407770805781" ID="CMP-002.06" LOG_CI_END="-0.19880818316200594" LOG_CI_START="-0.5123785156043864" LOG_EFFECT_SIZE="-0.35559334938319626" METHOD="MH" MODIFIED="2009-07-25 10:26:33 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="2.36820005453664E-5" P_Q="0.02029655313636025" P_Z="8.778737898670758E-6" Q="5.386212353339489" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.34262952142718295" TOTALS="YES" TOTAL_1="1312" TOTAL_2="1538" WEIGHT="100.0" Z="4.4452557262323245">
<NAME>RTIs according to blinding of the studies</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="39.31665294346481" CI_END="0.7490286037044015" CI_START="0.35876716818609966" DF="13" EFFECT_SIZE="0.5183887258046961" ESTIMABLE="YES" EVENTS_1="247" EVENTS_2="437" I2="66.93513046826929" ID="CMP-002.06.01" LOG_CI_END="-0.12550159726209786" LOG_CI_START="-0.44518730734481865" LOG_EFFECT_SIZE="-0.2853444523034583" MODIFIED="2008-02-13 10:01:07 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.7794963928918772E-4" P_Z="4.672838845583201E-4" STUDIES="14" TAU2="0.28425203746030453" TOTAL_1="1166" TOTAL_2="1387" WEIGHT="84.74483500525653" Z="3.4988417190019034">
<NAME>Double-blind</NAME>
<DICH_DATA CI_END="1.5975128891721608" CI_START="0.19915453483947404" EFFECT_SIZE="0.5640495867768595" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.2034443708515732" LOG_CI_START="-0.700809800058886" LOG_EFFECT_SIZE="-0.24868271460365646" ORDER="1" O_E="0.0" SE="0.5311633761231399" STUDY_ID="STD-Ferrer-1994" TOTAL_1="51" TOTAL_2="50" VAR="0.28213453213453216" WEIGHT="5.430366017355326"/>
<DICH_DATA CI_END="0.671930208140419" CI_START="0.13997394460039791" EFFECT_SIZE="0.3066801619433198" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="38" LOG_CI_END="-0.1726758337818444" LOG_CI_START="-0.853952798388802" LOG_EFFECT_SIZE="-0.5133143160853232" ORDER="238" O_E="0.0" SE="0.40018546138549066" STUDY_ID="STD-Bergmans-2001" TOTAL_1="87" TOTAL_2="139" VAR="0.16014840350431803" WEIGHT="6.7479046256633595"/>
<DICH_DATA CI_END="1.3533142348536038" CI_START="0.4492821493403727" EFFECT_SIZE="0.7797563261480788" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="33" LOG_CI_END="0.13139864997362607" LOG_CI_START="-0.34748083624111786" LOG_EFFECT_SIZE="-0.10804109313374592" ORDER="240" O_E="0.0" SE="0.2812961806942281" STUDY_ID="STD-Gastinne-1992" TOTAL_1="220" TOTAL_2="225" VAR="0.07912754127315984" WEIGHT="8.044198391378695"/>
<DICH_DATA CI_END="1.4158408660902455" CI_START="0.441640237525855" EFFECT_SIZE="0.7907542579075426" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="30" LOG_CI_END="0.1510144434225211" LOG_CI_START="-0.3549313652169108" LOG_EFFECT_SIZE="-0.1019584608971948" ORDER="241" O_E="0.0" SE="0.2971950724669467" STUDY_ID="STD-Hammond-1992" TOTAL_1="162" TOTAL_2="160" VAR="0.08832491109863372" WEIGHT="7.872520223175703"/>
<DICH_DATA CI_END="0.7842094649382524" CI_START="0.21699676833675877" EFFECT_SIZE="0.41251778093883357" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="37" LOG_CI_END="-0.10556792033006301" LOG_CI_START="-0.6635467339116726" LOG_EFFECT_SIZE="-0.3845573271208679" ORDER="242" O_E="0.0" SE="0.3277595171375104" STUDY_ID="STD-Korinek-1993" TOTAL_1="96" TOTAL_2="95" VAR="0.10742630107421397" WEIGHT="7.538392607544078"/>
<DICH_DATA CI_END="2.217475353924042" CI_START="0.024772153849553735" EFFECT_SIZE="0.234375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3458588015751184" LOG_CI_START="-1.6060362314315304" LOG_EFFECT_SIZE="-0.630088714928206" ORDER="243" O_E="0.0" SE="1.1465528044243463" STUDY_ID="STD-Laggner-1994" TOTAL_1="33" TOTAL_2="34" VAR="1.3145833333333334" WEIGHT="2.0472309731250418"/>
<DICH_DATA CI_END="1.8261037950853203" CI_START="0.6518235992244097" EFFECT_SIZE="1.0910075839653304" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="71" LOG_CI_END="0.26152545904257407" LOG_CI_START="-0.18586991998716226" LOG_EFFECT_SIZE="0.037827769527705925" ORDER="244" O_E="0.0" SE="0.2628022602849106" STUDY_ID="STD-Lingnau-1997" TOTAL_1="90" TOTAL_2="177" VAR="0.06906502801085791" WEIGHT="8.24081224771545"/>
<DICH_DATA CI_END="1.5268916306076445" CI_START="0.5381069466440779" EFFECT_SIZE="0.9064386317907445" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="71" LOG_CI_END="0.18380821459457922" LOG_CI_START="-0.2691314014310799" LOG_EFFECT_SIZE="-0.04266159341825034" ORDER="245" O_E="0.0" SE="0.2660589725407314" STUDY_ID="STD-Lingnau-1997b" TOTAL_1="90" TOTAL_2="177" VAR="0.07078737686942968" WEIGHT="8.206479946285492"/>
<DICH_DATA CI_END="0.2789118286048895" CI_START="0.02489835041841142" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="24" LOG_CI_END="-0.5545330669856574" LOG_CI_START="-1.6038294251095921" LOG_EFFECT_SIZE="-1.0791812460476249" ORDER="246" O_E="0.0" SE="0.6163618748627414" STUDY_ID="STD-Pugin-1991" TOTAL_1="38" TOTAL_2="41" VAR="0.37990196078431376" WEIGHT="4.695570461431607"/>
<DICH_DATA CI_END="0.614021813661682" CI_START="0.15351209051596904" EFFECT_SIZE="0.30701754385964913" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="38" LOG_CI_END="-0.21181619989365566" LOG_CI_START="-0.8138574140787381" LOG_EFFECT_SIZE="-0.5128368069861969" ORDER="247" O_E="0.0" SE="0.35364198936439095" STUDY_ID="STD-Quinio-1995" TOTAL_1="76" TOTAL_2="73" VAR="0.12506265664160401" WEIGHT="7.254124923226131"/>
<DICH_DATA CI_END="0.40376398770443706" CI_START="0.00436016420127471" EFFECT_SIZE="0.04195804195804196" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.3938724190196639" LOG_CI_START="-2.3604971551431726" LOG_EFFECT_SIZE="-1.3771847870814182" ORDER="248" O_E="0.0" SE="1.155205104948396" STUDY_ID="STD-Rodriguez_x002d_Rolda-1990" TOTAL_1="14" TOTAL_2="17" VAR="1.3344988344988344" WEIGHT="2.0229205912229906"/>
<DICH_DATA CI_END="0.905755529414" CI_START="0.03611030374777444" EFFECT_SIZE="0.18085106382978725" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.042989006024688754" LOG_CI_START="-1.4423688584181606" LOG_EFFECT_SIZE="-0.7426789322214247" ORDER="249" O_E="0.0" SE="0.8220026523379126" STUDY_ID="STD-Stoutenbeek-1996" TOTAL_1="49" TOTAL_2="42" VAR="0.6756883604505632" WEIGHT="3.331668377531261"/>
<DICH_DATA CI_END="3.2723302284791824" CI_START="0.33400516766290156" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.5148571242075897" LOG_CI_START="-0.47624681381681633" LOG_EFFECT_SIZE="0.019305155195386624" ORDER="250" O_E="0.0" SE="0.582179359239153" STUDY_ID="STD-Wiener-1995" TOTAL_1="30" TOTAL_2="31" VAR="0.3389328063241107" WEIGHT="4.9778242534624315"/>
<DICH_DATA CI_END="1.5591177368390494" CI_START="0.5764814772919735" EFFECT_SIZE="0.948051948051948" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="53" LOG_CI_END="0.1928789121925828" LOG_CI_START="-0.23921464229663475" LOG_EFFECT_SIZE="-0.02316786505202598" ORDER="251" O_E="0.0" SE="0.2538138928045568" STUDY_ID="STD-Camus-2005" TOTAL_1="130" TOTAL_2="126" VAR="0.06442149218060306" WEIGHT="8.334821366138973"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.625282680946201" CI_END="0.4091880273878896" CI_START="0.10057100360888925" DF="3" EFFECT_SIZE="0.20286066789582877" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="46" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="-0.38807708198686186" LOG_CI_START="-0.9975272159785799" LOG_EFFECT_SIZE="-0.6928021489827207" MODIFIED="2008-07-29 23:34:01 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4530744468083062" P_Z="8.34872403967586E-6" STUDIES="4" TAU2="0.0" TOTAL_1="146" TOTAL_2="151" WEIGHT="15.255164994743472" Z="4.456040567337174">
<NAME>Open</NAME>
<DICH_DATA CI_END="0.6229021368690192" CI_START="0.050738208140471794" EFFECT_SIZE="0.17777777777777778" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="15" LOG_CI_END="-0.20558017927382535" LOG_CI_START="-1.2946648742929747" LOG_EFFECT_SIZE="-0.7501225267834001" ORDER="2" O_E="0.0" SE="0.6397337409104347" STUDY_ID="STD-Georges-1994" TOTAL_1="31" TOTAL_2="33" VAR="0.4092592592592592" WEIGHT="4.512233155320278"/>
<DICH_DATA CI_END="2.0891650904476964" CI_START="0.11966502845709831" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.31997276024718874" LOG_CI_START="-0.9220327515751512" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="252" O_E="0.0" SE="0.7295601856708801" STUDY_ID="STD-Brun_x002d_Buisson-1989" TOTAL_1="65" TOTAL_2="68" VAR="0.532258064516129" WEIGHT="3.8778667566401257"/>
<DICH_DATA CI_END="0.6115464173133797" CI_START="0.007539211293396412" EFFECT_SIZE="0.06790123456790123" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.21357057375769592" LOG_CI_START="-2.122674085011116" LOG_EFFECT_SIZE="-1.1681223293844059" ORDER="255" O_E="0.0" SE="1.1214168527250505" STUDY_ID="STD-Unertl-1987" TOTAL_1="19" TOTAL_2="20" VAR="1.2575757575757576" WEIGHT="2.1201639126204044"/>
<DICH_DATA CI_END="0.5564677792688406" CI_START="0.050882611857369246" EFFECT_SIZE="0.16826923076923078" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" LOG_CI_END="-0.2545599772247965" LOG_CI_START="-1.2934306040001753" LOG_EFFECT_SIZE="-0.7739952906124858" ORDER="256" O_E="0.0" SE="0.610237748660397" STUDY_ID="STD-Pneumatikos-2002" TOTAL_1="31" TOTAL_2="30" VAR="0.3723901098901099" WEIGHT="4.744901170162666"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-03-16 10:29:30 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-03-16 10:29:30 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-03-16 10:14:52 +1000" MODIFIED_BY="[Empty name]">Embase.com search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-03-16 10:29:30 +1000" MODIFIED_BY="[Empty name]">
<P>1. 'respiratory tract infection'/exp <BR/>2. 'respiratory tract infection':ti,ab OR 'respiratory tract infections':ti,ab <BR/>3. 'pneumonia'/exp <BR/>4. pneumon*:ti,ab <BR/>5. hap:ti,ab OR vap:ti,ab <BR/>6. bronchopneumonia*:ti,ab OR pleuropneumonia*:ti,ab <BR/>7. 'bronchitis'/exp<BR/>8. bronchit*:ti,ab OR bronchiolit*:ti,ab <BR/>9. 'pharyngitis'/exp <BR/>10. pharyngit*:ti,ab <BR/>11. 'tracheitis'/exp <BR/>12. tracheit*:ti,ab <BR/>13. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12<BR/>14. 'intensive care unit'/exp <BR/>15. icu:ti,ab OR 'critical care':ti,ab OR 'intensive care':ti,ab OR 'burn unit':ti,ab OR 'burn units':ti,ab OR 'care unit':ti,ab OR 'care units':ti,ab OR 'recovery room':ti,ab OR 'recovery rooms':ti,ab<BR/>16. 'critical illness'/exp<BR/>17. 'critically ill':ti,ab OR 'critical illness':ti,ab <BR/>18. 'ventilator'/exp <BR/>19. ventilator*:ti,ab <BR/>20. 'artificial ventilation'/exp <BR/>21. respirator*:ti,ab <BR/>22. #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR # 21<BR/>23. #13 AND #22 <BR/>24. 'ventilator associated pneumonia'/exp <BR/>25. 'ventilator associated pneumonia':ti,ab <BR/>26. #24 OR #25 <BR/>27. #23 OR #26 <BR/>28. 'antibiotic prophylaxis'/exp <BR/>29. 'antibiotic agent'/exp <BR/>30. antibiotic*:ti,ab <BR/>31. #28 OR #29 OR #30 <BR/>32. #27 AND #31 <BR/>33. 'randomized controlled trial'/exp<BR/>34. 'controlled clinical trial'/exp <BR/>35. 'single blind procedure'/exp <BR/>36. 'crossover procedure'/exp <BR/>37. random*:ti,ab OR placebo*:ti,ab OR factorial*:ti,ab OR crossover*:ti,ab OR assign*:ti,ab OR allocat*:ti,ab OR volunteer*:ti,ab OR 'double blind':ti,ab OR 'double blinding':ti,ab OR 'double blinded':ti,ab OR 'single blind':ti,ab OR 'single blinded':ti,ab OR 'single blinding':ti,ab <BR/>38. #33 OR #34 OR #35 OR #36 OR #37 <BR/>39. #32 AND #38 <BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>